

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 January 2002 (03.01.2002)

PCT

(10) International Publication Number
WO 02/00907 A1

(51) International Patent Classification⁷: **C12N 15/90**,
15/68, 15/67 // 15/75

(21) International Application Number: PCT/DK01/00436

(22) International Filing Date: 21 June 2001 (21.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2000 00981 23 June 2000 (23.06.2000) DK
60/217,929 13 July 2000 (13.07.2000) US

(71) Applicant (for all designated States except US):
NOVOZYMES A/S [DK/DK]; Krogshøjvej 36, DK-2880
Bagsværd (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JØRGENSEN, Steen, Troels** [DK/DK]; Prunusvej 5, DK-3450 Allerød (DK). **ANDERSEN, Jens, Toenne** [DK/DK]; Alfred Christensens Vej 35, DK-2850 Nærum (DK). **RAS-MUSSEN, Michael, Dolbjerg** [DK/DK]; Syvbjergvej 151, DK-2625 Vallensbæk (DK). **OLSEN, Carsten** [DK/DK]; c/o Novozymes A/S, Krogshøjvej 36, DK-2880 Bagsværd (DK).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- entirely in electronic form (except for this front page) and available upon request from the International Bureau
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR STABLE CHROMOSOMAL MULTI-COPY INTEGRATION OF GENES

(57) Abstract: The present invention solves the problem of integrating multiple copies of a gene of interest by homologous recombination into well defined positions adjacent to conditionally essential genes in a bacterial host strain chromosome, which already comprises at least one copy of the gene of interest in a different position.



WO 02/00907 A1

Method for stable chromosomal multi-copy integration of genes**Field of the Invention**

The invention relates to a method for inserting genes
5 into the chromosome of bacterial strains, and the resulting
strains. In the biotech industry it is desirable to construct
polypeptide production strains having several copies of a gene
of interest stably chromosomally integrated, without leaving
antibiotic resistance marker genes in the strains.

10

Background of the Invention

In the industrial production of polypeptides it is of
interest to achieve a product yield as high as possible. One
way to increase the yield is to increase the copy number of a
15 gene encoding a polypeptide of interest. This can be done by
placing the gene on a high copy number plasmid, however
plasmids are unstable and are often lost from the host cells
if there is no selective pressure during the cultivation of
the host cells. Another way to increase the copy number of the
20 gene of interest is to integrate it into the host cell
chromosome in multiple copies. It has previously been
described how to integrate a gene into the chromosome by
double homologous recombination without using antibiotic
markers (Hone et al., Microbial Pathogenesis, 1988, 5: 407-
25 418); integration of two genes has also been described (Novo
Nordisk: WO 91/09129 and WO 94/14968). A problem with
integrating several copies of a gene into the chromosome of a
host cell is instability. Due to the sequence identity of the
copies there is a high tendency for the them to recombine out
30 of the chromosome again during cultivation of the host cell
unless a selective marker or other essential DNA is included
between the copies and selective pressure is applied during
cultivation, especially if the genes are located in relative
close vicinity of each other. It has been described how to

integrate two genes closely spaced in anti-parallel tandem to achieve better stability (Novo Nordisk: WO 99/41358).

The present day public debate concerning the industrial use of recombinant DNA technology has raised some questions
5 and concern about the use of antibiotic marker genes.

Antibiotic marker genes are traditionally used as a means to select for strains carrying multiple copies of both the marker genes and an accompanying expression cassette coding for a polypeptide of industrial interest. In order to comply with
10 the current demand for recombinant production host strains devoid of antibiotic markers, we have looked for possible alternatives to the present technology that will allow substitution of the antibiotic markers we use today with non-antibiotic marker genes. Thus in order to provide recombinant
15 production strains devoid of antibiotic resistance markers, it remains of industrial interest to find new methods to stably integrate genes in multiple copies into host cell chromosomes.

Summary of the Invention

20 The present invention solves the problem of integrating multiple copies of a gene of interest by homologous recombination into well defined chromosomal positions of a bacterial host strain which already comprises at least one copy of the gene of interest in a different position. This can
25 be done by making a deletion of part of one or more conditionally essential gene(s) (hereafter called the "integration gene") in the host chromosome of a strain which already comprises at least one copy of a gene of interest, or by otherwise altering the gene(s) to render it non-functional;
30 or by integrating at least one partial non-functional conditionally essential gene into the host chromosome, so that the resulting strain has a deficiency (e.g. specific carbon-source utilization) or a growth requirement (e.g. amino acid

auxotrophy) or is sensitive to a given stress. The next (i.e. second or third etc.) copy of the gene of interest is then introduced on a vector, on which the gene is flanked upstream by a partial fragment of the integration gene, and downstream 5 is flanked by a fragment homologous to a DNA sequence downstream of the integration gene on the host chromosome. Thus, neither host chromosome nor the incoming vector contain a full version of the integration gene. In a non-limiting example the host chromosome may comprise the first two thirds 10 of the integration gene and the vector the last two thirds, effectively establishing a sequence overlap of one third of the integration gene on the vector and the chromosome.

Expression of the full version of the integration gene will only occur if homologous recombination between vector and 15 host chromosome takes place via the partial integration gene sequences, and this particular recombination event can be efficiently selected for, even against the background of homologous integration into the chromosome directed by the gene of interest into the identical gene(s) comprised on the 20 chromosome already.

This strategy will enable directed gene integration by homologous recombination at predetermined loci, even though extended homology exists between the gene of interest on the incoming vector and other copies of this gene at other 25 locations in the chromosome, and even though it is not feasible to identify the desired integrants based on the qualitative phenotype resulting from expression of the gene of interest, as this gene is already present in one or more copies in the host.

30 In a non-limiting example herein a *Bacillus* enzyme production strain is provided that comprises two anti-parallel copies (inverted orientation) of a gene encoding the commercially available amylase Termamyl® (Novo Nordisk,

Denmark). A gene homologous to the *dal* gene of *Bacillus subtilis*, encoding a D-alanine racemase, was identified in the *Bacillus* production strain, it was sequenced and a partial deletion was made in the *dal* gene of the *Bacillus* two-copy
5 Termamyl[®] strain. A vector was constructed to effect a stable non-tandem chromosomal insertion of a third Termamyl[®] gene copy adjacent to the *dal* locus, in the process effectively restoring the complete *dal* gene, according to the above strategy.

10 In another non-limiting example herein, an additional copy of the amylase encoding gene was introduced into the xylose isomerase operon of the *Bacillus* enzyme production strain which already comprised at least two copies of the amylase gene located elsewhere on the chromosome.

15 Also in a non-limiting example we demonstrate the method of the invention by integrating an additional amylase-encoding gene into the gluconat operon of the *Bacillus* enzyme production strain. Other non-limiting examples of integration into conditionally essential genes are given below.

20 Accordingly in a first aspect the invention relates to a method for constructing a cell comprising at least two copies of a gene of interest stably integrated into the chromosome in different positions, the method comprising the steps of:

- a) providing a host cell comprising at least one chromosomal
25 copy of the gene of interest, and comprising one or more conditionally essential chromosomal gene(s) which has been altered to render the gene(s) non-functional;
- b) providing a DNA construct comprising:
 - i) an altered non-functional copy of the conditionally
30 essential gene(s) of step a); and
 - ii) at least one copy of the gene of interest flanked on one side by i) and on the other side by a DNA fragment homologous to a host cell DNA sequence located on the

- host cell chromosome adjacent to the gene(s) of step a);
wherein a first recombination between the altered copy
of i) and the altered chromosomal gene(s) of step a)
restores the conditionally essential chromosomal gene(s)
5 to functionality and renders the cell selectable;
c) introducing the DNA construct into the host cell and
cultivating the cell under selective conditions that
require a functional conditionally essential gene(s); and
d) selecting a host cell that grows under the selective
10 conditions of the previous step ; wherein the at least one
copy of the gene of interest has integrated into the host
cell chromosome adjacent to the gene(s) of step a); and
optionally
e) repeating steps a) to d) at least once using a different
15 chromosomal gene(s) in step a) in each repeat.

Another way of describing the first aspect of the
invention relates to a method for constructing a cell
comprising at least two copies of a gene of interest stably
20 integrated into the chromosome in different positions, the
method comprising the steps of:

- a) providing a host cell comprising at least one chromosomal
copy of the gene of interest;
b) altering a conditionally essential chromosomal gene(s) of
25 the host cell whereby the gene becomes non-functional;
c) making a DNA construct comprising:
i) an altered non-functional copy of the chromosomal
gene(s) of step b); and
ii) at least one copy of the gene of interest flanked on
30 one side by i) and on the other side by a DNA fragment
homologous to a host cell DNA sequence adjacent to the
gene(s) of step b); wherein a first recombination
between the altered copy of i) and the altered

chromosomal gene(s) of step b) restores the chromosomal gene(s) to functionality and renders the cell selectable;

- d) introducing the DNA construct into the host cell and
5 cultivating the cell under selective conditions that require a functional gene(s) of step b); and
e) selecting a host cell that grows under the selective conditions of step d); wherein the at least one copy of the gene of interest has integrated into the host cell
10 chromosome adjacent to the gene(s) of step b); and optionally
f) repeating steps a) to e) at least once using a different chromosomal gene(s) in step b) in each repeat.

Herein genetic tools are also described in the form of
15 DNA constructs necessary for carrying out the method of the invention.

Consequently in a second aspect the invention relates to a DNA construct comprising:

- i) an altered non-functional copy of a conditionally
20 essential chromosomal gene(s) from a host cell, preferably the copy is partially deleted; and
ii) at least one copy of a gene of interest flanked on one side by i) and on the other side by a DNA fragment homologous to a host cell DNA sequence located on the host
25 cell chromosome adjacent to the conditionally essential gene(s) of i).

The present invention provides a method for obtaining a host cell comprising at least two copies of a gene of interest
30 stably integrated on the chromosome adjacent to conditionally essential loci.

Accordingly in a third aspect the invention relates to a host cell comprising at least two copies of a gene of interest

stably integrated into the chromosome, where at least one copy is integrated adjacent to a conditionally essential *locus* and wherein the cell is obtainable by any of the methods defined in the first aspects.

5 Another way of describing an aspect of the invention relates to a host cell comprising at least two copies of a gene of interest stably integrated into the chromosome, where each copy is integrated adjacent to different conditionally essential *loci* and wherein the cell is obtainable by any of
10 the methods defined in the first aspects.

The method of the invention relies on complementing a conditionally essential gene(s) that was rendered non-functional, and a number of suitable host cells comprising such non-functional genes are described herein. To carry out
15 multiple rounds of gene integration according to the invention it is advantageous to provide a host cell comprising several non-functional conditionally essential genes.

In a fourth aspect the invention relates to a *Bacillus licheniformis* cell, wherein at least two conditionally
20 essential genes are rendered non-functional, preferably the genes are chosen from the group consisting of *xylA*, *galE*, *gntK*, *gntP*, *glpP*, *glpF*, *glpK*, *glpD*, *araA*, *metC*, *lysA*, and *dal*.

Any host cell as described herein for use in a method of the invention is intended to be encompassed by the scope of
25 the invention.

Another aspect of the invention relates to the use of a cell as defined in the previous aspect in a method as defined in the first aspects.

As mentioned above, genetic tools of the invention are
30 described herein, and it is intended that the scope of the invention comprises such constructs when present in or propagated in host cells as is common in the art.

Yet another aspect of the invention relates to a cell comprising a DNA construct as defined in the second aspect.

In a final aspect the invention relates to a process for producing an enzyme of interest, comprising cultivating a cell as defined in any of the preceding aspects under conditions appropriate for producing the enzyme, and optionally purifying the enzyme.

Figures

Figure 1: Schematic representation of the *B. licheniformis* xylose isomerase region, PCR fragments, Deletion and Integration plasmids and strains.

Figure 2: Schematic representation of the *B. licheniformis* gluconat region, PCR fragments, Deletion and Integration plasmids and strains.

Figure 3: Schematic representation of the *B. licheniformis* D-alanine racemase encoding region, PCR fragments, Deletion and Integration plasmids and strains.

Definitions

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook et al., 1989"); *DNA Cloning: A Practical Approach*, Volumes I and II /D.N. Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid Hybridization* (B.D. Hames & S.J. Higgins eds (1985)); *Transcription And Translation* (B.D. Hames & S.J. Higgins, eds. (1984)); *Animal Cell Culture* (R.I. Freshney, ed. (1986)); *Immobilized Cells And Enzymes* (IRL Press, (1986)); B. Perbal, *A Practical Guide To Molecular Cloning* (1984).

A "polynucleotide" is a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases, the sequence of the polynucleotide is the actual sequence of the bases read from the 5' to the 3' end of the polymer.

5 Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized *in vitro*, or prepared from a combination of natural and synthetic molecules.

A "nucleic acid molecule" or "nucleotide sequence" refers to the phosphate ester polymeric form of ribonucleosides
10 (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules") in either single stranded form, or a double-stranded helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible.
15 The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary or quaternary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear or circular DNA
20 molecules (e.g., restriction fragments), plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of
25 DNA (i.e., the strand having a sequence homologous to the mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone a molecular biological manipulation.

A DNA "coding sequence" or an "open reading frame (ORF)" is a double-stranded DNA sequence which is transcribed and
30 translated into a polypeptide in a cell *in vitro* or *in vivo* when placed under the control of appropriate regulatory sequences. The ORF "encodes" the polypeptide. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3'

(carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. If the coding sequence is
5 intended for expression in a eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

An expression vector is a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of
10 interest operably linked to additional segments that provide for its transcription. Such additional segments may include promoter and terminator sequences, and optionally one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression
15 vectors are generally derived from plasmid or viral DNA, or may contain elements of both.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, terminators, and the like, that provide for the expression of
20 a coding sequence in a host cell e.g. in eukaryotic cells, polyadenylation signals are control sequences.

A "secretory signal sequence" is a DNA sequence that encodes a polypeptide (a "secretory peptide" that, as a component of a larger polypeptide, directs the larger
25 polypeptide through a secretory pathway of a cell in which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

The term "promoter" is used herein for its art-recognized
30 meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.

A chromosomal gene is rendered "non-functional" if the polypeptide that the gene encodes can no longer be expressed in a functional form. Such non-functionality of a gene can be induced by a wide variety of genetic manipulations or
5 alterations as known in the art, some of which are described in Sambrook et al. *vide supra*. Partial deletions within the ORF of a gene will often render the gene non-functional, as will mutations e.g. substitutions, insertions, frameshifts etc.

10 "Operably linked", when referring to DNA segments, indicates that the segments are arranged so that they function in concert e.g. the transcription process takes place via the RNA-polymerase binding to the promoter segment and proceeding with the transcription through the coding segment until the
15 polymerase stops when it encounters a transcription terminator segment.

"Heterologous" DNA in a host cell, in the present context refers to exogenous DNA not originating from the cell.

As used herein the term "nucleic acid construct" is
20 intended to indicate any nucleic acid molecule of cDNA, genomic DNA, synthetic DNA or RNA origin. The term "construct" is intended to indicate a nucleic acid segment which may be single- or double-stranded, and which may be based on a complete or partial naturally occurring nucleotide sequence
25 encoding a polypeptide of interest. The construct may optionally contain other nucleic acid segments.

The nucleic acid construct of the invention encoding the polypeptide of the invention may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or
30 cDNA library and screening for DNA sequences coding for all or part of the polypeptide by hybridization using synthetic oligonucleotide probes in accordance with standard techniques (cf. Sambrook et al., *supra*).

The nucleic acid construct of the invention encoding the polypeptide may also be prepared synthetically by established standard methods, e.g. the phosphoramidite method described by Beaucage and Caruthers, Tetrahedron Letters 22 (1981), 1859 - 5 1869, or the method described by Matthes et al., EMBO Journal 3 (1984), 801 - 805. According to the phosphoramidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and cloned in suitable vectors.

10 Furthermore, the nucleic acid construct may be of mixed synthetic and genomic, mixed synthetic and cDNA or mixed genomic and cDNA origin prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate), the fragments corresponding to various parts of the entire nucleic
15 acid construct, in accordance with standard techniques. The nucleic acid construct may also be prepared by polymerase chain reaction using specific primers, for instance as described in US 4,683,202 or Saiki et al., Science 239 (1988), 487 - 491.

20 The term nucleic acid construct may be synonymous with the term "expression cassette" when the nucleic acid construct contains the control sequences necessary for expression of a coding sequence of the present invention

The term "control sequences" is defined herein to include
25 all components that are necessary or advantageous for expression of the coding sequence of the nucleic acid sequence. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, a
30 polyadenylation sequence, a propeptide sequence, a promoter, a signal sequence, and a transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of

introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a polypeptide.

The control sequence may be an appropriate promoter
5 sequence, a nucleic acid sequence that is recognized by a host cell for expression of the nucleic acid sequence. The promoter sequence contains transcription and translation control sequences that mediate the expression of the polypeptide. The promoter may be any nucleic acid sequence
10 that shows transcriptional activity in the host cell of choice and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

The control sequence may also be a suitable transcription
15 terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present
20 invention.

The control sequence may also be a polyadenylation sequence, a sequence which is operably linked to the 3' terminus of the nucleic acid sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine
25 residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in the present invention.

The control sequence may also be a signal peptide-coding region, which codes for an amino acid sequence linked to the
30 amino terminus of the polypeptide which can direct the expressed polypeptide into the cell's secretory pathway of the host cell. The 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide-coding region naturally linked in translation reading frame with the

segment of the coding region which encodes the secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide-coding region which is foreign to that portion of the coding sequence which encodes the secreted polypeptide. A foreign signal peptide-coding region may be required where the coding sequence does not normally contain a signal peptide-coding region. Alternatively, the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to obtain enhanced secretion of the polypeptide relative to the natural signal peptide coding region normally associated with the coding sequence. The signal peptide-coding region may be obtained from a glucoamylase or an amylase gene from an *Aspergillus* species, a lipase or proteinase gene from a *Rhizomucor* species, the gene for the alpha-factor from *Saccharomyces cerevisiae*, an amylase or a protease gene from a *Bacillus* species, or the calf preprochymosin gene. However, any signal peptide coding region capable of directing the expressed polypeptide into the secretory pathway of a host cell of choice may be used in the present invention.

The control sequence may also be a propeptide coding region, which codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the *Bacillus subtilis* alkaline protease gene (*aprE*), the *Bacillus subtilis* neutral protease gene (*nprT*), the *Saccharomyces cerevisiae* alpha-factor gene, or the *Myceliophthora thermophilum* laccase gene (WO 95/33836).

It may also be desirable to add regulatory sequences which allow the regulation of the expression of the

polypeptide relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory
5 compound. Regulatory systems in prokaryotic systems would include the *lac*, *tac*, and *trp* operator systems. Other examples of regulatory sequences are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the
10 presence of methotrexate, and the metallothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the polypeptide would be placed in tandem with the regulatory sequence.

Examples of suitable promoters for directing the
15 transcription of the nucleic acid constructs of the present invention, especially in a bacterial host cell, are the promoters obtained from the *E. coli lac* operon, the *Streptomyces coelicolor* agarase gene (*dagA*), the *Bacillus subtilis* levansucrase gene (*sacB*), the *Bacillus subtilis*
20 alkaline protease gene, the *Bacillus licheniformis* alpha-amylase gene (*amyL*), the *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), the *Bacillus amyloliquefaciens* alpha-amylase gene (*amyQ*), the *Bacillus amyloliquefaciens* BAN AMYLASE GENE, the *Bacillus licheniformis* penicillinase gene
25 (*penP*), the *Bacillus subtilis* *xylA* and *xylB* genes, and the prokaryotic beta-lactamase gene (Villa-Kamaroff et al., 1978, *Proceedings of the National Academy of Sciences USA* 75:3727-3731), as well as the *tac* promoter (DeBoer et al., 1983, *Proceedings of the National Academy of Sciences USA* 80:21-25).
30 Further promoters are described in "Useful proteins from recombinant bacteria" in *Scientific American*, 1980, 242:74-94; and in Sambrook et al., 1989, *supra*.

The present invention also relates to recombinant expression vectors comprising a nucleic acid sequence of the

present invention, a promoter, and transcriptional and translational stop signals. The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one
5 or more convenient restriction sites to allow for insertion or substitution of the nucleic acid sequence encoding the polypeptide at such sites. Alternatively, the nucleic acid sequence of the present invention may be expressed by inserting the nucleic acid sequence or a nucleic acid
10 construct comprising the sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression, and possibly secretion.

15 The recombinant expression vector may be any vector (e.g., a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleic acid sequence. The choice of the vector will typically depend on the compatibility of the
20 vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids. The vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal
25 replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and
30 replicated together with the chromosome(s) into which it has been integrated. The vector system may be a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon.

The vectors of the present invention preferably contain one or more "selectable markers" which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide, antibiotic or viral
5 resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like.

A "conditionally essential gene" may function as a "non-antibiotic selectable marker". Non-limiting examples of bacterial conditionally essential selectable markers are the
10 *dal* genes from *Bacillus subtilis* or *Bacillus licheniformis*, that are only essential when the bacterium is cultivated in the absence of D-alanine. Also the genes encoding enzymes involved in the turnover of UDP-galactose can function as conditionally essential markers in a cell when the cell is
15 grown in the presence of galactose or grown in a medium which gives rise to the presence of galactose. Non-limiting examples of such genes are those from *B. subtilis* or *B. licheniformis* encoding UTP-dependent phosphorylase (EC 2.7.7.10), UDP-glucose-dependent uridylyltransferase (EC 2.7.7.12), or UDP-
20 galactose epimerase (EC 5.1.3.2). Also a xylose isomerase gene such as *xylA*, of *Bacilli* can be used as selectable markers in cells grown in minimal medium with xylose as sole carbon source. The genes necessary for utilizing gluconate, *gntK*, and *gntP* can also be used as selectable markers in cells grown in
25 minimal medium with gluconate as sole carbon source. Other non-limiting examples of conditionally essential genes are given below.

Antibiotic selectable markers confer antibiotic resistance to such antibiotics as ampicillin, kanamycin,
30 chloramphenicol, erythromycin, tetracycline, neomycin, hygromycin or methotrexate.

Furthermore, selection may be accomplished by co-transformation, e.g., as described in WO 91/17243, where the selectable marker is on a separate vector.

The vectors of the present invention preferably contain an element(s) that permits stable integration of the vector, or of a smaller part of the vector, into the host cell genome or autonomous replication of the vector in the cell
5 independent of the genome of the cell.

The vectors, or smaller parts of the vectors, may be integrated into the host cell genome when introduced into a host cell. For chromosomal integration, the vector may rely on the nucleic acid sequence encoding the polypeptide or any
10 other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous recombination.

Alternatively, the vector may contain additional nucleic acid sequences for directing integration by homologous
15 recombination into the genome of the host cell. The additional nucleic acid sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements
20 should preferably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous
25 recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleic acid sequences.

The copy number of a vector, an expression cassette, an
30 amplification unit, a gene or indeed any defined nucleotide sequence is the number of identical copies that are present in a host cell at any time. A gene or another defined chromosomal nucleotide sequence may be present in one, two, or more copies

on the chromosome. An autonomously replicating vector may be present in one, or several hundred copies per host cell.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to
5 replicate autonomously in the host cell in question. Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, pACYC184, pUB110, pE194, pTA1060, and pAM β 1. The origin of replication may be one having a mutation which makes its functioning
10 temperature-sensitive in the host cell (see, e.g., Ehrlich, 1978, *Proceedings of the National Academy of Sciences USA* 75:1433).

The present invention also relates to recombinant host cells, comprising a nucleic acid sequence of the invention, which are
15 advantageously used in the recombinant production of the polypeptides. The term "host cell" encompasses any progeny of a parent cell which is not identical to the parent cell due to mutations that occur during replication.

The cell is preferably transformed with a vector
20 comprising a nucleic acid sequence of the invention followed by integration of the vector into the host chromosome.

"Transformation" means introducing a vector comprising a nucleic acid sequence of the present invention into a host cell so that the vector is maintained as a chromosomal
25 integrant or as a self-replicating extra-chromosomal vector. Integration is generally considered to be an advantage as the nucleic acid sequence is more likely to be stably maintained in the cell. Integration of the vector into the host chromosome may occur by homologous or non-homologous
30 recombination as described above.

The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source. The host cell may be a unicellular microorganism, e.g., a prokaryote, or a non-unicellular microorganism, e.g., a

eukaryote. Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a *Bacillus* cell, e.g., *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*,
5 *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*; or a *Streptomyces* cell, e.g., *Streptomyces lividans* or *Streptomyces murinus*, or gram negative bacteria
10 such as *E. coli* and *Pseudomonas* sp. In a preferred embodiment, the bacterial host cell is a *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus stearothermophilus* or *Bacillus subtilis* cell.

The transformation of a bacterial host cell may, for
15 instance, be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, *Molecular General Genetics* 168:111-115), by using competent cells (see, e.g., Young and Spizizin, 1961, *Journal of Bacteriology* 81:823-829, or Dubnar and Davidoff-Abelson, 1971, *Journal of Molecular Biology* 56:209-
20 221), by electroporation (see, e.g., Shigekawa and Dower, 1988, *Biotechniques* 6:742-751), or by conjugation (see, e.g., Koehler and Thorne, 1987, *Journal of Bacteriology* 169:5771-5278).

The transformed or transfected host cells described above
25 are cultured in a suitable nutrient medium under conditions permitting the expression of the desired polypeptide, after which the resulting polypeptide is recovered from the cells, or the culture broth.

The medium used to culture the cells may be any conventional
30 medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection). The media are prepared

using procedures known in the art (see, e.g., references for bacteria and yeast; Bennett, J.W. and LaSure, L., editors, *More Gene Manipulations in Fungi*, Academic Press, CA, 1991).

If the polypeptide is secreted into the nutrient medium, 5 the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it is recovered from cell lysates. The polypeptide are recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating 10 the proteinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by a variety of chromatographic procedures, e.g. ion exchange chromatography, gelfiltration chromatography, affinity chromatography, or the like, dependent on the type of 15 polypeptide in question.

The polypeptides may be detected using methods known in the art that are specific for the polypeptides. These detection methods may include use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme 20 substrate. For example, an enzyme assay may be used to determine the activity of the polypeptide.

The polypeptides of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, 25 hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing (IEF), differential solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g., *Protein Purification*, J.-C. Janson and Lars Ryden, editors, VCH 30 Publishers, New York, 1989).

Detailed description of the invention

A method for constructing a cell comprising at least two copies of a gene of interest stably integrated into the

chromosome in different positions according to the first aspect of the invention.

In the method of the invention it is envisioned that after the directed and selectable integration of the DNA construct into the chromosome of the host cell by the first homologous recombination, a second recombination can take place between a DNA fragment comprised in the construct and a homologous host cell DNA sequence located adjacent to the gene(s) of step b) of the method of the first aspect, where
10 the DNA fragment of the construct is homologous to said host cell DNA sequence.

Accordingly a preferred embodiment of the invention relates to the method of the first aspect, wherein subsequent to the step of introducing the DNA construct and cultivating
15 the cell under selective conditions, or subsequent to the step of selecting a host cell, a second recombination takes place between the DNA fragment and the homologous host cell DNA sequence.

A preferred embodiment of the invention relates to the
20 method of the first aspect, wherein subsequent to step d) and prior to step e) a second recombination takes place between the DNA fragment and the homologous host cell DNA sequence.

Further it is envisioned that one might add a marker gene to the DNA construct, which could ease selection of first
25 recombination integrants, where the marker gene would be excised from the host cell chromosome again by the second recombination as described above.

In a preferred embodiment the invention relates to the method of the first aspect, where the DNA construct further
30 comprises at least one marker gene which is located in the construct such that it is recombined out of the chromosome by the second recombination; preferably the at least one marker gene confers resistance to an antibiotic, more preferably the antibiotic is chosen from the group consisting of

chloramphenicol, kanamycin, ampicillin, erythromycin, spectinomycin and tetracycline; and most preferably a host cell is selected which grows under the selective conditions, and which does not contain the at least one marker gene in the 5 chromosome.

The method of the invention can also be carried out by including a marker gene in that part of the DNA construct which remains integrated in the chromosome after the second recombination event. However as it is preferred not to have 10 marker genes in the chromosome, an alternative way of removing the marker gene must be employed after the integration has been carried out. Specific restriction enzymes or resolvases that excise portions of DNA, if it is flanked on both sides by certain recognition sequences known as resolvase sites or *res-* 15 sites, are well known in the art, see e.g. WO 96/23073 (Novo Nordisk A/S) which is included herein by reference.

A preferred embodiment of the invention relates to the method of the first aspect, where the DNA construct further comprises at least one marker gene located between the altered 20 copy and the DNA fragment, and wherein the at least one marker gene is flanked by nucleotide sequences that are recognized by a specific resolvase, preferably the nucleotide sequences are *res*; even more preferably the at least one marker gene is excised from the chromosome by the action of a resolvase 25 enzyme subsequent to selecting a host cell that grows under the selective conditions.

The gene of interest may encode an enzyme that is naturally produced by the host cell, indeed one may simply want to increase the number of copies of a gene endogenous to 30 the host cell.

Accordingly a preferred embodiment of the invention relates to the method of the first aspect, wherein the gene of interest originates from the host cell.

In another preferred embodiment the invention relates to the method of the first aspect, wherein the gene of interest encodes an enzyme, preferably an amylolytic enzyme, a lipolytic enzyme, a proteolytic enzyme, a cellulytic enzyme, 5 an oxidoreductase or a plant cell-wall degrading enzyme, and more preferably an enzyme with an activity selected from the group consisting of aminopeptidase, amylase, amyloglucosidase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, 10 deoxyribonuclease, esterase, galactosidase, beta-galactosidase, glucoamylase, glucose oxidase, glucosidase, haloperoxidase, hemicellulase, invertase, isomerase, laccase, ligase, lipase, lyase, mannosidase, oxidase, pectinase, peroxidase, phytase, phenoloxidase, polyphenoloxidase, 15 protease, ribonuclease, transferase, transglutaminase, or xylanase.

As mentioned above, the gene of interest may be endogenous to the host cell, however it may be advantageous if the production cell obtained by the method of the invention 20 contains as little exogenous, foreign, or heterologous DNA as possible when the integration procedure is completed.

Consequently a preferred embodiment of the invention relates to the method of the first aspect, wherein the selected host cell that grows under the selective conditions 25 comprises substantially no exogenous DNA, preferably less than 500 basepairs per integrated gene of interest, more preferably less than 300 bp, even more preferably less than 100 bp, still more preferably less than 50 bp, more preferably less than 25 bp per integrated gene of interest, or most preferably no 30 exogenous DNA.

Yet a preferred embodiment of the invention relates to the method of the first aspect, wherein the selected host cell that grows under the selective conditions comprises DNA only of endogenous origin.

Another embodiment relates to the method, wherein the host cell selected in step e) of the first aspect comprises DNA only of endogenous origin.

Many ways exist in the art of rendering a gene non-
5 functional by alteration or manipulation, such as partially deleting the gene or the promoter of the gene, or by introducing mutations in the gene or the promoter region of the gene.

A preferred embodiment of the invention relates to the
10 method of the first aspect, wherein the conditionally essential chromosomal gene(s) of the host cell is altered by partially deleting the gene(s), or by introducing one or more mutations in the gene(s).

The present invention relies on rendering at least one
15 conditionally essential chromosomal gene(s) in the host cell non-functional in a step, and in particular relies on a number of conditionally essential genes to be rendered non-functional. The gene(s) may be rendered non-functional by a partial deletion or a mutation as known in the art;
20 specifically the gene(s) may be rendered non-functional through the use of a "Deletion plasmid(s)" as shown herein in non-limiting examples below. For each of the preferred embodiments relating to the altered chromosomal gene(s) of step b) of the method of the first aspect, the most preferred
25 embodiment is shown by non-limiting examples herein and reference is made to the genetic tools constructed for that purpose, such as the PCR primer sequences used for constructing the "Deletion plasmid(s)".

Accordingly a preferred embodiment of the invention relates to
30 the method of the first aspect, wherein the conditionally essential chromosomal gene(s) of the host cell that is altered encodes a D-alanine racemase, preferably the gene(s) is a *dal* homologue from a *Bacillus* cell, more preferably the gene is

homologous to *dal* from *Bacillus subtilis*, and most preferably the gene(s) is the *dal* gene of *Bacillus licheniformis*.

Another preferred embodiment of the invention relates to the method of the first aspect, wherein the conditionally
5 essential chromosomal gene(s) of the host cell that is altered encodes a D-alanine racemase and is at least 75% identical, preferably 80% identical, or preferably 85% identical, more preferably 90% identical, or more preferably 95% and most preferably at least 97% identical to the *dal* sequence of
10 *Bacillus licheniformis* shown in positions 1303 to 2469 in SEQ ID 12.

The conditionally essential gene(s) may encode polypeptides involved in the utilization of specific carbon sources such as xylose or arabinose, in which case the host
15 cell is unable to grow in a minimal medium supplemented with only that specific carbon source when the gene(s) are non-functional.

A preferred embodiment of the invention relates to the method of the first aspect, wherein the conditionally
20 essential chromosomal gene(s) of the host cell that is altered is one or more genes that are required for the host cell to grow on minimal medium supplemented with only one specific main carbon-source.

A preferred embodiment of the invention relates to the
25 method of the first aspect, wherein the conditionally essential chromosomal gene(s) of the host cell that is altered is of a xylose operon, preferably the gene(s) is homologous to the *xylA* gene from *Bacillus subtilis*, and most preferably the gene(s) is homologous to one or more genes of the xylose
30 isomerase operon of *Bacillus licheniformis*.

A preferred embodiment of the invention relates to the method of the first aspect, wherein the conditionally essential chromosomal gene(s) of the host cell that is altered encodes a galactokinase (EC 2.7.1.6), an UTP-dependent

pyrophosphorylase (EC 2.7.7.10), an UDP-glucose-dependent uridylyltransferase (EC 2.7.7.12), or an UDP-galactose epimerase (EC 5.1.2.3), preferably the gene(s) encodes an UDP-galactose epimerase (EC 5.1.2.3), more preferably the gene(s) is homologous to *galE* of a *Bacillus*, and most preferably the gene is *galE* of *Bacillus licheniformis*.

A preferred embodiment of the invention relates to the method of the first aspect, wherein the conditionally essential chromosomal gene(s) of the host cell that is altered is one or more gene(s) of a gluconate operon, preferably the gene(s) encodes a gluconate kinase (EC 2.7.1.12) or a gluconate permease or both, more preferably the gene(s) is one or more genes homologous to the *gntK* or *gntP* genes from *Bacillus subtilis*, and most preferably the gene(s) is the *gntK* or *gntP* gene from *Bacillus licheniformis*.

Another preferred embodiment of the invention relates to the method of the first aspect, wherein the conditionally essential chromosomal gene(s) of the host cell that is altered is one or more gene(s) of a gluconate operon, preferably the gene(s) encodes a gluconate kinase (EC 2.7.1.12) or a gluconate permease or both and is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to any of the *gntK* and *gntP* sequences of *Bacillus licheniformis*.

Another preferred embodiment of the invention relates to the method of the first aspect, wherein the conditionally essential chromosomal gene(s) of the host cell that is altered is one or more gene(s) of a glycerol operon, preferably the gene(s) encodes a glycerol uptake facilitator (permease), a glycerol kinase, or a glycerol dehydrogenase, more preferably the gene(s) is one or more genes homologous to the *glpP*, *glpF*, *glpK*, and *glpD* genes from *Bacillus subtilis*, and most preferably the gene(s) is one or more genes of *glpP*, *glpF*,

glpK, and *glpD* genes from *Bacillus licheniformis* shown in SEQ ID No:26.

Still another preferred embodiment of the invention relates to the method of the first aspect, wherein the
5 conditionally essential chromosomal gene(s) of the host cell that is altered is one or more gene(s) of a glycerol operon, preferably the gene(s) encodes a glycerol uptake facilitator (permease), a glycerol kinase, or a glycerol dehydrogenase, and is at least 75% identical, preferably 85% identical, more
10 preferably 95% and most preferably at least 97% identical to any of the *glpP*, *glpF*, *glpK*, and *glpD* sequences of *Bacillus licheniformis* shown in SEQ ID No:26.

One preferred embodiment of the invention relates to the method of the first aspect, wherein the conditionally
15 essential chromosomal gene(s) of the host cell that is altered is one or more gene(s) of an arabinose operon, preferably the gene(s) encodes an arabinose isomerase, more preferably the gene(s) is homologous to the *araA* gene from *Bacillus subtilis*, and most preferably the gene(s) is the *araA* gene from *Bacillus*
20 *licheniformis* shown in SEQ ID No:38.

A preferred embodiment of the invention relates to the method of the first aspect, wherein the conditionally
essential chromosomal gene(s) of the host cell that is altered is one or more gene(s) of an arabinose operon, preferably the
25 gene(s) encodes an arabinose isomerase, and is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *araA* sequence of *Bacillus licheniformis* shown in SEQ ID No:38.

Other conditionally essential genes are well-described in
30 the literature, for instance genes that are required for a cell to synthesize one or more amino acids, where a non-functional gene encoding a polypeptide required for synthesis of an amino acid renders the cell auxotrophic for that amino acid, and the cell can only grow if the amino acid is supplied

to the growth medium. Restoration of the functionality of such a gene allows the cell to synthesise the amino acid on its own, and it becomes selectable against a background of auxotrophic cells.

5 Consequently, a preferred embodiment of the invention relates to the method of the first aspect, wherein the conditionally essential chromosomal gene(s) of the host cell encodes one or more polypeptide(s) involved in amino acid synthesis, and the non-functionality of the gene(s) renders
10 the cell auxotrophic for one or more amino acid(s), and wherein restoration of the functionality of the gene(s) renders the cell prototrophic for the amino acid(s).

A particularly preferred embodiment of the invention relates to the method of the first aspect, wherein the
15 conditionally essential chromosomal gene(s) of the host cell encodes one or more polypeptide(s) involved in lysine or methionine synthesis, more preferably the gene(s) is homologous to the *metC* or the *lysA* genes from *Bacillus subtilis*, and most preferably the gene(s) is the *metC* or the
20 *lysA* gene from *Bacillus licheniformis*.

Another particularly preferred embodiment of the invention relates to the method of the first aspect, wherein the conditionally essential chromosomal gene(s) of the host cell is at least 75% identical, preferably 85% identical, more
25 preferably 95% identical and most preferably at least 97% identical to the *metC* sequence of *Bacillus licheniformis* shown in SEQ ID No:42 or the *lysA* sequence of *Bacillus licheniformis* shown in SEQ ID No:48.

As described herein the method of the invention is very
30 relevant for the biotech industry and a number of preferred organisms are very well known in this industry, especially Gram positive host cells, and certainly host cells of the *Bacillus* genus, specifically *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*,

Bacillus clausii, *Bacillus coagulans*, *Bacillus lautus*,
Bacillus lentus, *Bacillus licheniformis*, *Bacillus megaterium*,
Bacillus stearothermophilus, *Bacillus subtilis*, and *Bacillus*
thuringiensis.

5 A preferred embodiment of the invention relates to the
method of the first aspect, wherein the host cell is a Gram-
positive bacterial cell, preferably a *Bacillus* cell, and most
preferably a *Bacillus* cell chosen from the group consisting of
Bacillus alkalophilus, *Bacillus amyloliquefaciens*, *Bacillus*
10 *brevis*, *Bacillus circulans*, *Bacillus clausii*, *Bacillus*
coagulans, *Bacillus lautus*, *Bacillus lentus*, *Bacillus*
licheniformis, *Bacillus megaterium*, *Bacillus*
stearothermophilus, *Bacillus subtilis*, and *Bacillus*
thuringiensis.

15 Another preferred embodiment of the invention relates to
the method of the first aspect, wherein the DNA construct is a
plasmid.

As described elsewhere herein, the present invention
provides genetic tools for carrying out the method of the
20 invention, such as host cells, and DNA constructs of the
invention, such as a DNA construct of the second aspect
comprising:

- i) an altered non-functional copy of a conditionally
essential chromosomal gene(s) from a host cell, preferably
25 the copy is partially deleted; and
- ii) at least one copy of a gene of interest flanked on one
side by i) and on the other side by a DNA fragment
homologous to a host cell DNA sequence located on the host
cell chromosome adjacent to the conditionally essential
30 gene(s) of i).

A preferred embodiment of the invention relates to the
DNA construct of the second aspect, wherein the conditionally
essential chromosomal gene(s) of the host cell that is altered
in i) encodes a D-alanine racemase, preferably the gene(s) is

a *dal* homologue from a *Bacillus* cell, more preferably the gene is homologous to *dal* from *Bacillus subtilis*, and most preferably the gene is the *dal* gene of *Bacillus licheniformis*.

Another preferred embodiment of the invention relates to the DNA construct of the second aspect, wherein the conditionally essential chromosomal gene(s) of the host cell that is altered in i) encodes a D-alanine racemase and is at least 75% identical, preferably 80% identical, or preferably 85% identical, more preferably 90% identical, or more preferably 95% and most preferably at least 97% identical to the *dal* sequence of *Bacillus licheniformis* shown in positions 1303 to 2469 in SEQ ID 12.

Yet another preferred embodiment of the invention relates to the DNA construct of the second aspect, wherein the altered non-functional copy of a conditionally essential chromosomal gene(s) from a host cell is one or more gene(s) that is required for the host cell to grow on minimal medium supplemented with only one specific main carbon-source.

A preferred embodiment of the invention relates to the DNA construct of the second aspect, wherein the conditionally essential chromosomal gene(s) of the host cell that is altered in i) is one or more genes of a xylose operon, preferably the gene(s) is homologous to the *xylA* gene from *Bacillus subtilis*, and most preferably the gene(s) is homologous to one or more genes of the xylose isomerase operon of *Bacillus licheniformis*.

Still another preferred embodiment of the invention relates to the DNA construct of the second aspect, wherein the chromosomal gene(s) of the host cell that is altered in i) encodes a galactokinase (EC 2.7.1.6), an UTP-dependent pyrophosphorylase (EC 2.7.7.10), an UDP-glucose-dependent uridylyltransferase (EC 2.7.7.12), or an UDP-galactose epimerase (EC 5.1.2.3), preferably the gene(s) encodes an UDP-galactose epimerase (EC 5.1.2.3), more preferably the gene(s)

is homologous to the *galE* gene of *Bacillus subtilis*, and most preferably the gene(s) is the *galE* gene of *Bacillus licheniformis*.

One more preferred embodiment of the invention relates to
5 the DNA construct of the second aspect, wherein the
conditionally essential chromosomal gene(s) is one or more
genes of a gluconate operon, preferably the gene(s) encodes a
gluconate kinase (EC 2.7.1.12) or a gluconate permease or
both, more preferably the gene(s) is homologous to the *gntK* or
10 *gntP* genes from *Bacillus subtilis*, and most preferably the
gene(s) is one or more genes of *gntK* and *gntP* from *Bacillus licheniformis*.

Still another preferred embodiment of the invention
relates to the DNA construct of the second aspect, wherein the
15 conditionally essential chromosomal gene(s) is one or more
gene(s) of a glycerol operon, preferably the gene(s) encodes a
glycerol uptake facilitator (permease), a glycerol kinase, or
a glycerol dehydrogenase, more preferably the gene(s) is one
or more genes homologous to the *glpP*, *glpF*, *glpK*, and *glpD*
20 genes from *Bacillus subtilis*, and most preferably the gene(s)
is one or more genes of *glpP*, *glpF*, *glpK*, and *glpD* genes from
Bacillus licheniformis shown in SEQ ID No:26.

A particularly preferred embodiment of the invention
relates to the DNA construct of the second aspect, wherein the
25 conditionally essential chromosomal gene(s) is one or more
gene(s) of a glycerol operon, preferably the gene(s) encodes a
glycerol uptake facilitator (permease), a glycerol kinase, or
a glycerol dehydrogenase, and is at least 75% identical,
preferably 85% identical, more preferably 95% and most
30 preferably at least 97% identical to any of the *glpP*, *glpF*,
glpK, and *glpD* sequences of *Bacillus licheniformis* shown in
SEQ ID No:26.

One more preferred embodiment of the invention relates to
the DNA construct of the second aspect, wherein the

conditionally essential chromosomal gene(s) is one or more gene(s) of an arabinose operon, preferably the gene(s) encodes an arabinose isomerase, more preferably the gene(s) is homologous to the *araA* gene from *Bacillus subtilis*, and most preferably the gene(s) is the *araA* gene from *Bacillus licheniformis* shown in SEQ ID No:38.

A preferred embodiment of the invention relates to the DNA construct of the second aspect, wherein the conditionally essential chromosomal gene(s) is one or more gene(s) of an arabinose operon, preferably the gene(s) encodes an arabinose isomerase, and is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *araA* sequence of *Bacillus licheniformis* shown in SEQ ID No:38.

Yet another preferred embodiment of the invention relates to the DNA construct of the second aspect, wherein the conditionally essential chromosomal gene(s) encodes one or more polypeptide(s) involved in amino acid synthesis, and where and the non-functionality of the gene(s) when present in a cell with no other functional copy(ies) of the gene(s) renders the cell auxotrophic for one or more amino acid(s), and wherein restoration of the functionality of the gene(s) renders the cell prototrophic for the amino acid(s); preferably the conditionally essential chromosomal gene(s) encodes one or more polypeptide(s) involved in lysine or methionine synthesis, more preferably the gene(s) is homologous to the *metC* or the *lysA* genes from *Bacillus subtilis*, and most preferably the gene(s) is the *metC* or the *lysA* gene from *Bacillus licheniformis*. Still more preferably the conditionally essential chromosomal gene(s) is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *metC* sequence of *Bacillus licheniformis* shown in SEQ ID No:42 or

the *lysA* sequence of *Bacillus licheniformis* shown in SEQ ID No:48.

The present invention provides a method for constructing a production host cell that is very useful to the biotech
5 industry, such as a host cell of the third aspect comprising at least two copies of a gene of interest stably integrated into the chromosome, where at least one copy is integrated adjacent to a conditionally essential *locus* and wherein the cell is obtainable by any of the methods defined in the first
10 aspects.

The method of the first aspect describes the integration of a gene of interest into the chromosome of a host cell, so that the gene of interest is integrated in a position that is adjacent to the conditionally essential *locus*. The exact
15 relative positions of the gene of interest and the *locus* are not of major relevance for the method, however generally speaking it is of interest to minimize the distance in basepairs separating the two, both to achieve a more stable integration, but also to minimize the integration of
20 superfluous DNA sequence into the host cell genome.

Accordingly a preferred embodiment of the invention relates to the host cell of the third aspect, wherein the gene of interest is separated from the conditionally essential *locus* by no more than 1000 basepairs, preferably no more than
25 750 basepairs, more preferably no more than 500 basepairs, even more preferably no more than 250 basepairs, and most preferably no more than 100 basepairs.

As mentioned above, it is of interest to minimize the presence of integrated or superfluous DNA sequence in the host
30 cell genome, especially DNA of exogenous origin, and the ideal host cell contains only DNA of endogenous origin such as multiple copies of an endogenous gene of interest integrated in different well defined chromosomal locations.

Consequently a preferred embodiment of the invention relates to the host cell of the third aspect, which contains substantially no exogenous DNA, preferably less than 500 basepairs per integrated gene of interest, more preferably
5 less than 300 bp, even more preferably less than 100 bp, still more preferably less than 50 bp, more preferably less than 25 bp per integrated gene of interest, or most preferably no exogenous DNA.

Another preferred embodiment of the invention relates to
10 the host cell of the third aspect, which contains only endogenous DNA.

Certain bacterial strains are preferred as host cells in the biotech industry as mentioned previously.

A preferred embodiment of the invention relates to the
15 host cell of the third aspect, which is a Gram-positive bacterial cell, preferably a *Bacillus* cell, and most preferably a *Bacillus* cell chosen from the group consisting of *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus clausii*, *Bacillus*
20 *coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*.

Another preferred embodiment of the invention relates to
25 the host cell of the third aspect, wherein a copy of the gene of interest is integrated adjacent to a gene encoding a D-alanine racemase, preferably a gene homologous to the *dal* gene from *Bacillus subtilis*, more preferably a gene at least 75% identical to the *dal* sequence of *Bacillus licheniformis* shown
30 in positions 1303 to 2469 in SEQ ID 12, even more preferably 80% identical, or even more preferably a gene at least 85% identical, still more preferably 90% identical, more preferably at least 95% identical, and most preferably at

least 97% identical to the *dal* sequence of *Bacillus licheniformis* shown in positions 1303 to 2469 in SEQ ID 12.

A particularly preferred embodiment of the invention relates to the host cell of the third aspect, wherein a copy
5 of the gene of interest is integrated adjacent to a gene that is required for the host cell to grow on minimal medium supplemented with only one specific main carbon-source.

Yet another preferred embodiment of the invention relates to the host cell of the third aspect, wherein a copy of the
10 gene of interest is integrated adjacent to a gene of a xylose operon, preferably adjacent to genes homologous to the *xylR* or *xylA* genes from *Bacillus subtilis*, and most preferably adjacent to *xylR* or *xylA* from *Bacillus licheniformis*.

One more preferred embodiment of the invention relates to
15 the host cell of the third aspect, wherein a copy of the gene of interest is integrated adjacent to a gene encoding a galactokinase (EC 2.7.1.6), an UTP-dependent pyrophosphorylase (EC 2.7.7.10), an UDP-glucose-dependent uridylyltransferase (EC 2.7.7.12), or an UDP-galactose epimerase (EC 5.1.2.3),
20 preferably adjacent to a gene encoding an UDP-galactose epimerase (EC 5.1.2.3), more preferably adjacent to a gene homologous to the *galE* gene from *Bacillus subtilis*, and most preferably adjacent to *galE* from *Bacillus licheniformis*.

An additional preferred embodiment of the invention
25 relates to the host cell of the third aspect, wherein a copy of the gene of interest is integrated adjacent to a gene of a gluconate operon, preferably adjacent to a gene that encodes a gluconate kinase (EC 2.7.1.12) or a gluconate permease, more preferably adjacent to a gene homologous to a *Bacillus*
30 *subtilis* gene chosen from the group consisting of *gntR*, *gntK*, *gntP*, and *gntZ*, and most preferably adjacent to *gntR*, *gntK*, *gntP*, or *gntZ* from *Bacillus licheniformis*.

Yet an additional preferred embodiment of the invention relates to the host cell of the third aspect, wherein a copy

of the gene of interest is integrated adjacent to a gene of a glycerol operon, preferably the gene encodes a glycerol uptake facilitator (permease), a glycerol kinase, or a glycerol dehydrogenase, more preferably the gene is homologous to the
5 *glpP*, *glpF*, *glpK*, or *glpD* gene from *Bacillus subtilis*, and most preferably the gene is the *glpP*, *glpF*, *glpK*, or *glpD* gene from *Bacillus licheniformis* shown in SEQ ID No:26.

Another particularly preferred embodiment of the invention relates to the host cell of the third aspect,
10 wherein a copy of the gene of interest is integrated adjacent to a gene of an arabinose operon, preferably the gene encodes an arabinose isomerase, more preferably the gene is homologous to the *araA* gene from *Bacillus subtilis*, and most preferably the gene is the *araA* gene from *Bacillus licheniformis* shown in
15 SEQ ID No:38.

Still a preferred embodiment of the invention relates to the host cell of the third aspect, wherein a copy of the gene of interest is integrated adjacent to a gene which encodes one or more polypeptide(s) involved in amino acid synthesis, and
20 the non-functionality of the gene(s) renders the cell auxotrophic for one or more amino acid(s), and wherein restoration of the functionality of the gene(s) renders the cell prototrophic for the amino acid(s); preferably the gene of interest is integrated adjacent to a gene which encodes one
25 or more polypeptide(s) involved in lysine or methionine synthesis, more preferably the gene(s) is homologous to the *metC* or the *lysA* genes from *Bacillus subtilis*, and most preferably the gene(s) is the *metC* or the *lysA* gene from *Bacillus licheniformis*. Also preferably the gene of interest
30 is integrated adjacent to a gene which is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *metC* sequence of *Bacillus licheniformis* shown in SEQ ID No:42 or the *lysA* sequence of *Bacillus licheniformis* shown in SEQ ID No:48.

The host cell of the third aspect is especially interesting for the industrial production of polypeptides such as enzymes.

A preferred embodiment of the invention relates to the host
5 cell of the third aspect, wherein the gene of interest encodes an enzyme, preferably an amylolytic enzyme, a lipolytic enzyme, a proteolytic enzyme, a cellulolytic enzyme, an oxidoreductase or a plant cell-wall degrading enzyme, and more preferably an enzyme selected from the group consisting of
10 aminopeptidase, amylase, amyloglucosidase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, galactosidase, beta-galactosidase, glucoamylase, glucose oxidase, glucosidase, haloperoxidase, hemicellulase,
15 invertase, isomerase, laccase, ligase, lipase, lyase, mannosidase, oxidase, pectinase, peroxidase, phytase, phenoloxidase, polyphenoloxidase, protease, ribonuclease, transferase, transglutaminase, or xylanase. Also preferably the gene of interest encodes an antimicrobial peptide,
20 preferably an anti-fungal peptide or an anti-bacterial peptide; or the gene of interest encodes a peptide with biological activity in the human body, preferably a pharmaceutically active peptide, more preferably insulin/pro-insulin/pre-pro-insulin or variants thereof, growth hormone or
25 variants thereof, or blood clotting factor VII or VIII or variants thereof.

A further preferred embodiment of the invention relates to the host cell of the third aspect, wherein no antibiotic markers are present.

30 The present invention teaches the construction of host cells that are suitable for use in the method of the first aspect, especially host cells wherein one, two or more conditionally essential genes are rendered non-functional. In non-limiting examples below is shown how the preferred

conditionally essential genes of the invention are rendered non-functional through a partial deletion by using specific Deletion Plasmids of the invention. Specifically the present invention relates to a *Bacillus* cell of the fourth aspect,
5 which is preferably a *Bacillus licheniformis* cell, wherein at least two conditionally essential genes are rendered non-functional, preferably the genes are chosen from the group consisting of *xylA*, *galE*, *gntK*, *gntP*, *glpP*, *glpF*, *glpK*, *glpD*, *araA*, *metC*, *lysA*, and *dal*.

10 The use of such a host cell of the third aspect is likewise envisioned in the method of the first aspect.

Another genetic tool provided by the present invention for the method of the first aspect, is a host cell comprising a DNA construct of the second aspect.

15 A final aspect of the invention relatest to a process for producing an enzyme of interest, comprising cultivating a cell of the third aspect under conditions appropriate for producing the enzyme, and optionally purifying the enzyme.

20

Examples

Example 1

Bacillus licheniformis SJ4671 (WO 99/41358) comprises two
25 stably integrated *amyL* gene copies in its chromosome, inserted in opposite relative orientations in the region of the *B. licheniformis* alpha-amylase gene, *amyL*. The following example describes the insertion into this strain of a third *amyL* gene copy by selectable, directed integration into another defined
30 region of the *B. licheniformis* chromosome resulting in a strain comprising three stable chromosomal copies of the *amyL* gene but which is devoid of foreign DNA.

Xylose isomerase deletion/integration outline (Figure 1)

The sequence of the *Bacillus licheniformis* xylose isomerase region is available in GenBank/EMBL with accession number Z80222.

A plasmid denoted "Deletion plasmid" was constructed by
5 cloning two PCR amplified fragments from the xylose isomerase region on a temperature-sensitive parent plasmid. The PCR fragments were denoted "A" and "B", wherein A comprises the *xylR* promoter and part of the *xylR* gene; and B comprises an internal fragment of *xylA* missing the promoter and the first
10 70 basepairs of the gene. A spectinomycin resistance gene flanked by resolvase (*res*) sites was introduced between fragments A and B on the plasmid. This spectinomycin resistance gene could later be removed by resolvase-mediated site-specific recombination.

15 The xylose isomerase deletion was transferred from the Deletion plasmid to the chromosome of a *Bacillus* target strain by double homologous recombination via fragments A and B, mediated by integration and excision of the temperature-sensitive plasmid. The resulting strain was denoted "Deletion
20 strain". This strain is unable to grow on minimal media with xylose as sole carbon source.

An "Integration plasmid" was constructed for insertion of genes into the xylose isomerase region of the Deletion strain. We intended to PCR-amplify a fragment denoted "C" comprising
25 the *xylA* promoter and about 1 kb of the *xylA* gene. However, as later described, only a smaller fragment denoted "D" comprising the *xylA* promoter and the first 250 basepairs of the *xylA* gene was successfully amplified and cloned. The Integration plasmid comprises fragments A and D on a
30 temperature-sensitive vector. An expression cassette was also cloned in the Integration plasmid between fragments A and D.

The temperature-sensitive Integration plasmid was transferred to the *B. licheniformis* Deletion strain and it integrated in the chromosome; subsequent excision of the

temperature sensitive vector was ensured, and "Integration strains" could then be isolated which grow on minimal media with xylose as sole carbon source. Such Integration strains have restored the chromosomal *xylA* gene, by double homologous recombination via fragments A and D. In this process, the expression cassette has been integrated into the chromosome.

Plasmid constructs

PCR amplifications were performed with Ready-To-Go PCR Beads from amersham pharmacia biotech as described in the manufacturers instructions, using an annealing temperature of 55°C.

Plasmids pSJ5128 and pSJ5129:

The A fragment (*xylR* promoter and part of the *xylR* gene) was amplified from *Bacillus licheniformis* PL1980 chromosomal DNA using primers:

#183235; [*Hind*III ←Z80222 1242-1261→] (SEQ ID 1):

5'-GACTAAGCTTCTGCATAGTGAGAGAAGACG

#183234: [*Eco*RI; *Bgl*III; *Not*I; *Mlu*I; *Sal*I; *Sca*I ←Z80222 2137-2113→] (SEQ ID 2):

5'-

GACTGAATTCAGATCTGCGGCCGCACGCGTGTCTGACAGTACTGAAATAGAGGAAAAATAAG
TTTTC

The PCR fragment was digested with *Eco*RI and *Hind*III and purified, then ligated to *Eco*RI and *Hind*III digested pUC19. The ligation mixture was transformed by electroporation into *E. coli* SJ2, and transformants were selected for ampicillin resistance (200 µg/ml). The PCR-fragments of three such ampicillin resistant transformants were sequenced and all were

found to be correct. Two clones designated SJ5128 (SJ2/pSJ5128) and SJ5129 (SJ2/pSJ5129) were kept.

Plasmids pSJ5124, pSJ5125:

5 The B fragment (an internal part of *xylA*, missing the promoter and the first 70 basepairs of the coding region), was amplified from *B. licheniformis* PL1980 chromosomal DNA using primers:

10 #183230 [*EcoRI* ←Z80222 3328-3306→] (SEQ ID 3):

5'-GACTGAATTCCGTATCCATTCCTGCGATATGAG

#183227 [*BamHI*; *BglIII* ←Z80222 2318-2342→] (SEQ ID 4):

5'-GACTGGATCCAGATCTTATTACAACCCTGATGAATTTGTCG

15

The PCR fragment was digested with *EcoRI* and *BamHI*, and purified, then ligated to *EcoRI* + *BamHI* digested pUC19 and transformed by electroporation into *E. coli* SJ2. Transformants were selected for ampicillin resistance (200 µg/ml). Two clones were correct as confirmed by DNA sequencing, and were kept as SJ5124 (SJ2/pSJ5124) and SJ5125 (SJ2/pSJ5125).

Plasmid pSJ5130:

25 The C fragment (comprising the *xylA* promoter and about 1 kb of the *xylA* gene) was PCR amplified from *B. licheniformis* PL1980 chromosomal DNA using primers:

#183230 (see above, SEQ ID 3)

30 #183229 [*BamHI*; *BglIII*; *NheI*; *ClaI*; *SacII* ←Z80222 2131-2156→] (SEQ ID 5):

5'-

GACTGGATCCAGATCTGCTAGCATCGATCCGCGGCTATTTCCATTGAAAGCGATTAATTG

The PCR fragment was digested with *EcoRI* and *BamHI* and purified, then ligated to *EcoRI* and *BamHI* digested pUC19 and transformed by electroporation, into *E. coli* SJ2.

5 Transformants were selected for ampicillin resistance (200 $\mu\text{g/ml}$). One clone, comprising the full-length PCR fragment, was found to have a single basepair deletion in the promoter region, between the -35 and -10 sequences. This transformant was kept as SJ5130 (SJ2/pSJ5130).

10

Plasmid pSJ5131:

This plasmid was constructed as pSJ5130, above, but turned out to contain a 400 basepair PCR fragment only (the D fragment), comprising the *xylA* promoter and the first 250
15 basepairs of the *xylA* coding sequence. DNA sequencing confirmed that the no sequence errors were present in the fragment. The transformant was kept as SJ5131 (SJ2/pSJ5131).

Plasmids pSJ5197, pSJ5198:

20 These plasmids comprise the A (*xylR*) fragment on a temperature-sensitive, mobilizable vector. They were constructed by ligating the 0.9 kb *BglIII-HindIII* fragment from pSJ5129 to the 5.4 kb *BglIII-HindIII* fragment from pSJ2739, and transforming *B. subtilis* DN1885 competent cells with the
25 ligation mix followed by selecting for erythromycin resistance (5 $\mu\text{g/ml}$). Two clones were kept, SJ5197 (DN1885/pSJ5197) and SJ5198 (DN1885/pSJ5198).

Plasmids pSJ5211, pSJ5212:

30 These plasmids contain a *res-spc-res* cassette inserted next to the B fragment. They were constructed by ligating the 1.5 kb *BclI-BamHI* fragment from pSJ3358 into the *BglIII* site of pSJ5124, and transforming the ligation mix into *E. coli* SJ2 and selecting for ampicillin resistance (200 $\mu\text{g/ml}$) and

spectinomycin resistance (120 µg/ml) resistance. Two clones were kept, wherein the *res-spc-res* cassette was inserted in either of the possible orientations, SJ5211 (SJ2/pSJ5211) and SJ5212 (SJ2/pSJ5212).

5

The Deletion plasmid

Plasmid pSJ5218:

This plasmid contains the *res-spc-res* cassette flanked by the A and B fragments. It was constructed by ligating the 2.5 kb *EcoRI-BamHI* fragment from pSJ5211 to the 5.3 kb *EcoRI-BglIII* fragment from pSJ5197, and transforming the ligation mix into *B. subtilis* DN1885 and selecting for erythromycin (5 µg/ml) and spectinomycin resistance (120 µg/ml) resistance at 30°C. One transformant, SJ5218 (DN1885/pSJ5218) was kept.

15

The Integration plasmids

Plasmids pSJ5247, pSJ5248:

These plasmids comprise the short 400 basepairs D fragment (*PxylA-xylA*) as well as the A fragment (*xylR*) on a temperature-sensitive, mobilizable vector. They were made by ligating the 0.4 kb *BglIII-EcoRI* fragment from pSJ5131 to the 5.3 kb *BglIII-EcoRI* fragment from pSJ5197, and transforming the ligation mix into *B. subtilis* DN1885 and selecting for erythromycin resistance (5 µg/ml) at 30°C. Two transformants, SJ5247 (DN1885/pSJ5247) and SJ5248 (DN1885/pSJ5248) were kept.

Construction of strains with chromosomal *xylA* deletions.

The deletion plasmid pSJ5218 was transformed into competent cells of the *B. subtilis* conjugation donor strain PP289-5 (which contains a chromosomal *dal*-deletion, and plasmids pBC16 and pLS20), transformants were selected for resistance to spectinomycin (120 µg/ml), erythromycin (5 µg/ml) and tetracycline (5 µg/ml) on plates with D-alanine

(100 $\mu\text{g/ml}$) at 30°C. Two transformants were kept, SJ5219 and SJ5220.

The two-copy *B. licheniformis* alpha-amylase strain SJ4671, described in WO 99/41358 was used as recipient in 5 conjugations.

Donor strains SJ5219 and SJ5220 were grown overnight at 30°C on LBPSG plates (LB plates with phosphate (0.01 M K_3PO_4), glucose (0.4 %), and starch (0.5 %)) supplemented with D-alanine (100 $\mu\text{g/ml}$), spectinomycin (120 $\mu\text{g/ml}$), erythromycin 10 (5 $\mu\text{g/ml}$) and tetracycline (5 $\mu\text{g/ml}$). The recipient strain was grown overnight on LBPSG plates.

An inoculation needle loopful of donor and recipient were mixed on the surface of a LBPSG plate with D-alanine (100 $\mu\text{g/ml}$), and incubated at 30°C for 5 hours. This plate was then 15 replicated onto LBPSG with erythromycin (5 $\mu\text{g/ml}$) and spectinomycin (120 $\mu\text{g/ml}$), and incubation was at 30°C for 2 days. These four conjugations resulted in between 13 and 25 transconjugants.

Tetracycline-sensitive (indicating absence of pBC16) 20 transconjugants were reisolated on LBPSG with erythromycin (5 $\mu\text{g/ml}$) and spectinomycin (120 $\mu\text{g/ml}$) at 50°C, incubated overnight, and single colonies from the 50°C plates were inoculated into 10 ml TY liquid cultures and incubated with shaking at 26°C for 3 days. Aliquots were then transferred into 25 fresh 10 ml TY cultures and incubation proceeded overnight at 30°C. The cultures were plated on LBPSG with 120 $\mu\text{g/ml}$ spectinomycin, after overnight incubation at 30°C these plates were replica plated onto spectinomycin and erythromycin, respectively, and erythromycin sensitive, spectinomycin 30 resistant isolates were obtained from all strain conjugations.

The following strains, containing the chromosomal *xylA* promoter and the first 70 basepairs of the *xylA* coding sequence replaced by the *res-spc-res* cassette, were kept:

SJ5231: SJ4671 recipient, SJ5219 donor.

SJ5232: SJ4671 recipient, SJ5220 donor.

Strain phenotypes were assayed on TSS minimal medium agar plates, prepared as follows. 400 ml H₂O and 10 g agar is autoclaved at 121°C for 20 minutes, and allowed to cool to 60°C. The following sterile solutions are added:

1 M Tris pH 7.5	25 ml
10 2 % FeCl ₃ .6H ₂ O	1 ml
2 % trisodium citrate dihydrate	1 ml
1 M K ₂ HPO ₄	1.25 ml
10 % MgSO ₄ .7H ₂ O	1 ml
10 % glutamine	10 ml; and
15 20 % glucose	12.5 ml; or
15 % xylose	16.7 ml

Bacillus licheniformis SJ4671 grows well on both glucose and xylose TSS plates, forming brownish coloured colonies.

20 The *xylA* deletion strains SJ5231-SJ5232 grow well on glucose TSS plates, but only a very thin, transparent growth is formed on the TSS xylose plates, even after prolonged incubation. These strains are clearly unable to use xylose as the sole carbon source.

25

Directed and selectable integration into the *xyl* region.

Integration plasmid pSJ5247 (containing the D and A fragments), and as a negative control pSJ5198 (containing only the A fragment) were transformed into competent cells of the *B. subtilis* conjugation donor strain PP289-5 (which contains a chromosomal *dal*-deletion, and plasmids pBC16 and pLS20), transformants were selected for resistance to erythromycin (5

$\mu\text{g/ml}$) and tetracycline ($5 \mu\text{g/ml}$) on plates with D-alanine ($100 \mu\text{g/ml}$) at 30°C .

Transformants kept were:

- 5 SJ5255: PP289-5/pSJ5198.
- SJ5257: PP289-5/pSJ5248.

Donor strains SJ5255 and SJ5257 were used in conjugations to recipient SJ5231. Selection of transconjugants was on
10 erythromycin ($5 \mu\text{g/ml}$), at 30°C . Transconjugants were streaked on TSS plates with xylose, at 50°C . In parallel, SJ5221 was streaked as a xylose isomerase positive control strain (also at 50°C).

After overnight incubation, all strains had formed a very
15 thin, transparent growth. The control, however, was better growing and colonies were brownish.

After another day of incubation at 50°C , some brownish colonies were coming up on the background of thin, transparent growth, in transconjugants derived from SJ5257, i.e. the
20 strain containing the Integration plasmid with the *PxylA-xylA* fragment (D). These colonies were steadily growing, and further colonies were coming up, during subsequent days of continued incubation at 50°C .

No brownish colonies (and no further growth than the
25 thin, transparent growth seen after the first overnight incubation) were observed from transconjugants derived from SJ5255 (the negative control, unable to restore the chromosomal *xylA* gene).

30 Directed integration of an alpha-amylase gene into the *xyl* region.

Construction of an *amyL* containing integration plasmid

Plasmids pSJ5291 and pSJ5292 were constructed from the integration vector plasmid pSJ5247 by digestion of this

plasmid with *Bgl*III, and insertion of the 1.9 kb *amy*L containing *Bgl*III-*Bcl*I fragment from pSJ4457 (described in WO 99/41358). The ligation mixture was transformed into *B. subtilis* DN1885 and two transformants were kept as SJ5291 and 5 SJ5292.

Construction of conjugative donor strains, transfer to *B. licheniformis* hosts, and chromosomal integration

Plasmids pSJ5291 and pSJ5292 were transformed into 10 competent cells of the *B. subtilis* conjugation donor strain PP289-5 (which contains a chromosomal *dal*-deletion, and plasmids pBC16 and pLS20), transformants were selected for resistance to erythromycin (5 µg/ml) and tetracycline (5 µg/ml) on plates with D-alanine (100 µg/ml) at 30°C.

15 Transformants kept were SJ5293 (PP289-5/pSJ5291) and SJ5294 (PP289-5/pSJ5292). These two strains were used as donors in conjugations to xylose isomerase deletion strains SJ5231 and SJ5232. Transconjugants were selected on LBPGA plates with erythromycin (5 µg/ml), and one or two 20 tetracyclin-sensitive transconjugants from each conjugation were streaked on a TSS-xylose plate which was incubated at 50°C. After two days incubation, well-growing colonies were inoculated into liquid TY medium (10 ml) without antibiotics, and these cultures were incubated with shaking at 30°C. After 25 overnight incubation, 100 µl from each culture were transferred into new 10 ml TY cultures, and incubation repeated. This procedure was repeated another two times, and in addition the cultures were plated on TSS-xylose plates at 30°C. After about a week, all plates were replicaplated onto 30 TSS-xylose as well as LBPSG with erythromycin (5 µg/ml). The following day, putative Em-sensitive strains were restreaked on the same plate types.

The following Em sensitive strains, which all grow well on TSS-xylose plates, were kept:

SJ5308 (from conjugation donor SJ5293, host SJ5231)
SJ5309 (from conjugation donor SJ5293, host SJ5231)
SJ5310 (from conjugation donor SJ5293, host SJ5232)
5 SJ5315 (from conjugation donor SJ5294, host SJ5231)

Southern analysis.

The two-copy *amyL* strain SJ4671, and strains SJ5308, SJ5309, SJ5310 and SJ5315, were grown overnight in TY-glucose, and chromosomal DNA was extracted. The chromosomal DNA was digested with *Hind*III, fragments separated by agarose gel electrophoresis, transferred to Immobilon-N[®] filters (Millipore[®]) and hybridised to a biotinylated probe based on *Hind*III digested pSJ5292 (using NEBlot Photope Kit and Photope Detection Kit 6K).

In the two-copy strain, the two *amyL* gene copies reside on a ~10 kb *Hind*III fragment. In addition, an ~2.8 kb fragment is hybridizing, which is due to hybridization to the *xyl* region. In the four strains with insertions of a third *amyL* gene into the xylose gene region, the ~2.8 kb fragment is missing and has been replaced by a fragment of ~4.6 kb. This is entirely as expected upon integration of the *amyL* gene into the xylose gene region. The ~10 kb fragment due to the two-copy insertion is retained.

25 In conclusion, the southern analysis shows that strains SJ5308, SJ5309, SJ5310 and SJ5315 have a correctly inserted third *amyL* gene copy in their chromosome.

Shake flask evaluation.

30 Strains with the *amyL* gene integrated in the xylose isomerase region, as well as several control strains, were inoculated into 100 ml BPX medium in shake flasks and incubated at 37°C with shaking at 300 rpm for 7 days.

Alpha-amylase activity in the culture broth was determined by the Phadebas assay:

		Relative alpha-
5 amylase		
Strain		Units/ml
SJ4270 (one copy <i>amyL</i> strain)		100
SJ4671 (two copy <i>amyL</i> strain)		161
10 SJ5231 (two copy <i>amyL</i> strain with <i>xylA</i> gene deletion)		148
SJ5308 (three-copy <i>amyL</i> strain)		200
SJ5309 (three-copy <i>amyL</i> strain)		245
15 SJ5310 (three-copy <i>amyL</i> strain)		200
SJ5315 (three-copy <i>amyL</i> strain)		200

20

Aliquots from each shake flask were plated on amylase indicator plates. All colonies were amylase positive. Four single colonies from each of SJ4671, SJ5309 and SJ5315 were inoculated into fresh BPX shake flasks, which were cultured as above. Alpha-amylase activity in the culture broth was determined by the Phadebas assay:

		Relative alpha-amylase
Strain		Units/ml
30 SJ4671 (two copy <i>amyL</i> 1 strain)		100
SJ4671		102
SJ4671		88
SJ4671		84

	SJ5309 (three-copy <i>amyL</i> strain)	149
	SJ5309	141
	SJ5309	135
	SJ5309	149
5	SJ5315 (three-copy <i>amyL</i> strain)	135
	SJ5315	147
	SJ5315	159
	SJ5315	153

10 Under these shake flask conditions, the three copy *amyL* strains (bold) seem to produce about 50% more alpha-amylase than the two-copy strain.

15 Example 2

A strain of *Bacillus licheniformis* having two stably integrated *amyL* gene copies in its chromosome, inserted in opposite relative orientations in the region of the *B. licheniformis* alpha-amylase gene, *amyL*, has been described in
 20 WO 99/41358, as SJ4671. A third copy of the *amyL* gene was inserted in *xylRA* as described above

This describes the insertion into this three-copy strain of a fourth *amyL* gene copy by selectable, directed integration into another region of the *B. licheniformis* chromosome.

25

Gluconat deletion/integration outline (Figure 2)

The sequence region of the *Bacillus licheniformis* gluconate operon comprising the *gntR*, *gntK*, *gntP*, *gntZ* genes for utilization of gluconate is available in Genbank/EMBL with
 30 accession number D31631. The region can be schematically drawn as shown in figure 2.

A deletion was introduced by cloning, on a temperature-sensitive plasmid, the PCR amplified fragments denoted as "A" (containing part of the *gntK* and part of the *gntP* gene) and

"B" (containing an internal fragment of *gntZ*). As a help in the selection of deletion strains, a kanamycine resistance gene flanked by resolvase sites was introduced between fragments "A" and "B", resulting in the plasmid denoted
5 "Deletion plasmid" in figure 2. This kanamycine resistance gene could later be removed by resolvase-mediated site-specific recombination, as described in WO 96/23073.

The deletion was transferred to the chromosome of target strains by double homologous recombination via fragments "A"
10 and "B", mediated by integration and excision of the temperature-sensitive plasmid. The result was the strain, labelled "Deletion strain" in figure 2. This strain is unable to grow on minimal media with gluconate as sole carbon source.

15 **Plasmid constructs**

To construct an Integration plasmid to be used for gene insertions, the PCR fragment "C" was amplified. This fragment contained an internal fragment of *gntP* of about 1 Kb. The Integration plasmid consists of fragments "B" and "C" on a
20 temperature-sensitive vector. The expression cassette destined for integration is cloned between "B" and "C". Upon transfer to the *B. licheniformis* Deletion strain and integration and excision of the temperature-sensitive vector, strains could be isolated which grew on minimal media with gluconate as sole
25 carbon source. Such strains had restored the chromosomal *gntP* gene by double homologous recombination via fragments "B" and "C". In this process, the expression cassette was integrated into the chromosome resulting in the "Integration strain" of figure 2.

30 PCR amplifications were performed with Ready-To-Go PCR Beads from amersham pharmacia biotech as described in the manufacturers instructions, using an annealing temperature of 55°C.

The Deletion Plasmids pMOL1789 and pMOL1790:

The "B" fragment (containing the internal part of the *gntZ*) was amplified from chromosomal DNA from *Bacillus licheniformis* using primers

5

#187338 [AvaI ←D31631 4903-4922→] (SEQ ID 6):

5'-TATTTCCCGAGATTCTGTTATCGACTCGCTC

#187339 [EagI ←D31631 5553-5538→] (SEQ ID 7):

10 5'-GTTTTCGGCCGCTGTCCGTTCGTCTTT

The fragment was digested with AvaI + EagI, ligated to AvaI + EagI digested pMOL1642, and the ligated plasmid was introduced, by transformation, into *B. subtilis* JA578 selecting for erythromycin resistance (5 µg/ml). The insert on three clones was sequenced, and all found to be correct. MOL1789 (JA578 (*repF*⁺)/pMOL1789) and MOL1790 (JA578/pMOL1790) were kept. The endpoint of the "B" fragment relative to *gntZ* is shown in fig. 2.

20

Plasmids pMOL1820 and pMOL1821:

The "A" fragment (containing part of the *gntK* and part of the *gntP* gene), was amplified from chromosomal DNA of *Bacillus licheniformis* using primers

25

#184733 [←D31631 3738-3712→] (SEQ ID 8):

5'-GTGTGACGGATAAGGCCCGTCATTG

#184788 [←D31631 3041-3068→] (SEQ ID 9):

30 5'-CTCTTGTCCTCGGAGCCTGCATTTTGGGG

The fragment was digested with ClaI + EcoRI, ligated to EcoRI + ClaI digested pMOL1789, and transformed, by

transformation, into *B. subtilis* PL1801 selecting for erythromycin resistance (5 µg/ml). The insert on three clones was sequenced, and all found to be correct. MOL1820 (JA578/pMOL1820) and MOL1821 (JA578/pMOL1821) were kept. The
5 endpoint of the "A" fragment relative to *gntZ* is shown in fig. 2.

The Integration plasmids pMOL1912 and pMOL1913:

These plasmids contain a short C-terminal part of *gntK*
10 and the entire open reading frame of *gntP* (the "C" fragment) on a temperature-sensitive, mobilizable vector. They were made by ligating a 0.9 kb fragment amplified from chromosomal DNA of *Bacillus licheniformis* using primers:

15 #B1656D07 [←D31631 3617-3642→] (SEQ ID 10):

5'-AGCATTATTCTTCGAAGTCGCATTGG

#B1659F03 [*Bgl*III←D31631 4637-4602→] (SEQ ID 11):

5'-TTAAGATCTTTTTTATACAAATAGGCTTAACAATAAAGTAAATCC

20

The fragment was digested with *Bgl*III + *Eco*RI, ligated to *Bgl*III + *Eco*RI digested pMOL1820, and the ligation mixture transformed, by transformation, into *B. subtilis* PL1801 selecting for erythromycin resistance (5 µg/ml). The insert on
25 three clones was sequenced, and all found to be correct. MOL1912 (PL1801/pMOL1789) and MOL1913 (PL1801/pMOL1913) were kept. The endpoint of the "C" fragment relative to *gntZ* is shown in fig. 2.

These plasmids were found to express functional GntP even
30 if they do not have a promoter sequence directly upstream of the *gntP* gene. In order to enable directed integration in the *gntP* region by selecting for growth on gluconate it was

necessary to delete part of the N- terminal sequence of the *gntP* gene on the integration plasmid pMOL1912.

Plasmids pMOL1972 and pMOL1973:

5 These plasmids are Deletion derivatives of pMOL1912 which contain the entire *gntP* gene except for the first 158 bp coding for 53 amino acids of the N-terminal. The plasmid pMOL1912 was digested with *StuI* + *EcoRV* and re-ligated. The ligation mixture was transformed, by competence, into *B. subtilis* PL1801 selecting for erythromycin resistance (5 $\mu\text{g/ml}$). The deletion was verified by restriction digest. MOL1972 (PL1801/pMOL1972) and MOL1973 (PL1801/pMOL1973) were kept.

15 These plasmids do not support growth on TSS gluconate plates when introduced as free plasmids in a *gntP* deleted background.

Construction of strains with chromosomal *gntP* deletions

20 The Deletion plasmid pMOL1920 was transformed into competent cells of the *B. subtilis* conjugation donor strain PP289-5 (which contains a chromosomal *dal*-deletion, and plasmids pBC16 and pLS20), selecting resistance to kanamycine (10 $\mu\text{g/ml}$), erythromycin (5 $\mu\text{g/ml}$) and tetracycline (5 $\mu\text{g/ml}$) on plates with D-alanine (100 $\mu\text{g/ml}$) at 30°C. Two transformants 25 were kept, MOL1822 and MOL1823.

 The two-copy *B. licheniformis* alpha-amylase strain SJ4671, described in WO 99/41358 was used as recipient in conjugations.

30 Donor strains MOL1822 and MOL1823 were grown overnight at 30°C on LBPSG plates (LB plates with phosphate (0.01 M K_3PO_4), glucose (0.4 %), and starch (0.5 %)) supplemented with D-alanine (100 $\mu\text{g/ml}$), kanamycine (10 $\mu\text{g/ml}$), erythromycin (5 $\mu\text{g/ml}$) and tetracycline (5 $\mu\text{g/ml}$). The recipient strain was grown overnight on LBPSG plates.

A loopful of donor and recipient were mixed on the surface of a LBPSG plate with D-alanine (100 $\mu\text{g/ml}$), and incubated at 30°C for 5 hours. This plate was then replicated onto LBPSG with erythromycin (5 $\mu\text{g/ml}$) and kanamycine (10 $\mu\text{g/ml}$), and 5 incubation was at 30°C for 2 days. These four conjugations resulted in between 25 and 50 transconjugants.

Tetracycline-sensitive (indicating absence of pBC16) transconjugants were reisolated on LBPSG with erythromycin (5 $\mu\text{g/ml}$) and kanamycine (10 $\mu\text{g/ml}$) at 50°C, incubated overnight, 10 and single colonies from the 50°C plates were inoculated into 10 ml TY liquid cultures and incubated with shaking at 26°C for 3 days, then aliquots were transferred into fresh 10 ml TY cultures and incubation continued overnight at 30°C. The cultures were then plated on LBPSG with 10 $\mu\text{g/ml}$ kanamycine, 15 after overnight incubation at 30°C these plates were replica plated onto kanamycine and erythromycin, respectively, and erythromycin sensitive, kanamycine resistant isolates were obtained from all strain combinations. The following strains, where part of the *gntP* gene coding for the C-terminal was 20 replaced by the *res-kana-res* cassette, were kept:

MOL1871: SJ4671 recipient, MOL1822 donor.

MOL1872: SJ4671 recipient, MOL1823 donor.

25 Strain phenotypes were assayed on TSS minimal medium agar plates, prepared as follows:

400 ml H₂O is added 10 g agar and is autoclaved at 121°C for 20 minutes, and allowed to cool to 60°C. The following sterile solutions are added:

30

1 M Tris pH 7.5	25 ml
2 % FeCl ₃ .6H ₂ O	1 ml
2 % trisodium citrate dihydrate	1 ml
1 M K ₂ HPO ₄	1.25 ml

57

10 % MgSO ₄ .7H ₂ O	1 ml
10 % glutamine	10 ml, and
20 % glucose	12.5 ml, or
15 % gluconate	16.7 ml

5

Bacillus licheniformis SJ4671 grows well on both glucose and gluconate TSS plates, forming brownish coloured colonies. The *gntP* Deletion strains MOL1871 and MOL1872 grow well on glucose TSS plates, but only a very thin, transparent growth is formed on the TSS gluconate plates, even after prolonged incubation. These strains are clearly unable to use gluconate as the sole carbon source.

The same *gntP* deletion procedure is performed on the three copy strain SJ5309 described earlier to prepare for integration of a fourth copy of the amylase expression cassette.

Directed and selectable integration into the *gnt* region

Integration plasmid pMOL1972 (containing the "B" and "C" fragments), and as a negative control pMOL1789 (containing only the "B" fragment), were transformed into competent cells of the *B. subtilis* conjugation donor strain PP289-5 (which contains a chromosomal *dal*-deletion, and plasmids pBC16 and pLS20), selecting resistance to erythromycin (5 µg/ml) and tetracycline (5 µg/ml) on plates with D-alanine (100 µg/ml) at 30°C. Transformants kept were:

MOL1974: PP289-5/pMOL1972.

MOL1975: PP289-5/pMOL1973.

30

Donor strains MOL1974 and MOL1975 were used in conjugations to recipient MOL1871 and MOL1872. Selection of transconjugants was on erythromycin (5 µg/ml), at 30°C. Transconjugants were streaked on TSS plates with gluconate, at

50°C. In parallel, SJ4671 was streaked as a gluconate positive control strain (also at 50°C).

After overnight incubation, all strains had formed a very thin, transparent growth. The control, however, was better
5 growing and colonies were brownish. After another day of incubation at 50°C, some brownish colonies were coming up on the background of thin, transparent growth, in transconjugants derived from MOL1871 and MOL1872. These colonies were steadily growing, and further colonies appeared, during subsequent days
10 of continued incubation at 50°C.

No colonies were observed from the *gntP* deleted strains MOL1871 and MOL1872.

15 **Directed integration of an alpha-amylase gene into the *gnt* region**

Construction of an *amyL* containing Integration plasmid.

The following is a construction plan for integrating an expression cassette with the alpha-amylase gene in the *gnt* region making use of the selection principle described above.
20 The integration plasmid pMOL1972 is digested with *Bgl*II, and a 1.9 kb *Bgl*III-*Bcl*I fragment containing *amyL* from pSJ4457 (described in WO 99/41358) is inserted by ligation. The ligation mixture is then transformed into *B. subtilis* DN1885 and transformants selected on LBPSG plates with erythromycin
25 (5 µg/ml) are verified by restriction digestion of plasmid DNA.

Conjugative donor strains, transfer to *B. licheniformis*, and chromosomal integration.

30 The Integration plasmid with the expression cassette is transformed into competent cells of the *B. subtilis* conjugation donor strain PP289-5 (which contains a chromosomal *dal*-deletion, and plasmids pBC16 and pLS20), selecting

resistance to erythromycin (5 $\mu\text{g/ml}$) and tetracycline (5 $\mu\text{g/ml}$) on plates with D-alanine (100 $\mu\text{g/ml}$) at 30°C.

Transformants comprising the Integration plasmid with the expression cassette are preserved and used as donors in
5 conjugations with a *gntP* Deletion recipient of the three-copy strain SJ5309, which in turn was constructed as described for the Deletion strains MOL1871 and MOL1872 described above.

Transconjugants are selected on LBPGA plates with erythromycin (5 $\mu\text{g/ml}$), and one or two tetracyclin-sensitive
10 transconjugants from each conjugation is streaked on a TSS-gluconate plate which is incubated at 50°C. After two days incubation, well-growing colonies are inoculated into liquid TY medium (10 ml) without antibiotics, and these cultures are incubated with shaking at 30°C. After overnight incubation, 100
15 μl from each culture is transferred into new 10 ml TY cultures, and incubated. This procedure is repeated twice, and in addition the cultures are plated on TSS-gluconate plates at 30°C.

After about a week, all plates are replica-plated onto
20 TSS-gluconate as well as LBPSG with erythromycin (5 $\mu\text{g/ml}$) and incubated. The following day putative Em-sensitive strains are restreaked on the same plate types

As for integration in the xylose region described earlier, Southern analysis and shake flask evaluation is
25 performed to verify the site of integration in the *gnt* region of the alpha-amylase expression cassette and the increased yield from this four copy strain.

Example 3

30 *Bacillus licheniformis* SJ4671 (WO 99/41358) comprises two stably integrated *amyL* gene copies in its chromosome, inserted in opposite relative orientations in the region of the *B. licheniformis* alpha-amylase gene, *amyL*. The following example describes the insertion into this strain of a third *amyL* gene

copy by selectable, directed integration into another region of the *B. licheniformis* chromosome.

D-alanine racemase deletion/integration outline

- 5 The DNA sequence of the *Bacillus licheniformis* D-alanine racemase region was determined in this work and is shown in positions 1303 to 2469 in SEQ ID 12. A plasmid denoted "Dal-Deletion plasmid" was constructed by cloning one 2281 bp PCR amplified fragment from the D-alanine racemase region of
- 10 *Bacillus licheniformis* on a temperature-sensitive parent plasmid. The PCR 2281 bp fragment was denoted "A", wherein A comprises the sequence from 245 basepairs upstream of the ATG start codon of the *dal* gene to 867 basepairs downstream of the *dal* gene.
- 15 A deletion of 586 basepairs of the C-terminal part of the *dal* gene on the cloned fragment A was done resulting in a plasmid containing the fragments "B" and "C" as shown below. A spectinomycin resistance gene flanked by resolvase (*res*) sites was introduced between fragments "B" and "C" on the plasmid.
- 20 This spectinomycin resistance gene could later be removed by resolvase-mediated site-specific recombination.

 The D-alanine racemase deletion was transferred from the Dal-Deletion plasmid to the chromosome of a *Bacillus* target strain by double homologous recombination via fragments "B"

25 and "C", mediated by integration and excision of the temperature-sensitive Dal-Deletion plasmid. The resulting strain was denoted "Dal-Deletion strain". This strain was unable to grow on media without D-alanine.

 An Integration plasmid was constructed for insertion of

30 genes into the D-alanine region of the Deletion strain. We intended to PCR-amplify a fragment denoted "D" comprising 1117 basepairs of the *dal* gene starting from 41 basepairs downstream of the ATG start codon. The promoter region was substituted with the T1 and T2 terminators from the 3'-

terminal sequence of the *Escherichia coli* *rrnB* ribosome RNA operon (EMBL/e09023: basepair 197-295).

The Integration plasmid comprises fragments D and C on a temperature-sensitive vector. An expression cassette destined
5 for integration was cloned between the fragments D and C. Upon transfer to the *B. licheniformis* deletion strain, integration, and excision of the temperature-sensitive vector, strains could be isolated which grow on media without D-alanine. Such "Integration strains" have restored the chromosomal *dal* gene,
10 by double homologous recombination via fragments D and C. In this process, the expression cassette was integrated into the chromosome.

Plasmid constructs

15 PCR amplifications were performed with Ready-To-Go PCR Beads from amersham pharmacia biotech as described in the manufacturers instructions, using an annealing temperature of 55°C.

20 Plasmids pJA744:

The A fragment (*dal*-region) was amplified from *Bacillus licheniformis* SJ4671 chromosomal DNA using primers:

#148779; [Upstream of a *SphI* site in the *dal* region] (SEQ ID
25 14):

5'-GATGAACTTCTGATGGTTGC

#148780: [*BamHI* < *dal*] (SEQ ID 15):

5'-AAAGGATCCCCCTGACTACATCTGGC

30

The PCR fragment was digested with *SphI* and *BamHI* and purified, then ligated to *SphI* and *BamHI* digested pPL2438. Transforming *B. subtilis* JA691 (*repF*⁺, *dal*⁻) competent cells with the ligation mix followed by selecting for kanamycin

resistance (10 µg/ml). Correct clones could complement the JA691 *dal* phenotype.

Plasmid pJA770:

5 This plasmid contains a *res-spc-res* cassette inserted between the B and C fragments. It was constructed by ligating the 1.5 kb *Bcl*I-*Bam*HI fragment from pSJ3358 into the *Bcl*I - *Bcl*I sites of pJA744. Transforming *B. subtilis* JA691 competent cells with the ligation mix followed by selecting for
10 kanamycin resistance (10 µg/ml) and spectinomycin resistance (120 µg/ml). Orientation of the spectinomycin resistance gene was could be determined by cutting with *Bcl*I and *Bam*HI.

Dal Deletion plasmid

15 Plasmid pJA851:

A fragment (comprising the *ermC* gene and the replication origin of pE194) was PCR amplified from pSJ2739 plasmid DNA using primers:

20 #170046 [*Not*I; < *ermC* gene and the replication origin of pE194>] (SEQ ID 16)

5'-AAAGCGGCCGCGAGACTGTGACGGATGAATTGAAAAAGC

#170047 [*Eco*RI; ← *ermC* gene and the replication origin of
25 pE194→] (SEQ ID 17):

5'-AAAGAATTCGTGAAATCAGCTGGACTAAAAGG

The PCR fragment was digested with *Eco*RI and *Not*I and purified, then ligated to *Eco*RI and *Not*I digested pJA770.

30 Transforming *B. subtilis* JA691 competent cells with the ligation mix followed by selecting for erythromycin resistance (5 µg/ml) and spectinomycin resistance (120 µg/ml).

Plasmid PJA748:

A fragment (comprising the *dal* gene without the promotor region) was PCR amplified from *Bacillus licheniformis* SJ4671 DNA using primers:

5

#150506 [*Bam*HI; < *dal* gene] (SEQ ID 18)
5'-AAAGGATCCCGCAAGCAAAGTTGTTTTTCCGC

#150507 [*Kpn*I; <- *dal* gene] (SEQ ID 19):

10 5'-AAAGGTACCGAAAGACATGGGCCGAAATCG

The PCR fragment was digested with *Kpn*I and *Bam*HI and purified, then ligated to *Kpn*I and *Bam*HI digested pPL2438. Transforming *B. subtilis* JA691 competent cells with the
15 ligation mix followed by selecting for kanamycin resistance (10 µg/ml).

Plasmids pJA762:

A fragment (comprising the T₁ and T₂ Terminators from the
20 *E.coli rrnB* terminal sequence EMBL[e09023] from basepair 197 to 295) was PCR amplified from *Escherichia coli* SJ2 DNA using primers:

#158089 [*Kpn*I; < T₁ and T₂ Terminators of *rrnB*] (SEQ ID 20)

25 5'-AAAGGTACCGGTAATGACTCTCTAGCTTGAGG

#158090 [*Cla*I; < T₁ and T₂ Terminators of *rrnB*] (SEQ ID 21):

5'-CAAATCGATCATCACCGAAACGCGGCAGGCAGC

30 The PCR fragment was digested with *Kpn*I and *Cla*I and purified, then ligated to *Kpn*I and *Cla*I digested pJA748. Transforming *B. subtilis* JA691 competent cells with the ligation mix followed by selecting for kanamycin resistance (10 µg/ml).

Plasmids pJA767:

A fragment (comprising the 0.7kbp DNA sequence downstream of *dal* (DFS)) was PCR amplified from *B. licheniformis* SJ4671

5 (WO 99/41358) DNA using primers:

#150508 [*Hind*III; < DFS] (SEQ ID 22)

5'-ATTAAGCTTGATATGATTATGAATGGAATGG

10 #150509 [*Nhe*I; < DFS] (SEQ ID 23):

5'-AAAGCTAGCATCCCCCTGACTACATCTGGC

The PCR fragment was digested with *Hind*III and *Nhe*I and purified, then ligated to *Kpn*I and *Cla*I digested pJA762.

15 Transforming *B. subtilis* JA691 competent cells with the ligation mix followed by selecting for kanamycin resistance (10 µg/ml).

Plasmid pJA776

20 This plasmid contains the *amyL* cassette flanked by the D and C fragments. It was constructed by ligating the 2.8 kb *Hind*III-*Nhe*I fragment from pSJ4457 to the 4.2 kb *Bam*HI-*Hind*III fragment from pJA767, and transforming the ligation mix into *B. subtilis* JA691 competent cells followed by selecting for
25 kanamycin resistance (10 µg/ml).

Dal Integration plasmidPlasmid pJA1020:

30 This plasmid contains the *amyL* cassette flanked by the D and C fragments. Further the plasmid contains the plasmid pE194 replication origin, *repF* and the *Em^r*-gene. It was constructed by ligating the 2.7kb *Eco*RI-*Nhe*I fragment of pJA776 to the 3.8kb *Eco*RI-*Nhe*I fragment of pJA851, and transforming the ligation mix into *B. subtilis* JA691 competent

cells followed by selecting for erythromycin resistance (5 $\mu\text{g/ml}$).

5 Construction of chromosomal *dal* deletions

The Deletion plasmid pJA851 was transformed into competent cells of the *B. subtilis* conjugation donor strain PP289-5 (which contains a chromosomal *dal*-deletion, and plasmids pBC16 and pLS20), and transformants were selected for
10 resistance to spectinomycin (120 $\mu\text{g/ml}$), erythromycin (5 $\mu\text{g/ml}$), and tetracycline (5 $\mu\text{g/ml}$) on plates with D-alanine (100 $\mu\text{g/ml}$) at 30°C. Transformants were kept as JA954 and used as donor in the following conjugation experiments.

The two-copy *amyL* *B. licheniformis* SJ4671 (WO 99/41358)
15 was used as recipient in the following conjugation experiments.

Donor strain JA954 were grown overnight at 30°C on LBPSG plates (LB plates with phosphate (0.01 M K_3PO_4), glucose (0.4 %), and starch (0.5 %)) supplemented with D-alanine (100
20 $\mu\text{g/ml}$), spectinomycin (120 $\mu\text{g/ml}$), erythromycin (5 $\mu\text{g/ml}$) and tetracycline (5 $\mu\text{g/ml}$). The recipient strain SJ4671 was grown overnight on LBPSG plates.

Approx. one loop of an inoculation needle of donor and recipient each were mixed on the surface of a LBPSG plate with
25 D-alanine (100 $\mu\text{g/ml}$), and incubated at 30°C for 5 hours. This plate was then replicated onto LBPSG with erythromycin (5 $\mu\text{g/ml}$) and spectinomycin (120 $\mu\text{g/ml}$), and was incubated at 30°C for 2 days. These four conjugations resulted in 13 - 25 transconjugants.

30 Tetracycline-sensitive (indicating absence of pBC16) transconjugants were reisolated on LBPSG plates with erythromycin (5 $\mu\text{g/ml}$) and spectinomycin (120 $\mu\text{g/ml}$) at 50°C, and incubated overnight. Single colonies from the 50°C plates were inoculated into 10 ml TY liquid medium with D-alanine

(100 µg/ml) and incubated with shaking at 26°C for 3 days, whereafter aliquots were transferred into fresh 10 ml TY cultures and incubation was continued overnight at 30°C. The cultures were plated on LBPSG with 120 µg/ml spectinomycin and D-alanine (100 µg/ml), after overnight incubation at 30°C these plates were replica plated onto LBPSG with/without D-alanine (100 µg/ml), spectinomycin and erythromycin, respectively.

D-Alanine autotrophic, erythromycin sensitive, and spectinomycin resistant isolates were obtained from all strain combinations. The following strain comprising the chromosomal *dal* promoter and the first 672 basepairs of the *dal* coding sequence replaced by the *res-spc-res* cassette, was kept:

B. licheniformis JA967: SJ4671 recipient, JA954 donor.

15

Strain phenotypes were assayed on LBPG with 120µg spectinomycin supplemented with or without D-alanine (100 µg/ml)

Bacillus licheniformis SJ4671 grows well on both plates with or without D-alanine. The *dal* deletion strain JA967 growth well on LBPG D-alanine plates, but not on LBPG plates without D-alanine. These strains are clearly unable to grow without adding D-alanine to the media.

25 **The sequence of the *B. licheniformis* *dal*-region (SEQ ID 12):**

The *dal*-region (comprising the *ydcC* gene, a terminator, the *dal* gene and the sequence downstream of *dal* (*DFS*)) was PCR amplified from *Bacillus licheniformis* ATCC14580 chromosomal DNA using the primers:

30

#145507 [< *ydcC* - *dal* - *DFS* >] (SEQ ID 24):

5'-GCGTACCGTTAAAGTCGAACAGCG

#150509 [*NheI*; < *ydcC* - *dal* - *DFS* >] (SEQ ID 25):

5' -AAAGCTAGCATCCCCCTGACTACATCTGGC

Sequencing of the D-alanine encoding sequence of *Bacillus licheniformis* that is shown in positions 1303-2469 of SEQ ID
5 12 and a subsequent homology search in the public databases revealed that the newly isolated *dal* gene has a sequence identity of only approx. 67% with the *dal* gene of *Bacillus subtilis*, no other D-alanine racemase encoding genes show a higher homolgoy to this new *B. licheniformis dal* gene.

10

Conjugative donor strains, transfer to *B. licheniformis*, and chromosomal integration

The Integration plasmid pJA1020 with the expression cassette is transformed into competent cells of the *B.*
15 *subtilis* conjugation donor strain PP289-5 (which contains a chromosomal *dal*-deletion, and plasmids pBC16 and pLS20), selecting resistance to erythromycin (5 µg/ml) and tetracycline (5 µg/ml) on plates with D-alanine (100 µg/ml) at 30°C.

20 Transformants comprising the Integration plasmid with the expression cassette are preserved and used as donors in conjugations with a *dal* deletion recipient of the two-copy strain JA967

Transconjugants are selected on LBPGA plates with
25 erythromycin (5 µg/ml), and one or two tetracyclin-sensitive transconjugants from each conjugation is streaked on LBPG plate which is incubated at 50°C. After two days incubation, well-growing colonies are inoculated into liquid TY medium (10 ml) without antibiotics, and these cultures are incubated with
30 shaking at 30°C. After overnight incubation, 100 µl from each culture is transferred into new 10 ml TY cultures, and incubated. This procedure is repeated twice, and in addition the cultures are plated on LBPG plates at 30°C.

All plates are replica-plated onto LBPGS, LBPGS with spectinomycine(120 μ g/ml) and LBPSG with erythromycin (5 μ g/ml) and incubated. The following day putative Spectinomycin- and erythromycin-sensitive strains are
5 restreaked on the same plate types

As for integration in the xylose region described earlier, Southern analysis and shake flask evaluation is performed to verify the site of integration in the *dal* region of the alpha-amylase expression cassette and the increased
10 yield from this three copy strain.

Example 4

In this work we did a homology study on the *Bacillus subtilis* genome and a particular region of the *B. licheniformis* chromosome (SEQ ID No:26), and we found that the
15 *B. licheniformis* region contains the genes *glpP*, *glpF*, *glpK* and *glpD*. The size of the analyzed region is 5761 nucleotides, and the DNA sequence is shown in SEQ ID No: 26.

The *glpP* coding region extends from pos. 261 to pos. 818
20 in SEQ ID No: 26. A search of EMBL and Swiss-prot databases using the blast program revealed the closest homolog to be the *B. subtilis glpP* gene (on the DNA level) and the *B. subtilis* GlpP protein (on the protein level). The identity, on the DNA level, to the *B. subtilis glpP* coding region was 72.4 % in an
25 alignment constructed using the GAP program in the GCG program package (Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, Wisc.). The identity of the deduced GlpP protein to the *B. subtilis* GlpP protein was 78.9 %.

The *glpF* coding region extends from pos. 1048 to pos.
30 1863 in SEQ ID No: 26. A search of EMBL and Swiss-prot databases using the blast algorithm revealed the closest homolog to be the *B. subtilis glpF* gene (on DNA level) and the *B. subtilis* GlpF protein (on the protein level). The identity, on the DNA level, to the *B. subtilis glpF* coding region was

72.8%. The identity of the deduced GlpF protein to the *B. subtilis* GlpF protein was 79.3 %.

The *glpK* coding region extends from pos. 1905 to pos. 3395 in SEQ ID No: 26. A search of EMBL and Swiss-prot
5 databases using the blast program revealed the closest homolog to be the *B. subtilis glpK* gene (on the DNA level) and the *B. subtilis* GlpK protein (on the protein level). The identity, on the DNA level, to the *B. subtilis glpK* coding region was 75.6 %.

10 The identity of the deduced GlpK protein to the *B. subtilis* GlpK protein was 85.9 %.

The *glpD* coding region extends from pos. 3542 to pos. 5209 in SEQ ID No: 26. A search of EMBL and Swiss-prot
databases using the blast program revealed the closest homolog to be the *B. subtilis glpD* gene (on the DNA level) and the *B.*
15 *subtilis* GlpD protein (on the protein level). The identity, on the DNA level, to the *B. subtilis glpD* coding region was 72.9 %.

The identity of the deduced GlpD protein to the *B. subtilis* GlpD protein was 81.9 %.

The *B. licheniformis* region in addition contains a part
20 of the *yhxB* gene, with the coding region starting at pos. 5394 and extending beyond the end of the sequenced fragment shown in SEQ ID No: 26.

Use of the *glpD* gene for directed chromosomal integration

25 In analogy with the strategy of the previous examples, segments of the *glpD* gene and the downstream region were PCR amplified from chromosomal DNA of *B. licheniformis*, and combined to provide vectors useful for, in a first step, deletion of the 3' end of the *glpD* gene, and, in a second
30 step, restoration of the *glpD* gene and the simultaneous insertion of an expression cassette for a gene of interest into the chromosome.

An internal fragment of the *glpD* gene, denoted '*glpD*', was PCR amplified using the two primers below, according to standard PCR protocol also described elsewhere herein.

- 5 (SEQ ID No: 27) 5'-GACTGAATTCGCAATTTGAAGTGAAAATGGTAGC, and
(SEQ ID No: 28) 5'-GACTGGATCCAGATCTCATCTTTTCGGGAAATC.

The resulting fragment was purified and digested with EcoRI and BamHI, ligated to pUC19 digested with EcoRI and
10 BamHI, and the ligation mixture transformed into *E. coli* SJ2 with selection for ampicillin resistance (200 µg/ml). A clone with the correct sequence was kept and denoted SJ5767 (SJ2/pSJ5767).

- 15 A fragment of DNA, derived from the *B. licheniformis* chromosome 55 to 555 basepairs downstream of the 3'-end of the *glpD* gene, was amplified using primers:

- (SEQ ID No: 29) 5'-
20 GACTGAATTCAGATCTGCGGCCGCACGCGTAGTACTCCCGGCGTGAGGCTGTCTTG and
(SEQ ID No: 30) 5'-GACTAAGCTTCAGTTACGCTCAAACACGTACG.

The resulting fragment was purified and digested with EcoRI and HindIII, ligated to pUC19 digested with EcoRI and
25 HindIII, and the ligation mixture transformed into *E. coli* SJ2 selecting ampicillin resistance (200 µg/ml). A clone with the correct sequence was kept as SJ5789 (SJ2/pSJ5789).

The internal fragment of the *glpD* gene was then combined
30 with a spectinomycin resistance gene, flanked by resolvase sites, by excision of a 1.5 kb BclI-BamHI fragment from pSJ3358 and insertion of this into pSJ5767 which had been digested with BglII. The ligation mixture was transformed into *E. coli* SJ2 selecting ampicillin (200 µg/ml) and spectinomycin

(120 $\mu\text{g/ml}$) resistance. A clone with the correct sequence was kept and denoted SJ5779 (SJ2/pSJ5779).

To construct the final plasmid for deletion of the 3'-end of *glpD* in the *B. licheniformis* chromosome, pSJ5789 is digested with HindIII and BglII, and the 0.5 kb fragment is ligated to the 5.5 kb HindIII-BglII fragment of pSJ2739. The ligation mixture is transformed into *B. subtilis* DN1885, selecting for erythromycin resistance (5 $\mu\text{g/ml}$) at 30°C. The resulting plasmid is digested with EcoRI and BglII, the 4.8 kb fragment is ligated to the 2.4 kb EcoRI-BamHI fragment excised from pSJ5779, and the ligation mixture is transformed into *B. subtilis* DN1885 selecting for erythromycin resistance (5 $\mu\text{g/ml}$) and spectinomycin resistance (120 $\mu\text{g/ml}$) at 30°C.

The deletion plasmid is transferred into *B. licheniformis* by use of the *B. subtilis* conjugation donor strain PP289-5, as described in previous examples, and the deletion is transferred to the chromosome using essentially the same procedures as described in previous examples.

The resulting *glpD* deletion strain is tested for growth on TSS minimal medium agar plates with glycerol as the sole carbon source.

The integration plasmid was designed to be able to repair the chromosomal *glpD* gene by homologous recombination, and carries a fragment containing the complete 3'-end of the *glpD* gene. It was useful to remove a BglII site present within the *glpD* gene by site-specific mutation designed to retain the amino acid sequence of the GlpD protein. This mutation was introduced by PCR, as follows.

An internal fragment of the *glpD* gene was amplified using primers

SEQ ID No.27 and SEQ ID No.28.

The 3'-end of the *glpD* gene was amplified using primers

(SEQ ID No: 31) 5' -

CCGAGATTTCCCGAAAAGATGAAATTTGGACTTCTGAATCCGGACTG, and

5 (SEQ ID No: 32) 5' -

GACTAAGCTTAGATCTGCTAGCATCGATTGATTATTAACGAAAATTCACC.

The two amplified fragments were mixed, and the mixture used as template for a PCR amplification using primers SEQ ID No:27 and SEQ ID No:32.

The resulting fragment was digested with EcoRI and HindIII, ligated to EcoRI and HindIII digested pUC19, and the ligation mixture transformed into *E. coli* SJ2 selecting ampicillin resistance (200 µg/ml). A clone with the correct sequence was identified and designated SJ5775 (SJ2/pSJ5775).

To construct the final integration vector plasmid, pSJ5789 is digested with HindIII and BglII, and the 0.5 kb fragment is ligated to the 5.5 kb HindIII-BglII fragment of pSJ2739. The ligation mixture is transformed into *B. subtilis* DN1885, selecting for erythromycin resistance (5 µg/ml) at 30°C. The resulting plasmid is digested with EcoRI and BglII, ligated to the 1.5 kb BglII-EcoRI fragment excised from pSJ5775, and the ligation mixture is transformed into *B. subtilis* DN1885 selecting for erythromycin resistance (5 µg/ml) at 30°C.

This integration vector plasmid has a number of restriction enzyme sites immediately downstream from the 3'-end of the *glpD* gene, into which an expression cassette is inserted.

The resulting integration plasmid is transferred into the *B. licheniformis glpD* deletion strain by use of the *B. subtilis* conjugation donor strain PP289-5, as described in previous examples.

Cells, in which the integration plasmid has integrated into the chromosome via the *glpD* sequences are isolated by their ability to grow on glycerol minimal media plates at 50°C. Such cells are used as a starting point for isolation of a strain, which by a second recombination event has lost the integrated plasmid, but has retained the repaired version of the *glpD* gene, together with the expression cassette on the chromosome.

The procedure for obtaining such a strain is equivalent to the procedure described in previous examples used to isolate strains with an expression cassette integrated at the xylose isomerase region of the chromosome.

Use of the *glpFK* genes for directed chromosomal integration.

In analogy with the strategy of the previous examples, segments of the *glpF* gene and the upstream *glpP* region were PCR amplified from chromosomal DNA of *B. licheniformis*, and combined to provide vectors useful for, in a first step, deletion of the promoter and 5' end of the *glpF* gene, and, in a second step, restoration of the promoter and *glpF* gene and the simultaneous insertion of an expression cassette for a gene of interest into the chromosome, upstream of the *glpF* promoter. Deletion of the *glpF* promoter is expected to abolish expression of the *glpF* gene and the downstream *glpK* gene. PCR amplifications were performed as previously described.

A DNA fragment containing the *glpP* gene was amplified using primers

(SEQ ID No: 33) 5'-GACTAAGCTTGTGAAGGAGATGGAACATGAG, and
(SEQ ID No: 34)

5' -

GACTGGATCCAGATCTGCGGCCGCACGCGTCGACAGTACTATTTTGTAGTTCCAGTATTTTCC.

The resulting fragment was purified and digested with HindIII and BamHI, ligated to HindIII and BamHI digested pUC19, and the ligation mixture transformed into *E. coli* SJ2 selecting ampicillin resistance (200 µg/ml). A correct clone kept was SJ5753 (SJ2/pSJ5753).

A DNA fragment containing most of the *glpF* gene, but lacking the first 160 basepairs of the coding sequence, was amplified using primers

10

(SEQ ID No: 35) 5'-GAGCTCTAGATCTTCGGCGGCATCAGCGGAGC, and
(SEQ ID No: 36) 5'-GACTGAATTCCTTTTTCGCAATATGGAC.

The resulting fragment was digested with XbaI and EcoRI, ligated to XbaI and EcoRI digested pUC19, and the ligation mixture transformed into *E. coli* SJ2 selecting ampicillin resistance (200 µg/ml). A correct clone was kept as SJ5765 (SJ2/pSJ5765).

20 In order to construct a plasmid useful for the deletion of the promoter and 5'-end of the *glpF* gene, the *glpP* containing fragment is excised from pSJ5753 as a HindIII-BglII fragment, the *glpF* fragment is excised from pSJ5765 as a BglII-EcoRI fragment, and these fragments ligated to the HindIII-EcoRI fragment of pSJ2739. The ligation mixture is transformed into *B. subtilis* DN1885, selecting for erythromycin resistance (5 µg/ml) at 30°C.

The resulting plasmid is digested with BglII, and ligated to a 1.5 kb BclI-BamHI fragment from pSJ3358, containing a spectinomycin resistance gene flanked by resolvase recognition sites. The ligation mixture is transformed into *B. subtilis* DN1885 selecting erythromycin resistance (5 µg/ml) and spectinomycin resistance (120 µg/ml) at 30°C.

30

The deletion plasmid thus constructed is transferred into *B. licheniformis* by use of the *B. subtilis* conjugation donor strain PP289-5, as described in previous examples, and the deletion is transferred to the chromosome using essentially
5 the same procedures as described in previous examples.

The resulting *glpF* deletion strain is tested for growth on TSS minimal medium agar plates with glycerol as the sole carbon source.

10 The integration plasmid is designed to be able to repair the *glpFK* gene region by homologous recombination, and carries the *glpF* promoter and intact *glpF* gene. This fragment is amplified from chromosomal *B. licheniformis* DNA using primers:
(SEQ ID No: 36) and

15

(SEQ ID No: 37)

5' -

GAGCTCTAGATCTGCTAGCATCGATCCGCGGTTAAAATGTGAAAAATTATTGACAACG.

20 The resulting fragment is digested with XbaI and EcoRI, ligated to pUC19 digested with XbaI and EcoRI, and the ligation mixture transformed into *E. coli* SJ2 selecting ampicillin resistance (200 µg/ml). The amplified fragment is subsequently excised from this plasmid as a BglII-EcoRI
25 fragment, which is ligated to the *glpP* containing fragment which is excised from pSJ5753 as a HindIII-BglII fragment, and to the HindIII-EcoRI fragment of pSJ2739. The ligation mixture is transformed into *B. subtilis* DN1885, selecting for erythromycin resistance (5 µg/ml) at 30°C. An expression
30 cassette of interest is subsequently inserted into the linker region between the end of the *glpP* gene and the *glpF* promoter.

The resulting integration plasmid is transferred into the *B. licheniformis glpF* deletion strain by use of the *B.*

subtilis conjugation donor strain PP289-5, as described in previous examples.

Colonies, in which the integration plasmid has integrated into the chromosome via the *glpF* sequences are isolated by
5 their ability to grow on glycerol minimal media plates at 50°C. Such colonies are used as starting point for isolation of strains, which by a second recombination event has lost the integrated plasmid, but has retained the repaired version of the *glpF* gene, together with the expression cassette.

10 The procedure for obtaining such strains is equivalent to the previously described procedure to isolate strains with an expression cassette integrated at the xylose isomerase region of the chromosome.

15 Sequential use of *glpD* and *glpFK* for chromosomal integration

This procedure envisages use of a strain having both the *glpD* gene deletion, and the *glpF* gene deletion, as the starting strain, and takes advantage of the ability of a strain, which is unable to express the *glpK* gene product, to
20 grow on minimal media supplemented with glycerol-3-phosphate, whereas the strain deficient in *glpD* is unable to grow on this substrate.

The procedure is then to first introduce the integration plasmid designed to repair the *glpD* gene, and to select for
25 proper integration using growth on minimal media with glycerol-3-phosphate. This inserts a copy of the expression cassette next to the *glpD* gene.

In a second step, another copy of the expression cassette can be inserted between the *glpP* and *glpF* genes using the
30 integration vector designed to repair the *glpF* gene, and selecting for proper integration using growth on minimal media with glycerol.

If the two expression cassettes are identical (or strongly homologous, or containing homologous regions), it may

be advantageous to insert these expression cassettes into the vector plasmids in such an orientation, that they in the final strain would be integrated in opposite orientation relative to each other, thus preventing their loss from the strain by
5 homologous recombination under conditions in which there is no selection for growth on glycerol.

Example 5

In this work we did a homology study on the *Bacillus*
10 *subtilis* genome and a second particular region of the *B. licheniformis* chromosome (SEQ ID No: 38), and we found that the region contains the 3'-end of the *abnA* gene, and the 5'-end of the *araA* gene of *B. licheniformis*. The size of the analyzed region is 1500 nucleotides, and the DNA sequence is
15 shown in SEQ ID No: 38.

The 3'-end of the *abnA* coding region extends from position 1 to position 592 in in SEQ ID No: 38. A search of EMBL and Swiss-prot databases using the blast program revealed the closest homolog to be the *B. subtilis abnA* gene (on the
20 DNA level) and the *B. subtilis* AbnA protein (on the protein level). The identity, on the DNA level, to the corresponding *B. subtilis abnA* coding region was 68.9 %. The identity of the deduced AbnA protein fragment to the corresponding *B. subtilis* AbnA protein fragment was 75.8 %.

25 The 5'-end of the *araA* coding region extends from position 859 to position 1500 in SEQ ID No: 38. A search of EMBL and Swiss-prot databases using the blast program revealed the closest homolog to be the *B. subtilis araA* gene (on the DNA level) and *Bacillus* AraA proteins (on the protein level).
30 The identity, on the DNA level, to the corresponding *B. subtilis araA* coding region was 68.2 %. The identity of the deduced AraA protein fragment to the corresponding *B. subtilis* AraA protein fragment was 62.6 %. The highest identity, scored

in an alignment to a *Bacillus stearothermophilus* AraA protein fragment, was 68.4 %.

Use of the *araA* gene for directed chromosomal integration

5 In analogy with the strategy of the previous examples, segments of the *araA* gene and the upstream *abnA* region were PCR amplified from chromosomal DNA of *B. licheniformis*, and combined to provide vectors useful for, in a first step, deletion of the promoter and 5' end of the *araA* gene, and, in
10 a second step, restoration of the promoter and *araA* gene and the simultaneous insertion of an expression cassette for a gene of interest into the chromosome, upstream of the *araA* promoter. PCR amplifications were performed as previously described.

15 A fragment of the *abnA* gene upstream of *araA* was amplified using primers:

(SEQ ID No: 39) 5'-GACTAAGCTTCATCCGGCGATCAGTTTAATGC, and
(SEQ ID No: 40)

20 5' -
GACTGAATTCAGATCTGCGGCCGCACGCGTCGACAGTACTATTTTTTTTTTGACAGAT
TTCAGAAC.

The resulting fragment was digested with HindIII
25 and EcoRI, ligated to HindIII and EcoRI digested pUC19, the ligation mixture transformed into *E. coli* SJ2 selecting ampicillin resistance (200 µg/ml), and a correct transformant kept as SJ5751 (SJ2/pSJ5751).

A fragment containing an internal part of the *araA*
30 gene was amplified using primers:

(SEQ ID No: 41) 5'-GACTGGATCCAGATCTAGTCGAGTACAAAGCGGTGGC,
and
(SEQ ID No: 42) 5'-GACTGAATTCGACCAGCCAAGCTGAATCTGC.

The resulting fragment was digested with BamHI and EcoRI, ligated to BamHI and EcoRI digested pUC19, the ligation mixture transformed into *E. coli* SJ2 selecting
5 ampicillin resistance (200 µg/ml), and a correct transformant kept as SJ5752 (SJ2/pSJ5760).

The *abnA* gene fragment was excised from pSJ5751 as a HindIII-BglII fragment, ligated to the 5.5 kb HindIII-BglII fragment of pSJ2739, and the ligation mixture
10 transformed into *B. subtilis* DN1885, selecting for erythromycin resistance (5 µg/ml) at 30°C. A transformant kept was SJ5756 (DN1885/pSJ5756).

Plasmid pSJ5760 was digested with BglII, and a 1.5 kb BamHI-BclI fragment from pSJ3358, containing a
15 spectinomycin resistance gene flanked by resolvase recognition sites, was inserted. A clone was kept as SJ5777 (SJ2/pSJ5777).

The final deletion plasmid was constructed by excision of the *araA-res-spc-res* fragment from pSJ5777 as
20 a EcoRI-BamHI fragment, and ligation of this to the large EcoRI-BglII fragment of pSJ5756. The ligation mixture was transformed into *B. subtilis* DN1885, selecting erythromycin resistance (5 µg/ml) and spectinomycin resistance (120 µg/ml) at 30°C. A correct transformant
25 kept was SJ5803 (SJ2/pSJ5803).

The deletion plasmid pSJ5803 is transferred into *B. licheniformis* by use of the *B. subtilis* conjugation donor strain PP289-5, as described in previous examples, and the deletion is transferred to the chromosome using essentially
30 the same procedures as described in previous examples.

The resulting *araA* deletion strain is tested for growth on TSS minimal medium agar plates with arabinose as the sole carbon source.

An integration vector plasmid is designed to be able to repair the *araA* gene region by homologous recombination, and carries the *araA* promoter and the 5'-end of the *araA* gene in addition to the *abnA* gene fragment of pSJ5756. The *araA* promoter fragment is amplified from chromosomal *B. licheniformis* DNA using primers synthesized based on the sequence given as SEQ ID No: 26. The plasmid is constructed, so that an expression cassette for a gene of interest can be inserted downstream from the *abnA* gene, but upstream of the *araA* promoter.

The resulting integration plasmid is transferred into the *B. licheniformis araA* deletion strain by use of the *B. subtilis* conjugation donor strain PP289-5, as described in previous examples. Colonies, in which the integration plasmid has integrated into the chromosome via the *araA* sequences are isolated by their ability to grow on arabinose minimal media plates at 50°C. Such colonies are used as starting point for isolation of strains, which by a second recombination event has lost the integrated plasmid, but has retained the repaired version of the *araA* gene, together with the expression cassette.

The procedure for obtaining such strains is equivalent to the previously described procedure to isolate strains with an expression cassette integrated at the xylose isomerase region of the chromosome.

Example 6

In this work we did a homology study on the *Bacillus subtilis* genome and a third particular region of the *B. licheniformis* chromosome (SEQ ID No:42), and we found that the *B. licheniformis* region contains the 3'-end of the *ispA* gene and the *metC* gene. The size of the analyzed region is 4078 nucleotides, and the DNA sequence is shown in SEQ ID No: 42.

The 3'-end of the *ispA* coding region extends from pos. 1 to pos. 647 in SEQ ID No: 42. A BLAST search of the EMBL and Swiss-prot databases using this particular sequence revealed the closest homologue (on the DNA level) to be the *B. subtilis* *ispA* gene and (on the protein level) the *B. subtilis* IspA protein. The identity, on the DNA level, to the corresponding *B. subtilis* *ispA* coding region was 72.6 % in an alignment constructed using the AlignX™ program in the Vector NTI™ 6.0 program package (Informax™, Inc.). The identity of the deduced IspA protein fragment to the corresponding *B. subtilis* IspA protein fragment was 82.3 %.

The *metC* coding region extends from pos. 1121 to pos. 3406 in SEQ ID No: 42. A BLAST search of EMBL and Swiss-prot databases using this particular sequence revealed the closest homologue to be the *B. subtilis* *metC* gene (on the DNA level) and the *B. subtilis* MetC protein (on the protein level). The identity, on the DNA level, to the *B. subtilis* *metC* coding region was 72.6 %. The identity of the deduced MetC protein to the *B. subtilis* MetC protein was 84.6 %.

20

Use of the *metC* gene for directed chromosomal integration

Segments of the *metC* gene and the downstream region were PCR amplified from chromosomal DNA of *B. licheniformis*, and combined to provide a vector useful for deletion of the 3' end of the *metC* gene.

A fragment of DNA, derived from the *B. licheniformis* chromosome, 4 to 671 basepairs downstream of the 3'-end of the *metC* gene, was amplified using primers:

(SEQ ID No: 44) 5'-AAAAAACCCGAGTTTCACAAAAAATCCACTACAAACGCCGCC,
and

(SEQ ID No: 45) 5'-TTTTTTTAAAGCTTATGCCGCATGTTCTTGCTGTTTTCAC.

The resulting fragment was digested with *Ava*I and *Hind*III, ligated to pMOL1887 digested with *Ava*I and *Hind*III, and the ligation mixture transformed into *B. subtilis* PL1801 with selection for erythromycin (5 µg/ml) and kanamycin (10 µg/ml) at 30°C. One clone was kept as CLO57 (PL1801/pCLO57).

An internal fragment of the *metC* gene, derived from the *B. licheniformis* chromosome, 247 to 754 basepairs into the *metC* open reading frame, was amplified using primers:

10 (SEQ ID No: 46) 5'-AAAAAATCGATTTCAGGGATATAAACGATCCG, and
(SEQ ID No: 47) 5'-
TTTTTTTTTTCCATCGCACTGGGATATCAGCTCTTCATAAGCATC.

The resulting fragment was digested with *Cla*I and *Bst*XI, 15 ligated to pCLO57 digested with *Cla*I and *Bst*XI, and the ligation mixture transformed into *B. subtilis* PL1801 with selection for erythromycin (5 µg/ml) and kanamycin (10 µg/ml) at 30°C. One clone was kept as CLO58 (PL1801/pCLO58).

The resulting deletion plasmid pCLO58 has a cassette 20 consisting of the internal *metC* fragment followed by the kanamycin resistance gene flanked by resolvase sites, which finally is followed by the DNA fragment downstream of the *metC* gene. The deletion plasmid pCLO58 was transferred to the conjugation donor strain PP1060-1, which is isogen to PP289-5 25 that previously has been described, except that the gene encoding green fluorescent protein (GFP) has been integrated onto the chromosome. The resulting strain CLO71 (PP1060-1/pCLO58) was selected for erythromycin resistance at 30°C. The donor strain CLO71 was mated with the *B. licheniformis* 30 recipient SJ3047, selecting conjugants for erythromycin resistance and a *dal*⁺ phenotype at 30°C.

One conjugant CLO74 was streaked on kanamycine (20 µg/ml) selecting for cells having plasmids integrated into the chromosome. Plating a resulting strain CLO78 onto SMS-glucose

minimal plates revealed that the plasmid had integrated in the internal part of the *metC* gene resulting in a requirement for methionine. CLO78 was used as a starting point for isolation of strains, which by a second recombination event had lost the integrated plasmid, but had retained the deleted version of the *metC* gene.

Such a strain, denoted, CLO80 is appropriate to be used as a recipient for a plasmid carrying a cassette, which can be directed for integration at the *metC* locus essentially as described in previous examples, under conditions selective for an intact *metC* gene.

Example 7

In this work we did a homology study on the *Bacillus subtilis* genome and a fourth particular region of the *B. licheniformis* chromosome (SEQ ID No:48), and we found that the *B. licheniformis* region contains the 3'-end of the *spoVAF* gene and the *lysA* gene. The size of the analyzed region is 3952 nucleotides, and the DNA sequence is shown in SEQ ID No: 48.

The 3'-end of the *spoVAF* coding region extends from pos. 1 to pos. 310 in SEQ ID No: 42. The identity, on the DNA level to the *B. subtilis* *spoVAF* coding region was 62.7%. The identity of the deduced SpoVAF protein to the *B. subtilis* SpoVAF protein was 55.2%.

The *lysA* coding region extends from pos. 1048 to pos. 2367 in SEQ ID No: 48. A BLAST search of EMBL and Swiss-prot databases using this particular sequence revealed the closest homologue to be the *B. subtilis* *lysA* gene (on the DNA level) and the *B. subtilis* LysA protein (on the protein level). The identity, on the DNA level, to the *B. subtilis* *lysA* coding region was 73.0 %. The identity of the deduced LysA protein to the *B. subtilis* LysA protein was 82.2 %.

Use of the *lysA* gene for directed chromosomal integration

In analogy with the strategy of the previous examples herein, segments of the *lysA* gene is PCR amplified from chromosomal DNA of *B. licheniformis*, and combined to provide vectors useful for, in a first step, partial deletion of the
5 *lysA* gene, rendering a cell auxotrophic for lysine, and, in a second step, restoration of the *lysA* gene and the simultaneous insertion of an expression cassette for a gene of interest into the chromosome. Based on the strategies of the previous examples it is well within the skilled persons knowledge to
10 determine the necessary primers and selective conditions for performing this procedure.

General Materials and Methods

In vitro DNA work, transformation of bacterial strains
15 etc. were performed using standard methods of molecular biology (Maniatis, T., Fritsch, E. F., Sambrook, J. "Molecular Cloning. A laboratory manual". Cold Spring Harbor Laboratories, 1982; Ausubel, F. M., et al. (eds.) "Current Protocols in Molecular Biology". John Wiley and Sons, 1995;
20 Harwood, C. R., and Cutting, S. M. (eds.) "Molecular Biological Methods for Bacillus". John Wiley and Sons, 1990).

If not otherwise mentioned, enzymes for DNA manipulations were used according to the specifications of the suppliers. Media used (TY, BPX and LB agar) have been described in EP 0
25 506 780.

Amylase activity was determined with the Phadebas^R Amylase Test from Pharmacia & Upjohn as described by the supplier.

The use of a resistance gene, e.g. spectinomycin
30 resistance or kanamycin resistance, flanked by recognition sites for a site specific recombination enzyme (*res* sites recognized by Resolvase from plasmid pAMBeta1) for easy deletion, has been described in US Patent 5,882,888. In the

same patent are described plasmid pSJ3358, and strain *B. subtilis* PP289-5.

pUC19 is described in Yanisch-Perron, C., Vieira, J., Messing, J. (1985) Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. *Gene* 33, 103-119.

pE194 is described in Horinouchi, S., and Weisblum, B. (1982). Nucleotide sequence and functional map of pE194, a plasmid that specifies inducible resistance to macrolide, lincosamide, and streptogramin type B antibiotics. *J. Bacteriol.*, 150, 804-814.

Plasmid pSJ2739 is described in US Patent 6,100,063.

Plasmid pMOL1642 is shown in SEQ ID No:49 and the following table:

15

Feature	Basepairs	Reference
res-site	5870..6061	EMBL:AF007787/4852..4951
Kan(R)	6241..162	EMBL:SA110KAR/1390..2151
res-site	203..376	EMBL:AF007787/4852..4951
Promoter PamyQ	378..396	EMBL:A00607/67..181
<i>prsa'</i>	492..1008	<i>B.licheniformis</i>
Ery(R)	1133..1864 (compl.)	EMBL:SAE194/2857..2004
Pre	2276..3484	EMBL:SAE194/join(3150..3728,1..633
repF	4113..4709	EMBL:SAE194/1244..1594
oriT	4805..5368	EMBL:PP110CG/1021..1575
ups <i>prsa</i>	5375..5869	<i>B.licheniformis</i>

Strains *Escherichia coli* SJ2 and *Bacillus subtilis* DN1885 are described in Diderichsen, B., Wedsted, U., Hedegaard, L., Jensen, B. R., Sjøholm, C. (1990). Cloning of *aldB*, which

encodes acetolactate decarboxylase, an exoenzyme from *Bacillus brevis*. Journal of Bacteriology 172, 4315-4321.

Bacillus subtilis PL1801 is the *B. subtilis* DN1885 with disrupted *apr* and *npr* genes.

5 *Bacillus licheniformis* PL1980 is a strain of *B. licheniformis*, which was made unable to produce the alkaline protease by insertion of a chloramphenicol resistance gene into the alkaline protease gene.

10 *Bacillus subtilis* JA578 is a *B. subtilis* 168 *spo*, *amyE* with a *repF* expression cassette (SEQ ID No:50) inserted downstream of the *dal* gene (EMBL:BSDAL, Accession# M16207) on the chromosome. The *repF* expression cassette shown in SEQ ID No:50 comprises the maltogenic amylase promoter PamyM (position 1-181 in SEQ ID No:50) from *Bacillus*
15 *Stearothermophilus* (EMBL:BSAMYL02, Accession #M36539), a linker (position 182-211 in SEQ ID No:50) containing the RBS, fused to the *repF* gene (position 212-808 in SEQ ID No:50) from the plasmid pE194 (EMBL:PPCG2, accession #J01755), with the RepF start-codon in position 212 and Stop-codon in position
20 809 of SEQ ID No:50.

Bacillus subtilis JA691 is *B. subtilis* JA578 *dal*⁻.

Claims

1. A method for constructing a cell comprising at least two copies of a gene of interest stably integrated into the chromosome in different positions, the method comprising the 5 steps of:
- a) providing a host cell comprising at least one chromosomal copy of the gene of interest, and comprising one or more conditionally essential chromosomal gene(s) which has been altered to render the gene(s) non-functional;
 - 10 b) providing a DNA construct comprising:
 - i) an altered non-functional copy of the conditionally essential gene(s) of step a); and
 - ii) at least one copy of the gene of interest flanked on one side by i) and on the other side by a DNA fragment 15 homologous to a host cell DNA sequence located on the host cell chromosome adjacent to the gene(s) of step a); wherein a first recombination between the altered copy of i) and the altered chromosomal gene(s) of step a) restores the conditionally essential chromosomal gene(s) 20 to functionality and renders the cell selectable;
 - c) introducing the DNA construct into the host cell and cultivating the cell under selective conditions that require a functional conditionally essential gene(s); and
 - d) selecting a host cell that grows under the selective 25 conditions of the previous step ; wherein the at least one copy of the gene of interest has integrated into the host cell chromosome adjacent to the gene(s) of step a); and optionally
 - e) repeating steps a) to d) at least once using a different 30 chromosomal gene(s) in step a) in each repeat.
2. A method for constructing a cell comprising at least two copies of a gene of interest stably integrated into the

chromosome in different positions, the method comprising the steps of:

- a) providing a host cell comprising at least one chromosomal copy of the gene of interest;
- 5 b) altering a conditionally essential chromosomal gene(s) of the host cell whereby the gene becomes non-functional;
- c) making a DNA construct comprising:
 - i) an altered non-functional copy of the chromosomal gene(s) of step b); and
 - 10 ii) at least one copy of the gene of interest flanked on one side by i) and on the other side by a DNA fragment homologous to a host cell DNA sequence adjacent to the gene(s) of step b); wherein a first recombination between the altered copy of i) and the altered
 - 15 chromosomal gene(s) of step b) restores the chromosomal gene(s) to functionality and renders the cell selectable;
- d) introducing the DNA construct into the host cell and cultivating the cell under selective conditions that
- 20 require a functional gene(s) of step b); and
- e) selecting a host cell that grows under the selective conditions of step d); wherein the at least one copy of the gene of interest has integrated into the host cell chromosome adjacent to the gene(s) of step b); and
- 25 optionally
- f) repeating steps a) to e) at least once using a different chromosomal gene(s) in step b) in each repeat.

3. The method of claim 1 or 2, wherein subsequent to the step

30 of introducing the DNA construct and cultivating the cell under selective conditions, or subsequent to the step of selecting a host cell, a second recombination takes place between the DNA fragment and the homologous host cell DNA sequence.

4. The method of claim 3, where the DNA construct further comprises at least one marker gene which is located in the construct such that it is recombined out of the chromosome by
5 the second recombination.

5. The method of claim 4, wherein the at least one marker gene confers resistance to an antibiotic, preferably the antibiotic is chosen from the group consisting of chloramphenicol,
10 kanamycin, ampicillin, erythromycin, spectinomycin and tetracycline.

6. The method of claims 4 or 5, wherein a host cell is selected which grows under the selective conditions, and which
15 cell does not contain the at least one marker gene in the chromosome.

7. The method of any of claims 1 - 6, where the DNA construct further comprises at least one marker gene located between the
20 altered copy and the DNA fragment, and wherein the at least one marker gene is flanked by nucleotide sequences that are recognized by a specific resolvase, preferably the nucleotide sequences are *res*.

25 8. The method of claim 7, wherein the at least one marker gene is excised from the chromosome by the action of a resolvase enzyme subsequent to selecting a host cell that grows under the selective conditions.

30 9. The method of any of claims 1 - 8, wherein the gene of interest originates from the host cell.

10. The method of any of claims 1 - 9, wherein the gene of interest encodes an enzyme, preferably an amylolytic enzyme, a

lipolytic enzyme, a proteolytic enzyme, a cellulytic enzyme, an oxidoreductase or a plant cell-wall degrading enzyme, and more preferably an enzyme with an activity selected from the group consisting of aminopeptidase, amylase, amyloglucosidase, 5 carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, galactosidase, beta-galactosidase, glucoamylase, glucose oxidase, glucosidase, haloperoxidase, hemicellulase, invertase, isomerase, laccase, 10 ligase, lipase, lyase, mannosidase, oxidase, pectinase, peroxidase, phytase, phenoloxidase, polyphenoloxidase, protease, ribonuclease, transferase, transglutaminase, or xylanase.

15 11. The method of any of claims 1 - 10, wherein the selected host cell that grows under the selective conditions comprises substantially no exogenous DNA, preferably less than 500 basepairs per integrated gene of interest, more preferably less than 300 bp, even more preferably less than 100 bp, still 20 more preferably less than 50 bp, more preferably less than 25 bp per integrated gene of interest, or most preferably no exogenous DNA.

12. The method of any of claims 1 - 10, wherein the selected 25 host cell that grows under the selective conditions comprises DNA only of endogenous origin.

13. The method of any of claims 1 - 12, wherein the conditionally essential chromosomal gene(s) of the host cell 30 is altered by partially deleting the gene(s), or by introducing one or more mutations in the gene(s).

14. The method of any of claims 1 - 13, wherein the conditionally essential chromosomal gene(s) of the host cell

that is altered encodes a D-alanine racemase, preferably the gene(s) is a *dal* homologue from a *Bacillus* cell, more preferably the gene is homologous to *dal* from *Bacillus subtilis*, and most preferably the gene(s) is the *dal* gene of
5 *Bacillus licheniformis*.

15. The method of any of claims 1 - 13, wherein the ,
conditionally essential chromosomal gene(s) of the host cell that is altered encodes a D-alanine racemase and is at least
10 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *dal* sequence of *Bacillus licheniformis* shown in positions 1303 to 2469 in SEQ ID 12.

15 16. The method of any of claims 1 - 13, wherein the conditionally essential chromosomal gene(s) of the host cell that is altered is one or more genes that are required for the host cell to grow on minimal medium supplemented with only one specific main carbon-source.

20

17. The method of claim 16, wherein the conditionally essential chromosomal gene(s) of the host cell that is altered is of a xylose operon, preferably the gene(s) is homologous to the *xylA* gene from *Bacillus subtilis*, and most preferably the
25 gene(s) is homologous to one or more genes of the xylose isomerase operon of *Bacillus licheniformis*.

18. The method of claim 16, wherein the conditionally essential chromosomal gene(s) of the host cell that is altered
30 encodes a galactokinase (EC 2.7.1.6), an UTP-dependent pyrophosphorylase (EC 2.7.7.10), an UDP-glucose-dependent uridylyltransferase (EC 2.7.7.12), or an UDP-galactose epimerase (EC 5.1.2.3), preferably the gene(s) encodes an UDP-galactose epimerase (EC 5.1.2.3), more preferably the gene(s)

is homologous to *galE* of a *Bacillus*, and most preferably the gene is *galE* of *Bacillus licheniformis*.

19. The method of claim 16, wherein the conditionally
5 essential chromosomal gene(s) of the host cell that is altered is one or more gene(s) of a gluconate operon, preferably the gene(s) encodes a gluconate kinase (EC 2.7.1.12) or a gluconate permease or both, more preferably the gene(s) is one or more genes homologous to the *gntK* or *gntP* genes from
10 *Bacillus subtilis*, and most preferably the gene(s) is the *gntK* or *gntP* gene from *Bacillus licheniformis*.

20. The method of claim 16, wherein the conditionally
essential chromosomal gene(s) of the host cell that is altered
15 is one or more gene(s) of a gluconate operon, preferably the gene(s) encodes a gluconate kinase (EC 2.7.1.12) or a gluconate permease or both and is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to any of the *gntK* and *gntP*
20 sequences of *Bacillus licheniformis*.

21. The method of claim 16, wherein the conditionally
essential chromosomal gene(s) of the host cell that is altered is one or more gene(s) of a glycerol operon, preferably the
25 gene(s) encodes a glycerol uptake facilitator (permease), a glycerol kinase, or a glycerol dehydrogenase, more preferably the gene(s) is one or more genes homologous to the *glpP*, *glpF*, *glpK*, and *glpD* genes from *Bacillus subtilis*, and most preferably the gene(s) is one or more genes of *glpP*, *glpF*,
30 *glpK*, and *glpD* genes from *Bacillus licheniformis* shown in SEQ ID No:26.

22. The method of claim 16, wherein the conditionally
essential chromosomal gene(s) of the host cell that is altered

is one or more gene(s) of a glycerol operon, preferably the gene(s) encodes a glycerol uptake facilitator (permease), a glycerol kinase, or a glycerol dehydrogenase, and is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to any of the *glpP*, *glpF*, *glpK*, and *glpD* sequences of *Bacillus licheniformis* shown in SEQ ID No:26.

23. The method of claim 16, wherein the conditionally essential chromosomal gene(s) of the host cell that is altered is one or more gene(s) of an arabinose operon, preferably the gene(s) encodes an arabinose isomerase, more preferably the gene(s) is homologous to the *araA* gene from *Bacillus subtilis*, and most preferably the gene(s) is the *araA* gene from *Bacillus licheniformis* shown in SEQ ID No:38.

24. The method of claim 16, wherein the conditionally essential chromosomal gene(s) of the host cell that is altered is one or more gene(s) of an arabinose operon, preferably the gene(s) encodes an arabinose isomerase, and is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *araA* sequence of *Bacillus licheniformis* shown in SEQ ID No:38.

25. The method of any of claims 1 - 13, wherein the conditionally essential chromosomal gene(s) of the host cell encodes one or more polypeptide(s) involved in amino acid synthesis, and the non-functionality of the gene(s) renders the cell auxotrophic for one or more amino acid(s), and wherein restoration of the functionality of the gene(s) renders the cell prototrophic for the amino acid(s).

26. The method of claim 25, wherein the conditionally essential chromosomal gene(s) of the host cell encodes one or

more polypeptide(s) involved in lysine or methionine synthesis, more preferably the gene(s) is homologous to the *metC* or the *lysA* genes from *Bacillus subtilis*, and most preferably the gene(s) is the *metC* or the *lysA* gene from
5 *Bacillus licheniformis*.

27. The method of claim 25, wherein the conditionally essential chromosomal gene(s) of the host cell is at least 75% identical, preferably 85% identical, more preferably 95%
10 identical and most preferably at least 97% identical to the *metC* sequence of *Bacillus licheniformis* shown in SEQ ID No:42 or the *lysA* sequence of *Bacillus licheniformis* shown in SEQ ID No:48.

15 28. The method of any of claims 1 - 27, wherein the host cell is a Gram-positive bacterial cell, preferably a *Bacillus* cell, and most preferably a *Bacillus* cell chosen from the group consisting of *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*,
20 *Bacillus clausii*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*.

25 29. The method of any of claims 1 - 28, wherein the DNA construct is a plasmid.

30. A DNA construct comprising:

- 30 i) an altered non-functional copy of a conditionally essential chromosomal gene(s) from a host cell, preferably the copy is partially deleted; and
- ii) at least one copy of a gene of interest flanked on one side by i) and on the other side by a DNA fragment homologous to a host cell DNA sequence located on the host

cell chromosome adjacent to the conditionally essential gene(s) of i).

31. The DNA construct of claim 30, wherein the conditionally
5 essential chromosomal gene(s) of the host cell that is altered
in i) encodes a D-alanine racemase, preferably the gene(s) is
a *dal* homologue from a *Bacillus* cell, more preferably the gene
is homologous to *dal* from *Bacillus subtilis*, and most
preferably the gene is the *dal* gene of *Bacillus licheniformis*.

10

32. The DNA construct of claim 30, wherein the conditionally
essential chromosomal gene(s) of the host cell that is altered
in i) encodes a D-alanine racemase and is at least 75%
identical, preferably 85% identical, more preferably 95% and
15 most preferably at least 97% identical to the *dal* sequence of
Bacillus licheniformis shown in positions 1303 to 2469 in SEQ
ID 12.

33. The DNA construct of claim 30, wherein the altered non-
20 functional copy of a conditionally essential chromosomal
gene(s) from a host cell is one or more gene(s) that is
required for the host cell to grow on minimal medium
supplemented with only one specific main carbon-source.

25 34. The DNA construct of claim 33, wherein the conditionally
essential chromosomal gene(s) is one or more genes of a xylose
operon, preferably the gene(s) is homologous to the *xylA* gene
from *Bacillus subtilis*, and most preferably the gene(s) is
homologous to one or more genes of the xylose isomerase operon
30 of *Bacillus licheniformis*.

35. The DNA construct of claim 33, wherein the conditionally
essential chromosomal gene(s) encodes a galactokinase (EC
2.7.1.6), an UTP-dependent pyrophosphorylase (EC 2.7.7.10), an

UDP-glucose-dependent uridylyltransferase (EC 2.7.7.12), or an UDP-galactose epimerase (EC 5.1.2.3), preferably the gene(s) encodes an UDP-galactose epimerase (EC 5.1.2.3), more preferably the gene(s) is homologous to the *galE* gene of *Bacillus subtilis*, and most preferably the gene(s) is the *galE* gene of *Bacillus licheniformis*.

36. The DNA construct of claim 33, wherein the conditionally essential chromosomal gene(s) is one or more genes of a gluconate operon, preferably the gene(s) encodes a gluconate kinase (EC 2.7.1.12) or a gluconate permease or both, more preferably the gene(s) is homologous to the *gntK* or *gntP* genes from *Bacillus subtilis*, and most preferably the gene(s) is one or more genes of *gntK* and *gntP* from *Bacillus licheniformis*.

15

37. The DNA construct of claim 33, wherein the conditionally essential chromosomal gene(s) is one or more gene(s) of a glycerol operon, preferably the gene(s) encodes a glycerol uptake facilitator (permease), a glycerol kinase, or a glycerol dehydrogenase, more preferably the gene(s) is one or more genes homologous to the *glpP*, *glpF*, *glpK*, and *glpD* genes from *Bacillus subtilis*, and most preferably the gene(s) is one or more genes of *glpP*, *glpF*, *glpK*, and *glpD* genes from *Bacillus licheniformis* shown in SEQ ID No:26.

25

38. The DNA construct of claim 33, wherein the conditionally essential chromosomal gene(s) is one or more gene(s) of a glycerol operon, preferably the gene(s) encodes a glycerol uptake facilitator (permease), a glycerol kinase, or a glycerol dehydrogenase, and is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to any of the *glpP*, *glpF*, *glpK*, and *glpD* sequences of *Bacillus licheniformis* shown in SEQ ID No:26.

39. The DNA construct of claim 33, wherein the conditionally essential chromosomal gene(s) is one or more gene(s) of an arabinose operon, preferably the gene(s) encodes an arabinose isomerase, more preferably the gene(s) is homologous to the *araA* gene from *Bacillus subtilis*, and most preferably the gene(s) is the *araA* gene from *Bacillus licheniformis* shown in SEQ ID No:38.

40. The DNA construct of claim 33, wherein the conditionally essential chromosomal gene(s) is one or more gene(s) of an arabinose operon, preferably the gene(s) encodes an arabinose isomerase, and is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *araA* sequence of *Bacillus licheniformis* shown in SEQ ID No:38.

41. The DNA construct of claim 30, wherein the conditionally essential chromosomal gene(s) encodes one or more polypeptide(s) involved in amino acid synthesis, and where and the non-functionality of the gene(s) when present in a cell with no other functional copy(ies) of the gene(s) renders the cell auxotrophic for one or more amino acid(s), and wherein restoration of the functionality of the gene(s) renders the cell prototrophic for the amino acid(s)

42. The DNA construct of claim 41, wherein the conditionally essential chromosomal gene(s) encodes one or more polypeptide(s) involved in lysine or methionine synthesis, more preferably the gene(s) is homologous to the *metC* or the *lysA* genes from *Bacillus subtilis*, and most preferably the gene(s) is the *metC* or the *lysA* gene from *Bacillus licheniformis*.

43. The DNA construct of claim 41, wherein the conditionally essential chromosomal gene(s) is at least 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *metC* sequence of
5 *Bacillus licheniformis* shown in SEQ ID No:42 or the *lysA* sequence of *Bacillus licheniformis* shown in SEQ ID No:48.

44. A host cell comprising at least two copies of a gene of interest stably integrated into the chromosome, where at least
10 one copy is integrated adjacent to a conditionally essential locus and wherein the cell is obtainable by any of the methods defined in claims 1 - 29.

45. The cell of claim 44, wherein the gene of interest is
15 separated from the conditionally essential locus by no more than 1000 basepairs, preferably no more than 750 basepairs, more preferably no more than 500 basepairs, even more preferably no more than 250 basepairs, and most preferably no more than 100 basepairs.

20

46. The cell of claims 44 or 45, which contains substantially no exogenous DNA, preferably less than 500 basepairs per integrated gene of interest, more preferably less than 300 bp, even more preferably less than 100 bp, still more preferably
25 less than 50 bp, more preferably less than 25 bp per integrated gene of interest, or most preferably no exogenous DNA.

47. The cell of claims 44 or 45, which contains only
30 endogenous DNA.

48. The cell of any of claims 44 - 47, which is a Gram-positive bacterial cell, preferably a *Bacillus* cell, and most preferably a *Bacillus* cell chosen from the group consisting of

Bacillus alkalophilus, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus clausii*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus*
5 *stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*.

49. The cell of any of claims 44 - 48, wherein a copy of the gene of interest is integrated adjacent to a gene encoding a
10 D-alanine racemase, preferably a gene homologous to the *dal* gene from *Bacillus subtilis*, more preferably a gene at least 75% identical to the *dal* sequence of *Bacillus licheniformis* shown in positions 1303 to 2469 in SEQ ID 12, even more preferably a gene at least 85% identical, more preferably at
15 least 95% and most preferably at least 97% identical to the *dal* sequence of *Bacillus licheniformis* shown in positions 1303 to 2469 in SEQ ID 12.

50. The cell of any of claims 44 - 49, wherein a copy of the
20 gene of interest is integrated adjacent to a gene that is required for the host cell to grow on minimal medium supplemented with only one specific main carbon-source.

51. The cell of claim 50, wherein a copy of the gene of
25 interest is integrated adjacent to a gene of a xylose operon, preferably adjacent to genes homologous to the *xylR* or *xylA* genes from *Bacillus subtilis*, and most preferably adjacent to *xylR* or *xylA* from *Bacillus licheniformis*.

30 52. The cell of claim 50, wherein a copy of the gene of interest is integrated adjacent to a gene encoding a galactokinase (EC 2.7.1.6), an UTP-dependent pyrophosphorylase (EC 2.7.7.10), an UDP-glucose-dependent uridylyltransferase (EC 2.7.7.12), or an UDP-galactose epimerase (EC 5.1.2.3),

preferably adjacent to a gene encoding an UDP-galactose epimerase (EC 5.1.2.3), more preferably adjacent to a gene homologous to the *galE* gene from *Bacillus subtilis*, and most preferably adjacent to *galE* from *Bacillus licheniformis*.

5

53. The cell of claim 50, wherein a copy of the gene of interest is integrated adjacent to a gene of a gluconate operon, preferably adjacent to a gene that encodes a gluconate kinase (EC 2.7.1.12) or a gluconate permease, more preferably
10 adjacent to a gene homologous to a *Bacillus subtilis* gene chosen from the group consisting of *gntR*, *gntK*, *gntP*, and *gntZ*, and most preferably adjacent to *gntR*, *gntK*, *gntP*, or *gntZ* from *Bacillus licheniformis*.

15 54. The cell of claim 50, wherein a copy of the gene of interest is integrated adjacent to a gene of a glycerol operon, preferably the gene encodes a glycerol uptake facilitator (permease), a glycerol kinase, or a glycerol dehydrogenase, more preferably the gene is homologous to the
20 *glpP*, *glpF*, *glpK*, or *glpD* gene from *Bacillus subtilis*, and most preferably the gene is the *glpP*, *glpF*, *glpK*, or *glpD* gene from *Bacillus licheniformis* shown in SEQ ID No:26.

55. The cell of claim 50, wherein a copy of the gene of
25 interest is integrated adjacent to a gene of an arabinose operon, preferably the gene encodes an arabinose isomerase, more preferably the gene is homologous to the *araA* gene from *Bacillus subtilis*, and most preferably the gene is the *araA* gene from *Bacillus licheniformis* shown in SEQ ID No:38.

30

56. The cell of any of claims 44 - 50, wherein a copy of the gene of interest is integrated adjacent to a gene which encodes one or more polypeptide(s) involved in amino acid synthesis, and the non-functionality of the gene(s) renders

the cell auxotrophic for one or more amino acid(s), and wherein restoration of the functionality of the gene(s) renders the cell prototrophic for the amino acid(s).

5 57. The cell of claim 56, wherein a copy of the gene of interest is integrated adjacent to a gene which encodes one or more polypeptide(s) involved in lysine or methionine synthesis, more preferably the gene(s) is homologous to the *metC* or the *lysA* genes from *Bacillus subtilis*, and most
10 preferably the gene(s) is the *metC* or the *lysA* gene from *Bacillus licheniformis*.

58. The cell of claim 56, wherein a copy of the gene of interest is integrated adjacent to a gene which is at least
15 75% identical, preferably 85% identical, more preferably 95% and most preferably at least 97% identical to the *metC* sequence of *Bacillus licheniformis* shown in SEQ ID No:42 or the *lysA* sequence of *Bacillus licheniformis* shown in SEQ ID No:48.

20

59. The cell of any of claims 44 - 58, wherein the gene of interest encodes an enzyme, preferably an amylolytic enzyme, a lipolytic enzyme, a proteolytic enzyme, a cellulolytic enzyme, an oxidoreductase or a plant cell-wall degrading enzyme, and
25 more preferably an enzyme with an activity selected from the group consisting of aminopeptidase, amylase, amyloglucosidase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, galactosidase, beta-
30 galactosidase, glucoamylase, glucose oxidase, glucosidase, haloperoxidase, hemicellulase, invertase, isomerase, laccase, ligase, lipase, lyase, mannosidase, oxidase, pectinase, peroxidase, phytase, phenoloxidase, polyphenoloxidase,

protease, ribonuclease, transferase, transglutaminase, or xylanase.

60. The cell of any of claims 44 - 58, wherein the gene of
5 interest encodes an antimicrobial peptide, preferably an anti-fungal peptide or an anti-bacterial peptide.

61. The cell of any of claims 44 - 58, wherein the gene of
interest encodes a peptide with biological activity in the
10 human body, preferably a pharmaceutically active peptide, more preferably insulin/pro-insulin/pre-pro-insulin or variants thereof, growth hormone or variants thereof, or blood clotting factor VII or VIII or variants thereof.

15 62. The cell of any of claims 44 - 61, wherein no antibiotic markers are present.

63. A *Bacillus licheniformis* cell, wherein at least two conditionally essential genes are rendered non-functional,
20 preferably the genes are chosen from the group consisting of *xylA*, *galeE*, *gntK*, *gntP*, *glpP*, *glpF*, *glpK*, *glpD*, *araA*, *metC*, *lysA*, and *dal*.

64. Use of a cell as defined in claim 63 in a method as
25 defined in any of claims 1 - 29.

65. A cell comprising a DNA construct as defined in claims 30 - 43.

30 66. A process for producing an enzyme of interest, comprising cultivating a cell as defined in any of claims 44 - 62 under conditions appropriate for producing the enzyme, and optionally purifying the enzyme.

1/3




Fig 1

2/3




Fig 2

3/3




Fig 3

10022.204-WO.ST25
SEQUENCE LISTING

<110> Novozymes A/S
Jørgensen, Steen Troels
Rasmussen, Michael Dolberg
Andersen, Jens Tønne
Olsen, Carsten

<120> Multiple insertion of genes

<130> 10022.204-WO

<150> DK PA 2000 00981
<151> 2000-06-23

<150> US 60/217,929
<151> 2000-07-13

<160> 50

<170> PatentIn version 3.1

<210> 1
<211> 30
<212> DNA
<213> Artificial Sequence: Primer #183235

<400> 1
gactaagctt ctgcatagtg agagaagacg

<210> 2
<211> 67
<212> DNA
<213> Artificial Sequence: Primer #183234

30

10022.204-WO.ST25

<400> 2
gactgaattc agatctgcgg ccgcacgcgt gtcgacagta ctgaaataga ggaaaaaata 60
agttttc 67

<210> 3

<211> 33

<212> DNA

<213> Artificial Sequence: Primer #183230

<400> 3
gactgaattc cgtatccatt cctgcgatat gag 33

<210> 4

<211> 41

<212> DNA

<213> Artificial Sequence: Primer #183227

<400> 4
gactggatcc agatcttatt acaaccctga tgaattgtc g 41

<210> 5

<211> 60

<212> DNA

<213> Artificial Sequence: Primer #183229

<400> 5
gactggatcc agatctgcta gcatcgatcc gcggctattt ccattgaaag cgattaattg 60

<210> 6

<211> 31

<212> DNA

<213> Artificial Sequence: Primer #187338

<400> 6
tatttcccga gattctgtta tcgactcgct c 31

<210> 7

<211> 27

<212> DNA

10022.204-wo.ST25
<213> Artificial Sequence: Primer #187339

<400> 7
gttttcggcc gctgtccgtt cgtcttt 27

<210> 8

<211> 27

<212> DNA

<213> Artificial Sequence:Primer #184733

<400> 8
gtgtgacgga taaggccgcc gtcattg 27

<210> 9

<211> 28

<212> DNA

<213> Artificial Sequence: Primer #184788

<400> 9
ctcttgtctc ggagcctgca ttttgggg 28

<210> 10

<211> 26

<212> DNA

<213> Artificial Sequence: Primer #B1656D07

<400> 10
agcattattc ttcgaagtcg cattgg 26

<210> 11

<211> 45

<212> DNA

<213> Artificial Sequence: Primer #B1659F03

<400> 11
ttaagatctt ttttatacaa ataggcttaa caataaagta aatcc 45

<210> 12

<211> 3342

10022.204-WO.ST25

<212> DNA

<213> *Bacillus licheniformis*

<220>

<221> CDS

<222> (1303)..(2469)

<223> DNA sequence of the dal-gene encoding D-alanine racemase

<220>

<221> misc_feature

<222> (2685)..(2685)

<223> Not determined with certainty

<400> 12

```

gcgtaccggt aaagtcgaac agcggtttct tcctttttac atccatggat taaaaagggg      60
ttgaaaaaag gtgagaaaaa gctttgtttt gcttttaacg gggctgcatg taatccttat      120
gctttctgcc tgcggccaaa aatcgcaaga agatgttgtg acgggggctcg acaagaaggc      180
aaaagaatac acgtcctata aggcaaaagc gaaaatgacc attgaaacgg ggaatgaccc      240
gcaggagtac aacgtggaaa tctggcataa aaaaccttct ctttaccggg tctatttgga      300
aaacccgaaa aaagaccaga gccagggtgat cttgcgcaat gaaaacggcg tgtttgtttt      360
gactccgtcg ctgaataaaa gcttccgctt tcacagcgac tggcccaata acagcagcca      420
gggtatactta ttcgaatcgc tcgtaaagga tgtcaaaaat gatggggaag cttctttttc      480
cgcaaaggat tcaaaatata tttttgaaac gaaaacgaat tatcagcata atcagatgct      540
gccgactcag gaaatcgttt tccataaaaa gaccatggct cttcatcggg ttaaagtgat      600
ggataccgac cgcaaaccga tggtaaagggt tgagtttaca agctttgaat tcgataagcc      660
gctcgataaa gactcttttg atgaaaagaa aaatatgacg ctgtctcaaa ttgacgtagc      720
gacaagcgct gacgtgtcag actctttcgc tgtcaaaacg ccgctcgatg tgcctcaggg      780
cgtgaaaaag cttgaagaga aagagatggc gactgaagac ggcaaacgga tcgtcatcac      840
atatggcggt gaaaaatcct ttacattgat tcaggaaaaa gcccgcgtcg ccaaaacatc      900
cacttccgta tccatgaacg gagagcccgt tgacctcggc ttacaggctc gcgcactgac      960
ggataaatcg ttgtcatgga catatgacgg agtcgattac tttatctcat cagaagatct     1020
ttctcaagat gaacttctga tggttgcaaa aagcatgcag ggacagtctt cgaaatagac     1080
tgtgccgtat ccggcagcct gttttccgcc cggaagcgga aagcaggctt ttttatattt     1140
gcgtcgcaag cgtatgattt cgacagcttt tccgtaaaat gtataaccgtg ccagcaattt     1200
ttcttttggt cagggctgat gatcccgctg aaaatttccc tttctccgaa ctttttagta     1260

```

10022.204-WO.ST25

tgatgggaag	gacgagtgaa					acaaggaaca			ggaagtgtca			tg	atg	agc	tta	aaa	1314
													Met	Ser	Leu	Lys	
													1				
cca	ttc	tat	aga	aag	aca	tgg	gcc	gaa	atc	gat	tta	acg	gct	tta	aaa		1362
Pro	Phe	Tyr	Arg	Lys	Thr	Trp	Ala	Glu	Ile	Asp	Leu	Thr	Ala	Leu	Lys		
5					10					15					20		
gaa	aac	gtc	cgc	aat	atg	aag	cgg	cac	atc	ggc	gag	cat	gtc	cgc	ctg		1410
Glu	Asn	Val	Arg	Asn	Met	Lys	Arg	His	Ile	Gly	Glu	His	Val	Arg	Leu		
				25					30					35			
atg	gcc	gtc	gtt	aaa	gcg	aat	gcc	tac	gga	cac	ggg	gat	gca	cag	gta		1458
Met	Ala	Val	Val	Lys	Ala	Asn	Ala	Tyr	Gly	His	Gly	Asp	Ala	Gln	Val		
			40					45					50				
gcg	aag	gcg	gct	ctt	gca	gaa	ggg	gcg	tcc	att	ctt	gct	gtg	gct	tta		1506
Ala	Lys	Ala	Ala	Leu	Ala	Glu	Gly	Ala	Ser	Ile	Leu	Ala	Val	Ala	Leu		
		55					60					65					
ttg	gat	gaa	gcg	ctt	tcg	ctg	agg	gcg	cag	ggg	att	gaa	gaa	ccg	att		1554
Leu	Asp	Glu	Ala	Leu	Ser	Leu	Arg	Ala	Gln	Gly	Ile	Glu	Glu	Pro	Ile		
	70					75					80						
ctt	gtc	ctc	ggt	gca	gtg	ccg	acc	gaa	tat	gca	agc	att	gcc	gcg	gaa		1602
Leu	Val	Leu	Gly	Ala	Val	Pro	Thr	Glu	Tyr	Ala	Ser	Ile	Ala	Ala	Glu		
85					90					95					100		
aag	cgc	att	atc	gtg	act	ggc	tac	tcc	gtc	ggc	tgg	ctg	aaa	gac	gtg		1650
Lys	Arg	Ile	Ile	Val	Thr	Gly	Tyr	Ser	Val	Gly	Trp	Leu	Lys	Asp	Val		
				105					110					115			
ctc	ggt	ttt	ctg	aat	gag	gcc	gaa	gct	cct	ctt	gaa	tat	cat	ttg	aag		1698
Leu	Gly	Phe	Leu	Asn	Glu	Ala	Glu	Ala	Pro	Leu	Glu	Tyr	His	Leu	Lys		
			120					125					130				
atc	gac	acg	ggc	atg	ggc	cgc	ctt	ggc	tgc	aaa	acg	gaa	gaa	gag	atc		1746
Ile	Asp	Thr	Gly	Met	Gly	Arg	Leu	Gly	Cys	Lys	Thr	Glu	Glu	Glu	Ile		
		135					140				145						
aaa	gaa	atg	atg	gag	atg	acc	gaa	tcg	aac	gat	aag	ctc	aat	tgt	acg		1794
Lys	Glu	Met	Met	Glu	Met	Thr	Glu	Ser	Asn	Asp	Lys	Leu	Asn	Cys	Thr		
	150					155					160						
ggc	gtg	ttc	act	cat	ttc	gcc	acg	gcg	gac	gaa	aag	gac	acc	gat	tat		1842
Gly	Val	Phe	Thr	His	Phe	Ala	Thr	Ala	Asp	Glu	Lys	Asp	Thr	Asp	Tyr		
165					170				175						180		
ttc	aac	atg	cat	ctt	gac	cgc	ttt	aaa	gag	ctg	atc	agc	ccc	ttc	ccg		1890
Phe	Asn	Met	His	Leu	Asp	Arg	Phe	Lys	Glu	Leu	Ile	Ser	Pro	Phe	Pro		
				185					190					195			
ctt	gac	cgt	ttg	atg	gtg	cat	tcg	tca	aac	agc	gcc	gcg	ggt	ctg	cgc		1938
Leu	Asp	Arg	Leu	Met	Val	His	Ser	Ser	Asn	Ser	Ala	Ala	Gly	Leu	Arg		
			200					205					210				
ttc	agg	gaa	cag	cta	ttt	aat	gcc	gtc	cgc	ttc	ggc	atc	ggc	atg	tac		1986
Phe	Arg	Glu	Gln	Leu	Phe	Asn	Ala	Val	Arg	Phe	Gly	Ile	Gly	Met	Tyr		
		215					220					225					
ggt	ttg	gcg	ccg	tca	acc	gaa	ata	aaa	gac	gag	ctg	ccg	ttt	cgt	ctg		2034
Gly	Leu	Ala	Pro	Ser	Thr	Glu	Ile	Lys	Asp	Glu	Leu	Pro	Phe	Arg	Leu		
	230					235					240						
cgg	gaa	gtg	ttt	tcg	ctt	cat	acc	gaa	ctc	acc	cat	gtg	aaa	aaa	att		2082
Arg	Glu	Val	Phe	Ser	Leu	His	Thr	Glu	Leu	Thr	His	Val	Lys	Lys	Ile		
245					250					255					260		

10022.204-WO.ST25

aaa aaa ggc gag agc gtc agc tac ggg gcg aca tat aca gct cag cgc 2130
 Lys Lys Gly Glu Ser Val Ser Tyr Gly Ala Thr Tyr Thr Ala Gln Arg
 265 270 275
 gac gaa tgg atc ggg aca gtc ccc gtc ggg tat gcc gac gga tgg ctg 2178
 Asp Glu Trp Ile Gly Thr Val Pro Val Gly Tyr Ala Asp Gly Trp Leu
 280 285 290
 agg cgc ctg gcc gga acg gaa gtg ctg atc gac gga aaa cgc caa aaa 2226
 Arg Arg Leu Ala Gly Thr Glu Val Leu Ile Asp Gly Lys Arg Gln Lys
 295 300 305
 ata gca ggg aga atc tgc atg gac cag ttc atg att tcc ctt gcc gaa 2274
 Ile Ala Gly Arg Ile Cys Met Asp Gln Phe Met Ile Ser Leu Ala Glu
 310 315 320
 gaa tac cct gtc ggc aca aag gtt acc ttg atc gga aag caa aaa gac 2322
 Glu Tyr Pro Val Gly Thr Lys Val Thr Leu Ile Gly Lys Gln Lys Asp
 325 330 335 340
 gaa tgg atc tca gtc gac gaa atc gcc caa aat ttg cag acg atc aat 2370
 Glu Trp Ile Ser Val Asp Glu Ile Ala Gln Asn Leu Gln Thr Ile Asn
 345 350 355
 tat gaa att acc tgt atg ata agt tca agg gtg ccc cgt atg ttt ttg 2418
 Tyr Glu Ile Thr Cys Met Ile Ser Ser Arg Val Pro Arg Met Phe Leu
 360 365 370
 gaa aat ggg agt ata atg gaa ata agg aat ccg atc ttg cct gat caa 2466
 Glu Asn Gly Ser Ile Met Glu Ile Arg Asn Pro Ile Leu Pro Asp Gln
 375 380 385
 tcc tgaaaattga tgaattagcg gaaaaacaac tttgcttgcg aaaagaataa 2519
 Ser
 tgatatgatt atgaatggaa tggatagagt gttgtatccg taagtttggt ggaggtgtat 2579
 gtttttgtct gaatccagcg caacaactga aatattgatt cgcttgccag aagctttagt 2639
 atcagaactg gatggtgtcg tcatgcgaga taaccgggag cagganatga actgatttta 2699
 ccaagccaca aaaatgtagg aacgcgaacg caaaaaatcg acaaattcgg ggaatcgatg 2759
 agaagcgggtt atatggagat ggccaagatc caatttgaac atctcttctg aggctcaatt 2819
 tgcagagtat gaggctgaaa acacagtaga gcgcttacta agcggatgat aatcatttga 2879
 ttgttaaacg cggcgatgtt tattttgctg acctatctcc tgttggtggc tcagaacaag 2939
 gcggggtgcg cccggtttta gtgattcaaa acaacatcgg caatcgcttc agcccaactg 2999
 ctattgttgc agccataaca gcccaaatac agaaagcaaa attacctacc cacgtcgaaa 3059
 ttgatgcaaa acgctacggg tttgaaagag actccgttat attgctcgaa caaattcgga 3119
 cgattgacaa gcaaagatta acggacaaaa tcacccatct cgatgatgaa atgatggaaa 3179
 aggtcaacga agccttataa atcagtttgg cactcattga tttttaatat tgatgaaagt 3239
 tgctcgaggc gaaagagcaa ctttttttgt gttcaaaaat aacaatacga tataatggta 3299
 actgttagtc ctaaaaatgt tagccagatg tagtcagggg gat 3342

<210> 13

10022.204-WO.ST25

<211> 389

<212> PRT

<213> Bacillus licheniformis

<220>

<221> misc_feature

<222> (2685)..(2685)

<223> Not determined with certainty

<400> 13

Met Ser Leu Lys Pro Phe Tyr Arg Lys Thr Trp Ala Glu Ile Asp Leu
1 5 10 15

Thr Ala Leu Lys Glu Asn Val Arg Asn Met Lys Arg His Ile Gly Glu
20 25 30

His Val Arg Leu Met Ala Val Val Lys Ala Asn Ala Tyr Gly His Gly
35 40 45

Asp Ala Gln Val Ala Lys Ala Ala Leu Ala Glu Gly Ala Ser Ile Leu
50 55 60

Ala Val Ala Leu Leu Asp Glu Ala Leu Ser Leu Arg Ala Gln Gly Ile
65 70 75 80

Glu Glu Pro Ile Leu Val Leu Gly Ala Val Pro Thr Glu Tyr Ala Ser
85 90 95

Ile Ala Ala Glu Lys Arg Ile Ile Val Thr Gly Tyr Ser Val Gly Trp
100 105 110

Leu Lys Asp Val Leu Gly Phe Leu Asn Glu Ala Glu Ala Pro Leu Glu
115 120 125

Tyr His Leu Lys Ile Asp Thr Gly Met Gly Arg Leu Gly Cys Lys Thr
130 135 140

Glu Glu Glu Ile Lys Glu Met Met Glu Met Thr Glu Ser Asn Asp Lys
145 150 155 160

Leu Asn Cys Thr Gly Val Phe Thr His Phe Ala Thr Ala Asp Glu Lys
165 170 175

Asp Thr Asp Tyr Phe Asn Met His Leu Asp Arg Phe Lys Glu Leu Ile
180 185 190

Ser Pro Phe Pro Leu Asp Arg Leu Met Val His Ser Ser Asn Ser Ala
195 200 205

10022.204-WO.ST25

Ala Gly Leu Arg Phe Arg Glu Gln Leu Phe Asn Ala Val Arg Phe Gly
 210 215 220

Ile Gly Met Tyr Gly Leu Ala Pro Ser Thr Glu Ile Lys Asp Glu Leu
 225 230 235 240

Pro Phe Arg Leu Arg Glu Val Phe Ser Leu His Thr Glu Leu Thr His
 245 250 255

Val Lys Lys Ile Lys Lys Gly Glu Ser Val Ser Tyr Gly Ala Thr Tyr
 260 265 270

Thr Ala Gln Arg Asp Glu Trp Ile Gly Thr Val Pro Val Gly Tyr Ala
 275 280 285

Asp Gly Trp Leu Arg Arg Leu Ala Gly Thr Glu Val Leu Ile Asp Gly
 290 295 300

Lys Arg Gln Lys Ile Ala Gly Arg Ile Cys Met Asp Gln Phe Met Ile
 305 310 315 320

Ser Leu Ala Glu Glu Tyr Pro Val Gly Thr Lys Val Thr Leu Ile Gly
 325 330 335

Lys Gln Lys Asp Glu Trp Ile Ser Val Asp Glu Ile Ala Gln Asn Leu
 340 345 350

Gln Thr Ile Asn Tyr Glu Ile Thr Cys Met Ile Ser Ser Arg Val Pro
 355 360 365

Arg Met Phe Leu Glu Asn Gly Ser Ile Met Glu Ile Arg Asn Pro Ile
 370 375 380

Leu Pro Asp Gln Ser
 385

<210> 14

<211> 20

<212> DNA

<213> Artificial Sequence: Primer # 148779

<400> 14
 gatgaacttc tgatggttgc

20

<210> 15

<211> 26

10022.204-WO.ST25

<212> DNA

<213> Artificial Sequence: Primer # 148780

<400> 15

aaaggatccc cctgactaca tctggc

26

<210> 16

<211> 39

<212> DNA

<213> Artificial Sequence: Primer # 170046

<400> 16

aaagcggccg cgagactgtg acggatgaat tgaaaaagc

39

<210> 17

<211> 32

<212> DNA

<213> Artificial Sequence: Primer # 170047

<400> 17

aaagaattcg tgaaatcagc tggactaaaa gg

32

<210> 18

<211> 32

<212> DNA

<213> Artificial Sequence: Primer # 150506

<400> 18

aaaggatccc gcaagcaaag ttgtttttcc gc

32

<210> 19

<211> 30

<212> DNA

<213> Artificial Sequence: Primer # 150507

<400> 19

aaaggtaccg aaagacatgg gccgaaatcg

30

<210> 20

10022.204-WO.ST25

<211> 32

<212> DNA

<213> Artificial Sequence: Primer # 158089

<400> 20

aaaggtaccg gtaatgactc tctagcttga gg

32

<210> 21

<211> 33

<212> DNA

<213> Artificial Sequence: Primer # 158090

<400> 21

caaatcgatc atcaccgaaa cgcggcaggc agc

33

<210> 22

<211> 31

<212> DNA

<213> Artificial Sequence: Primer # 150508

<400> 22

attaagcttg atatgattat gaatggaatg g

31

<210> 23

<211> 30

<212> DNA

<213> Artificial Sequence: Primer # 150509

<400> 23

aaagctagca tccccctgac tacatctggc

30

<210> 24

<211> 24

<212> DNA

<213> Artificial Sequence: Primer # 145507

<400> 24

gcgtaccgtt aaagtcgaac agcg

24

10022.204-WO.ST25

<210> 25

<211> 30

<212> DNA

<213> Artificial Sequence: Primer # 150509

<400> 25

aaagctagca tccccctgac tacatctggc

30

<210> 26

<211> 5761

<212> DNA

<213> Bacillus licheniformis

<400> 26

accggggccg ggcgttttgt cggcaacgtc tgtatatattc agccttgaaa ggcccttgat 60
 tccttcatgg atgatcgctt tcataaaaaa attcccccca ttcgagttgg ttgtgttaaa 120
 ttatggacat gaatgaaggt aaatgtaaaa tgatttgccc ggggccgctt agaggccttc 180
 tgttttataa aggattgcaa tgaggcggaa attccattag tgtaatacag aagcaagcta 240
 gcaagtgaag gagatggaac atgagttttc acgatcaaaa tattttacct gcggtacgca 300
 atatgaagca gttcgataca ttcctggaca gccctttttc atacgggggtg ctgcttgaca 360
 tccatcttgg acagctggga ggcgtgatca gcgcggcaag atcccatggg aaaaaaatgt 420
 ttgttcacgt cgatctgatc caaggaatta agcatgatga atacggtgcg gaattcattt 480
 gccaggaaat gaaaccggcg ggcattcttt ctacgagatc aagcgttatc gccaaagcaa 540
 agcagaagaa agtgtatgcg atccagcgca tgtttttaaat agacacaagc gccatgaaga 600
 agagcattga attggtgaaa aagcacagac ccgactatat agaagtgcct cccggagtag 660
 tgccggaatt gatcagggaa gtcaaagaaa taaccggcat tccgatcttt gcgggcgggt 720
 ttatccgtac cgaaaaagac gtcgagcagg cgcttgacagc aggggcgtcc gcagtcacca 780
 cctcagacac tgatttatgg aaaaaatact ggaactaaaa attttaaagt tgaaaaatta 840
 ttgacaacgc tttcactata cgatacgatc ttactaagtt aatacattgt gacggagacc 900
 cggagaccac agcagttctt tactcagtat gatgtaaaga aagtttgctg tgttttttta 960
 tggctctttta gacacagtgg agaagtgaa cttatggcgt tcatctatta gaataatact 1020
 tcataataga ttttaggagg gatagccttg acagcatttt ggggggaagt tatcggaacg 1080
 atgctgctca tcgtcttttg agctggagtt tgtgcaggag ttaatttgaa aaaatcgctg 1140
 tcccatcaat ccgatggat tgtgatcgtc ttcggctggg ggcttggcgt ggccatggcg 1200
 gtatatgccg tcggcggcat cagcggagcg catttaaadc cggccgttac attggggctg 1260
 gcatttgtcg gagattttcc ttgggaagaa gtgccttcat atattttggg acagatgatc 1320

10022.204-WO.ST25

```

ggcgcatTTTT taggagcggT gctcgTTTT cttcactact tgccgcactg gaaagaaacc 1380
gaggatcaag gcgcgaaGct tggagtatTT tgcacaggTc cggcgattcc aaatacatTT 1440
gcaaacctgt tcagtgaAAC attggggact tttattctcg ttctcggact tttAACgatc 1500
ggTgcaaaca agtttactga cggactgaat cctcttgTtg tcggatttct gatcgTggcg 1560
atcggtatct cgctcggcgG aacaacaggc tatgcgatta accctgcccG cgatctgggg 1620
ccgagaattg cccatTTTgt ctttccgatt gcaggcaaag ggagttcaaa ctggaagtac 1680
gcgtggatcc ctgTTTTagg accggcgctt ggcggttcat ttgcaggcgT tttttacaac 1740
gccgtattca aaggGcatat cacaacaca ttttgGattg taagcgTtat actagttgtg 1800
atattgttag gtttctatat tcatatgaaa aaacaagcag ttgatcaatc ggtcaacatt 1860
taaaaaaaaa caatcttaac agacataata gggggagttt caaaatggaa aagtacatTT 1920
tgtctcttga tcaaggcacc acaagcaca gggcgattgt tttcaacaaa gcaggcgaaa 1980
tcgtccatat tgcgcaaaag gaattccagc aatattttcc aaaccccggc tgggttgaac 2040
acaatgcaaa cgaaatctgG ggctctgttc tgtcggtgat cgcttcagcg ctttcagaat 2100
cggggatcga agccggacaa attgccgGaa tcgggatcac aaaccagcgG gaaacgaccg 2160
tggtttggga taaacatacc ggcaaaccgG tctacaacgc gattgtgtgG cagtcccgc 2220
aatcggtcga gatatgccag gaattaaaag agaaaggcta tgaagagacg atcagagaaa 2280
aaacagggct tttaatcgat ctttattttt caggcacgaa agtgaaatgG atcctggatc 2340
atgtggaagg ggcaaggGag aaagccgaaa acggcgacct tctcttcggT acgatcgatt 2400
cttggtgat ctggaaaatg tccggcgGaa aagcgcatgt gacagattat tcaaacgcct 2460
caagaacatt gatgttcaac atctatgacc taaaatggga tgatgaactt ctcgatattc 2520
tcggcgTgcc gaaatcgatg gttccggaag tcaagccttc atcgcatgta tacgctgaaa 2580
cggtcgatta tcatttcttc ggcaaaaaca ttccgattgc aggtgcagcc ggcgaccagc 2640
aggcagcatt gttcgggcag gcttgctttg aagaaggaaT ggTtaagaac acgtatggaa 2700
caggctgctt tatgctgatg aacaccggcg agaaagcgat taaatcagag cacggcctgc 2760
tgacgacaat cgcttggggc atcgacgGaa aggtggaata tgcgctggaa ggcagcgTct 2820
tcgtcgcggg ttccgctatt caatggctgc gtgatgggct gagaatgttt aaagacgcca 2880
aagaaagtga aaaatacgct gtaagagcag aatctgccga tggTgtttat gtggTccctg 2940
catttgtagg tttaggcacg ctttattggg acagcgatgt ccgcggcgct gtattcggac 3000
tgacccgggg tacgacgaaa gagcatTTta tcagagcaac gcttgaagcg cttgcctatc 3060
aaacgaaaga cgtgctggac gcaatgaagg aagactccgG gatcccggTt aaaacgctga 3120
gagtcgacgG cgagactgtc aaaaacaact tcctgatgga ttttcaggGc gacatttttag 3180
atgtccctgt agaacgtcct gaaatcaatg aaacaacagc gcttggTtca gcctattttag 3240
cgggccttgc tgtcggcttc tggagcgatc gttccgagat caaagaccag tggcagcttg 3300
acaaacgTtt tgaaccgaaa atggaagaaa aagagcgTga gagcctgtac aacgggtgga 3360

```

10022.204-WO.ST25

agaaagctgt	aaatgcagct	agggctttta	aataagctgc	atgtatgtta	caatctaatt	3420
aagttaatag	aaacggttgg	agaagaggag	agaccgcaga	caccaaagca	gtatcagcgc	3480
tttggaatgt	tgtggtctct	ttttctat	tttaccgtga	caacaaggga	ggacatgaaa	3540
catggaatca	ttattttcaa	gccgtaaacg	ggacgacatt	ttacagaata	tgacgaagca	3600
gaagtatgac	gtgtttatta	tcggcggagg	tattactggg	gctgggacgg	cattggatgc	3660
cgcacgcgcg	ggaatgaaaa	cggcgctttg	cgaaatgcag	gactttgcag	ccggaacgtc	3720
aagccgttcc	acgaaacttg	tacacggcgg	gcttcgctat	ttaaagcaat	ttgaagtga	3780
aatggtagcc	gaggtcggca	aagagcgggc	gatcgtctat	gaaaacgggc	cgcacgttac	3840
aacgcccga	tggatgctgc	ttccgatgca	taagggaggg	actttcggca	aattcagcac	3900
ttcaatcgg	ctgaggggtg	acgacttttt	ggcaggcgctc	aaaaaagctg	agcggaggag	3960
catgctgact	gccgaagaaa	cgcttcaaaa	agagccgctc	gtgaaaaaga	acggcctgaa	4020
gggcggcgcc	tattatgtcg	aataccggac	ggatgatgcc	agattgacga	tcgaagtcac	4080
gaaagaagcc	gttaaattcg	gagccgaggc	cgtcaattat	gcaaaagtaa	gcgattttat	4140
atatgaaaac	ggcaaggtca	ccggcggtgt	cattgaagac	gtcttcacga	aaaaaacgta	4200
ccgcgtctac	gcgaaaaaaa	ttgtcaatgc	cgcgggggccg	tgggtcgacc	gtctgcggga	4260
aaaagaccat	tcaaaagaag	gcaaacacct	tcagcataca	aaaggcgtgc	atcttgtttt	4320
tgatcaatcg	gtctttcctt	taaaacaagc	cgtttatttt	gatacgcttg	acggccgcat	4380
ggtgttcgcc	attccgagag	acggaaaggc	atatgtcggc	acaacagaca	ccgtctacaa	4440
cgagaatttg	gaacaccctc	gaatgacgac	agcagacagg	gattatgtca	tcaatgcaat	4500
caactatatg	ttccctgaac	ttggaatcaa	agccgaagat	gtcgaatcaa	gctgggctgg	4560
cctcagaccg	ctgattcatg	aagaaggaaa	agaccgtcc	gagatttccc	gaaaagatga	4620
gatctggact	tctgaatccg	gactgatcac	gatcgccggc	ggaaagctga	caggctacag	4680
aaaaatggct	gagcatatcg	tcgatcttgt	cagagaccga	ttaaaagaag	agggcgacag	4740
agacttcggg	ccttgcagaa	caaaaacgat	gccgatttca	ggcggccata	tcggcggtc	4800
caaaaatctg	gaggctttta	ttcaagcgaa	agcagccgaa	gggattgagg	ccggactgtc	4860
cgaagagacg	gccaaacaaa	tcgccgcacg	atacggttcg	aacgcagacc	gcctgtttga	4920
tcgtattcca	tcgctgaaag	atgaagcagc	aaaacgccgc	atccctgtcc	atgtactagc	4980
agaaatggat	tacgggatcg	aggaagaaat	ggcagccgtc	ccggcagact	tcttcgtccg	5040
cagaaccgggt	gcgctgttct	ttgacatcaa	ttgggtccgc	acttacaag	agagccttac	5100
ggactacatg	agcgagaagc	tgaactggga	tggcgaaacg	aaggcccgcc	atgtcaaggc	5160
attggaagga	ctactacacg	atgctgttgt	cccgtggaa	agcaaatgat	ttattaggtc	5220
aaataacctt	ggtgaatttt	cgtaataaat	caatcgaatg	gcccggcgtg	aggctgtctt	5280
gaacaggcag	cctcatTTTT	ttcatttggc	atgctaaatt	tggacaaagc	ggcggtttgt	5340
cgatatgata	aaagaaaagc	tgcaattact	tagctagaac	attggaggta	atcatgagct	5400

10022.204-WO.ST25

ggagaacgag ctatgaacgc tggagaaaca aagaaaactt agattccgaa ttaaaagcgc 5460
 ttcttttggg agcggaagga aatgaaaaag aactagagga ttgcttttat aaaaaacttg 5520
 agtttggtac agccggtatg cgcggtgaga tcggaccggg cccgaaccgc atgaacgttt 5580
 atacggttcg caaagcatcg gcgggccttg ccgcatacat aggagcgaac ggcggcgaag 5640
 caaaaaagcg cggcgttgtg atcgcgtacg attcccgcc caaatgcct gaatttgcaa 5700
 tggaagctgc taagacgctc gcagaaaacg gcgttcaaac gtacgtgttt gagcgtaact 5760
 g 5761

<210> 27

<211> 34

<212> DNA

<213> Artificial Sequence: Primer

<400> 27

gactgaattc gcaatttgaa gtgaaaatgg tagc 34

<210> 28

<211> 33

<212> DNA

<213> Artificial Sequence: Primer

<400> 28

gactggatcc agatctcatc ttttcgggaa atc 33

<210> 29

<211> 56

<212> DNA

<213> Artificial Sequence: Primer

<400> 29

gactgaattc agatctgcgg ccgcacgcgt agtactcccg gcgtgaggct gtcttg 56

<210> 30

<211> 32

<212> DNA

<213> Artificial Sequence: Primer

10022.204-WO.ST25

<400> 30
gactaagctt cagttacgct caaacacgta cg 32

<210> 31

<211> 47

<212> DNA

<213> Artificial Sequence: Primer

<400> 31
ccgagatttc ccgaaaagat gaaatttgga cttctgaatc cggactg 47

<210> 32

<211> 50

<212> DNA

<213> Artificial Sequence: Primer

<400> 32
gactaagctt agatctgcta gcatcgattg attattaacg aaaattcacc 50

<210> 33

<211> 31

<212> DNA

<213> Artificial Sequence: Primer

<400> 33
gactaagctt gtgaaggaga tggaacatga g 31

<210> 34

<211> 64

<212> DNA

<213> Artificial Sequence: Primer

<400> 34
gactggatcc agatctgcgg ccgcacgcgt cgacagtact attttttagtt ccagtatttt 60
ttcc 64

<210> 35

<211> 32

<212> DNA

10022.204-WO.ST25

<213> Artificial Sequence: Primer

<400> 35
gagctctaga tcttcggcgg catcagcgga gc 32

<210> 36

<211> 28

<212> DNA

<213> Artificial Sequence: Primer

<400> 36
gactgaattc cttttgcgca atatggac 28

<210> 37

<211> 58

<212> DNA

<213> Artificial Sequence: Primer

<400> 37
gagctctaga tctgctagca tcgatccgcg gttaaaatgt gaaaaattat tgacaacg 58

<210> 38

<211> 1500

<212> DNA

<213> *Bacillus licheniformis*

<400> 38
atcagcgata gggctcgcat cgacagaccg gatttcatcc ggccaatggc gggatgacgg 60
gctggtcatac aggtcgacat ccggcgatca gtttaatgcc attgaccctg atctggtcatac 120
tgacaaagac ggaaagccct ggctctcatt cggttccttc tggagcggca ttaagctgac 180
aaggcttgat aaaaacacga tgaaaccgac ggggaagcctg tattcgatcg cctcaaggcc 240
gaataacgga ggagcgggtg aagccccgaa cattacctac aaagacggct actattactt 300
atttgtctcg tttgacagct gctgcaaagg ggtggacagc acatataaaa tagcctatgg 360
ccgttcaacg agcattacgg gaccctatta tgataaaagc ggcaaaaata tgatgaacgg 420
cggagggacg atcctggact ccggcaatga ccgctggaaa gggccgggac atcaggatgt 480
tctgaacaac tcgatacctg tcaggcatgc ttacgacgag ctggacaatg gtgtatcaaa 540
gctgctcatc aatgacttgt actgggattc ccaaggatgg ccgacttatt aacagcagat 600
gacgggacgt ttccgcccgg ttttttttgt tctgaaatct gtcaaaaaaa aataaaaaac 660

10022.204-WO.ST25

```

ataccgga aa tt aaattgac agttttttttc ataatgat at aatgaagttg ttcgtacaaa 720
tatgtttttt atgttagttg tacgtacata taatcgcgat acagtttgag atcaaggat at 780
gatttatgtt tttttgtaag cgttttaata gtttgctatt ctacacagac accataaaga 840
cgaggaggag gaagctat tt gattcaggca aagacgcatg tgttttggtt tgtgacaggc 900
agccagcatt tatatggcga agaggcggta caagaggtag aagagcattc caaaatgatc 960
tgcaacggat taaatgacgg agatttaagg tttcaagtcg agtacaagc ggtggccact 1020
tcgctggacg gcgtcagaaa actgtttgaa gaggcgaacc gggacgatga gtgcgcaggc 1080
atcatcacct ggatgcatac gttttcaccg gccaaaatgt ggattcccgg cttttccgag 1140
ctgaataagc cgctgctcca ttttcatacc cagtttaacc gggacattcc gtgggataaa 1200
atcgacatgg atttcatgaa tattaatcag tctgcccacg gcgaccgcga atacggtttt 1260
atcggagcga gattgggcat tcctcgaaaa gtaatcgccg gatattggga agacagagaa 1320
gtaaagcgct cgatcgacaa atggatgagc gcagcggtcg catatattga aagccgccat 1380
atcaaagtcg cccgatttgg ggacaacatg cggaatgtgg cggtaacaga aggagataag 1440
attgaagcgc agattcagct tggctggtct gtcgacggat atggaatcgg cgatctcgtc 1500

```

<210> 39

<211> 32

<212> DNA

<213> Artificial Sequence: Primer

<400> 39

gactaagctt catccggcga tcagtttaat gc

32

<210> 40

<211> 65

<212> DNA

<213> Artificial Sequence: Primer

<400> 40

gactgaattc agatctgcgg ccgcacgcgt cgacagtact attttttttt gacagatttc

60

agaac

65

<210> 41

<211> 37

<212> DNA

<213> Artificial Sequence: Primer

10022.204-WO.ST25

<400> 41
gactggatcc agatctagtc gagtacaaag cggtggc 37

<210> 42

<211> 31

<212> DNA

<213> Artificial Sequence: Primer

<400> 42
gactgaattc gaccagccaa gctgaatctg c 31

<210> 43

<211> 4078

<212> DNA

<213> *Bacillus licheniformis*

<400> 43
tttccggcgt agcaccgaa gcgaacctat taatcgtcaa ggtgctcggc ggtgaagacg 60
gcagcgggga ttatgaatgg atcatcaacg ggatcaacta cgccgttgag caaaaagccg 120
acattatttc aatgtcgtc ggcggtcctg ccgacgttcc ggagttgaag gaagcgggta 180
caaacgccgt gaagagcggg gtgctcgtcg tctgcgccgc aggaacgaa ggcgacggca 240
atgaccgtac agaggagtac tcataacctg ctgcatacaa cgaagtcatc gccgtcggat 300
ccgtgtcatt gacgcgtgag tcttccgaat tttcaaatgc gaacaaagaa attgacctg 360
ttgcacctgg agaagaaatc ctctctacat tgcccgacca tcaatacggg aagctgacgg 420
gaacatcgat ggctacaccg cacgtcagcg gcgcgctcgc tctcatcaag tcagctgaag 480
aagaggcggt taaacggaaa ctgacagaac ccgaactgta tgctcagtta atccgccgca 540
cccttcctct tgattactca aaagcgctga tcggcaacgg attcttatat ttgtcagcgc 600
cggagggtact ggcggaaaaa gccggcgaag caaaacttct tcccttttaa cagtctaaag 660
gaggctgccg acaatgtcgg cggccttttt catggccatg tataaagctg aatcttttta 720
attgcaagaa ttcaaaaatt attttgacta aaagatcgcg gcggtatata atctactaaa 780
caatttcacg gccgggaaca tggtaatcta acgagggttag attttaaaag ggaagtttgg 840
tgaaaatcca acgcggtccc gccactgtga atgaggaggt tatttcataa aaccactgt 900
ttctatatgg gaagggggaa ataaccgtcg attcatgagc caggagacct gcctgttctg 960
acgcaccata aacctacggt cgataggagg tggttcgagtt gacgtaacaa tcgctacgtt 1020
tattttctcg tcgcaacatg ctgttttcag gcattcacct tctcattgtc cgaagtgtga 1080
gtgtcttttt ttattgaaca ctaaaaggag gagaccagac atgactaatg taaaaacgag 1140

10022.204-WO.ST25

cagcttgggc	tttccaagaa	tcggcttgaa	cagagaatgg	aaaaaatcgc	ttgaggctta	1200
ttgaaagga	aacacggacc	gcgagacctt	tttgaaagaa	atggatgaac	aatTTTTtagc	1260
agcgctccag	actcagcttg	atcagcaaat	cgatatcata	ccggtttccg	actttacaat	1320
gtacgaccat	gttcttgaca	cggcgggtgat	gttcaactgg	attccagatc	gattcaagga	1380
tataaacgat	ccgttagata	cttatttcgc	aatggcgaga	ggcacgaaag	atgctgtatc	1440
gagtgaatg	acaaaatggt	ttaatacaaa	ctaccattat	attgtgcctg	aatatgaaaa	1500
aggtgcacaa	taccgcgtga	cgagaaacaa	accgcttcaa	gattaccaa	gagcaaaagc	1560
agcattggga	acagaaacga	agcccgtcat	actcggcctt	tacactttcg	tagcccttgc	1620
aaaaggctat	gaacaacagg	atattaaaga	tatttataac	caaatgacac	ctctttacat	1680
ccaggTTTTg	aaagagcttg	agcaggaagg	cgTcaaatgg	gtgcaaattg	acgagcctgc	1740
tcttgtgacg	gcttcacctg	aagaagcggc	tgctgtcaaa	gaaatctatc	agacgattac	1800
agaagaagtc	tctgaactga	acatccttct	gcaaacctac	tttgactcgg	ttgatgctta	1860
tgaagagctg	atatcgtttc	ctgtcgcagg	aattggTctt	gattttgttc	atgataaagg	1920
gaaaaacttc	gaacacctga	aagcgcacgg	ttttcctaaa	gacaaagtcc	ttgccgccgg	1980
catttttagac	ggacgcaaca	tttggaagc	caatctcgaa	gagcgctcg	acctgacgct	2040
tgaactgata	cagagagcgg	gtgttgacga	agtctggatt	cagccttcaa	acagcctgct	2100
tcatgtccct	gtcgcaaaac	acccgggcga	acatcttgcc	gacgatctct	tgaacggttt	2160
atctttcgca	aaagagaaac	ttctggagct	tacactgctg	aagaacggac	ttgtttccgg	2220
aaaagcggcc	atccaagcgg	aaatcgatga	agcgcacgga	caccttcaag	atctcaaaca	2280
gtacgggtgca	gcgacaaatt	cggcctttgc	cgaagaaaga	ggcaagctga	ctgaggaaga	2340
ctttaaacgc	ccgacagctt	ttgaagaaag	gctgcggatt	caaaatgact	ctctcggact	2400
tcccctattg	ccgacaacaa	cgatcggcag	cttcccgcag	acggcggatg	tgccggagcgc	2460
gcggcaaaaa	tggcggaaaa	aagaatggtc	cgacgagcag	tatgaagcat	ttattcagga	2520
agaaacaaag	aatggattg	atattcagga	agatctcggga	cttgacgttc	tcgttcacgg	2580
agaattcgaa	cggacagaca	tggttgagta	tttcggcgaa	aagctcggag	gattcgcctt	2640
tactaaatac	gcctgggttc	agtcatacgg	ttcccgtgct	gtccggccgc	cggtcatcta	2700
cggagatgtc	gagtttaaag	agccgatgac	ggtaaaagaa	acggtttacg	cccaatcctt	2760
gacctcgaag	aaagtcaagg	gcatgctgac	agggcctgtt	accattttta	actggtcctt	2820
tgcccgttat	gacctgccga	gaaaagagat	cgccttccaa	atcgctgcg	ccctccgcaa	2880
agaggttgaa	gcgcttgaaa	aagcaggaat	tcaaatcatt	caggtcgatg	aacctgcctt	2940
gagagaaggc	ctgccgctta	aagaacggga	ttgggacgag	tatctcaa	gggctgcaga	3000
agcgttcaga	ctgtccactt	catctgtgga	agatacgacg	caaattccata	cgcatatgtg	3060
ctacagcaac	tttgaagata	tcgtagacgc	gatcgaagat	cttgacgcag	acgtcattac	3120
gatcgagcac	agcagaagcc	acggcggatt	tcttgattat	ctggaacagc	acccttacct	3180

10022.204-WO.ST25

gaaagggctt ggtcttggcg tatatgatat tcacagccct cgcgtccctt ccagcgatga 3240
 aatgctcacg atcatagaag acgcgctgaa agtctgcccg gctgatcgct tctgggtaaa 3300
 ccctgactgc ggtttaaaaa cgagacagcc agaggaaacg atcgacgcgc ttaagaatat 3360
 ggttgaagca gccaaacaag caagaggcaa actggctcag actgtttaat ttcacaaaaa 3420
 atccactaca aacgccgcct gttcacacgg gcggctcttt tcatggctcc agcccttttt 3480
 aggccaaaag aaccgttata caaggatatgt ccgcccaaaa aacattaaga cttttgattc 3540
 attcgtacga tttccttccg tatccttttc ttttaacata tttgtagtag atgatggaag 3600
 ggaaggaaaa tatgtagtga ttgacgatgg aatagcgta gaacgaaaaa tcaagcgaaa 3660
 aatatatcag gaagacattc actctcttca gctatacgta aaagatgtga atgccgccat 3720
 tgatgagctg aggcaggaaa gttcttctat tttaaaagca caccaaactg atatcaacgg 3780
 atggcgcgga caggcgcgcg aaatgtatga cgcgcttttg gacgatctcg accgggcgga 3840
 atcgcgctg tatgacaagc tgaggaccat taaagagcag gcggacgaag aaattgaacg 3900
 gcttcagctg aaagccgagg agctgatatg acgatccggc tgaacatcaa tgatctgcac 3960
 gccctcgccc gccaatctcg ttattccac cagcgaatca gcgatttaat acgccttttg 4020
 aaccgtcatt ttcattggtt ttttctccag cgtgaaaaca gcaaggaaca tgcgggcat 4078

<210> 44

<211> 42

<212> DNA

<213> Artificial Sequence: Primer

<400> 44
 aaaaaacccg agtttcacaa aaaatccact acaaacgccg cc 42

<210> 45

<211> 41

<212> DNA

<213> Artificial Sequence: Primer

<400> 45
 ttttttttaa gcttatgccg catgttcctt gctgttttca c 41

<210> 46

<211> 32

<212> DNA

<213> Artificial Sequence: Primer

10022.204-WO.ST25

<400> 46
 aaaaaaatcg attcagggat ataaacgatc cg 32

<210> 47

<211> 45

<212> DNA

<213> Artificial Sequence: Primer

<400> 47
 tttttttttt ccatcgact gggatatcag ctcttcataa gcatc 45

<210> 48

<211> 3952

<212> DNA

<213> *Bacillus licheniformis*

<400> 48
 ttatatacgtt tccctctcgg caatcggagc ctacacgaca ccaagctacg agctgagcct 60
 ggcgaataaa atggtgaagc tgtttatgct gatattggtg gcgcttttta aagtggaggg 120
 atttgtcatc ggattaacga tcttaactat agtgatgact tcgatcaggt cattgcgaac 180
 gccttactta tggcctctcc tcccgttcaa tggaaaagcg ttttgcatg ttctcgtgcg 240
 cacgtccgtt ccagggggaa aagtcaggcc gagcatcgtt catccgagaa accgctccag 300
 acagccgtga agccggcatt cgaagaggct tttccccggg gaaaagcctc tttttcaata 360
 atcgaattcc ggtctttgag taccgatgcc tttgtattca ttggcagaga tcgcgactgc 420
 ccggaggctg cagatgttgt tctgtcttct gatcggatag acgacataca gcatttcgcg 480
 gccgtacggg tcaatcgttg acgaatgaag gaaaacctca gttcctctcc gccaaaatct 540
 cgtatttcgcc ggagctgtaa taatctgccc ttcataaggc tcataaattc tctgttcata 600
 atgcgcagcc ggctgataag gggcgatac atcttcaggt gcatagccgg gagcgggggt 660
 gtagggataa cgatttggtg acatatgata acctctttcc cacttcgttt tttggttttc 720
 atctttaaga ttatattcag gtaaatgcct atttgatgg gcgaaaatct cagcttttcg 780
 gctctttttt tattgaatgg acgttggtga tgcctatttc tatcaagcgc tgttttctgt 840
 tattctataa tcaatagaat ggattagttg tttagggaaat catttccttt ataaatcaag 900
 aaaatttgga caaatggtgg tttagttttt aaaacgaaat gttataatac aacataagaa 960
 tcgcactatc atgaagccgg aagatgatc gggcagcaac cggagcggcc cttgcacctt 1020
 tgtcgataga gaaagaggga atgacaattg tttttacacg gtactagcag acaaaatgaa 1080
 agagggcacc tcgaaatcgg cgggtgtcgat gttctatcat tggcagaaag atacggaaca 1140

10022.204-WO.ST25

cctctttatg	tatacgatgt	cgcgctgatt	agagagcgcg	cccgaaaatt	ccagaaggca	1200
ttcaaggaag	ccggttttaa	agcgcaggta	gcgtatgcaa	gcaaggcggt	ttcatcggtt	1260
gccatgattc	agcttgccga	acaagagggg	ctgtctctgg	atgtggtatc	gggaggagag	1320
cttttctactg	cgatcaaagc	agggttccca	gctgagcgga	ttcattttca	cggaacaat	1380
aagagccctg	aagaactagc	catggcgctg	gagcatcaaa	tcggctgcat	cgtgctcgat	1440
aactttcacg	agatcgccat	tacagaagat	ctttgcaagc	gatcaggaca	aactgtagac	1500
gttttgctca	gaatcactcc	gggagttgaa	gcgcacacgc	acgattatat	tacgacgggg	1560
caggaagatt	ccaaattcgg	ttttgatctg	cataatggac	aggtcgaaca	agccatcgaa	1620
caagtccgcc	gctcgtctgc	gtttaagctc	ctcggcggtc	actgccacat	cggttcgcaa	1680
atttttgata	cggcaggatt	tgctcttgca	gcagacaaga	ttttcgagaa	gcttgcgga	1740
tggcgggaga	cttactcttt	cattccggaa	gtgctcaatc	ttggcggggg	cttcggcatc	1800
cgctatacaa	aagacgacga	gccgcttgca	gctgatgttt	atgttgaaaa	aatcatcgag	1860
gcggtcaaag	caaatgccga	gcatttcggc	tttgacatcc	ctgagatttg	gatcgaacca	1920
ggccggtctc	tcgtcgggtga	tgccgggact	acgctgtaca	cgatcggttc	tcaaaaagag	1980
gtgccgggca	ttcgcaata	tgtagccatc	gacggcggca	tgagcgataa	tatcaggccg	2040
gcgctttatg	aggcaaaata	tgaagcagcc	gtcgccaaca	ggatgaacga	tgcttgctcat	2100
gataccgcat	caatcgcagg	aaaatgctgc	gaaagcggag	atatgctgat	ttgggatttg	2160
gaaatccccg	aagttcgcg	cggagatgtg	ctcgccgttt	tctgcaccgg	tgcgtagcgg	2220
tacagcatgg	ccaacaacta	caaccgcatt	ccgcgcccgg	ccgtcgtctt	tgtagaggac	2280
ggggaagcgc	agctcgtcat	tcagagagag	acgtatgagg	atatcgtcaa	gctggatctg	2340
ccgctgaaat	cgaaagtcaa	acaataaaaa	aatggagatt	ccctaagagg	ggggtctcca	2400
tttttaattc	aagcacgaaa	aacacttccc	ggtgatcggg	aggtgttttt	tgttaaaaag	2460
atcatgacat	gcatagaaca	gcgaccgggc	tagttgtata	taatattgtg	aatttaacaa	2520
aaaattttaca	aaggagatga	taaaggcaat	gaccagggtg	aaaaggatga	gatttgctga	2580
tttgttggat	ttagaggcgg	agtagatgaa	accggccaaa	gtatccctac	tccaccgatt	2640
gctccagtgc	ctgaagcaat	gtgttgattg	taacacagta	aatcgtttta	cagcaataaa	2700
cattttttgtg	aatattttat	tgattttggc	tgtgatctca	ttcccatatt	ctgctgcggc	2760
ccatggcgca	acacagtccg	gcgatcaata	ttcaagcttt	gaagaattgg	agcggaatga	2820
agatccagct	tcttaccgaa	ttacggagaa	gaacgcaaga	gtgccgatgc	tcatcatggc	2880
catccatgga	ggcggcatcg	aacccggaac	gagcgaaatc	gccaatgaag	tgtccaaaaa	2940
ctattccctg	tacttgtttg	aagggctgaa	atcatcaggc	aatacggacc	ttcacattac	3000
aagcacgcgt	tttgacgagc	cagcggcgct	cgcaattact	gcaagccacc	agtatgtcat	3060
gtcgtccac	ggctattaca	gtgaagaccg	cgatattaaa	gtaggcggca	cagaccgcgc	3120
taaaatcaga	atattgggtg	atgagctgaa	ccgctcgggg	tttgccgctg	aaatgctggg	3180

10022.204-WO.ST25

```

gacagatgac aagtatgccg gaacccatcc gaataacatc gccaacaagt cgctttccgg 3240
gctgagcatt cagcttga aa tgagcacggg tttccgaaa tctttattcg accgggtttac 3300
actaaaagac agggcggcga cgcaaacga aacgttttac cgatttaca agctgctgac 3360
agattttatt catgaaaact atgaagaaga cggaggggat ttccccctctg caaaaataaa 3420
acacccccctt caagtga aaa aaggagggtgt ttcggcggtt gtgttaaccg ttggactctg 3480
agggtgccgcc gccggtgaat acggaaacga tggcggtcca cagagacaca aagaagtcga 3540
tcagtttttg aagaaagttt tgtccttctt cagaatccaa gaatttcgtg attttatcct 3600
ttgctttgtc aagctgggtc ccaacctggt tccagtcgat attaatattt ttcattgttat 3660
taaataaaga tataagagag tttttctgat cttctgtgag tgtcacgcca agttcggaag 3720
cagccgaatc aatcgttttc tccaattcct cttttgactc gggaaactccg tttttcgaga 3780
tttcttcctt gactttggcc atcagcgctg acgcgttttc actgccgatt ttctcgccaa 3840
gctctgaagt ggtgacaagc tcttcattcg cgacctttt cactcttcg gaaatTTTTT 3900
cgcccgaagt cgtttcatac gctttcatca atccgggtta agcggctgtg cc 3952

```

<210> 49

<211> 6837

<212> DNA

<213> Plasmid pMOL1642

<220>

<221> misc_feature

<222> (669)..(669)

<223> unknown

<400> 49

```

gatcttcctt caggttatga ccatctgtgc cagttcgtaa tgtctggtca actttccgac 60
tctgagaaac ttctggaatc gctagagaat ttctggaatg ggattcagga gtggacagaa 120
cgacacggat atatagtgga tgtgtcaaaa cgcataccat tttgaacgat gacctctaata 180
aattgttaat catgttggag ctcaagtgaga gcgaagcgaa cacttgattt tttaattttc 240
tatcttttat aggtcattag agtatactta tttgtcctat aaactattta gcagcataat 300
agattttattg aatagggtcat ttaagttgag catattagag gagggaaaatc ttggagaaat 360
atttgaagaa cccgaggatc catgctgtcc agactgtccg ctgtgtaaaa aataggaata 420
aagggggggtt gttattatct tactgatatg taaaatataa tttgtataag aaaatgagag 480
ggagaggaaa catgaagaag attgcaattg cggcgattac agcgacaagc gtgctggctc 540
tcagcgcatg cagcggggga gattctgagg ttgttgcgga aacaaaagct ggaaatatta 600

```

10022.204-WO.ST25

caaaagaaga	cctttatcaa	acattaaaag	acaatgccgg	agcggacgca	ctgaacatgc	660
ttgttcagna	aaaagtactc	gatgataaat	acgatgtctc	cgacaaagaa	atcgacaaaa	720
agctgaacga	gtacaaaaaa	tcaatgggtg	accagctcaa	ccagctcatt	gaccaaaaag	780
gcgaagactt	cgtcaaagaa	cagatcaaat	acgaacttct	gatgcaaaaa	gccgcaaagg	840
ataacataaa	agtaaccgat	gatgacgtaa	aagaatatta	tgacggcctg	aaaggcaaaa	900
tccacttaag	ccacattctt	gtgaaagaaa	agaaaacggc	tgaagaagtt	gagaaaaagc	960
tgaaaaaagg	cgaaaaattc	gaagaccttg	caaaagagta	ttcgggtacc	gggtctagag	1020
tcgacgcggc	cgcaaccatt	tgatcaaagc	ttgcatgcct	gcaggctgat	tcacaaaaaa	1080
taggcacacg	aaaaacaagt	taagggatgc	agtttatgca	tcccttaact	tacttattaa	1140
ataatttata	gctattgaaa	agagataaga	attgttcaaa	gctaataattg	tttaaactgt	1200
caattcctgc	atgttttaag	gaattgttaa	attgattttt	tgtaaataatt	ttcttgtatt	1260
ctttgttaac	ccatttcata	acgaaataat	tatacttttg	tttatctttg	tgtgatattc	1320
ttgatttttt	tctacttaat	ctgataagtg	agctattcac	tttaggttta	ggatgaaaat	1380
attctcttgg	aaccatactt	aatatagaaa	tatcaacttc	tgccattaaa	agtaatgcca	1440
atgagcgttt	tgtatttaat	aatcttttag	caaaccgta	ttccacgatt	aaataaatct	1500
cattagctat	actatcaaaa	acaattttgc	gtattatatc	cgtacttatg	ttataaggta	1560
tattaccata	tattttatag	gattggtttt	taggaaattt	aaactgcaat	atatacctgt	1620
ttaaaacttg	gaaattatcg	tgatcaacaa	gtttattttc	tgtagttttg	cataatttat	1680
ggctctatttc	aatggcagtt	acgaaattac	acctctttac	taattcaagg	gtaaaatggc	1740
cttttcctga	gccgatttca	aagatattat	catgttcatt	taatcttata	tttgtcatta	1800
ttttatctat	attatgtttt	gaagtaataa	agttttgact	gtgttttata	tttttctcgt	1860
tcattataac	cctctttaat	ttggttatat	gaattttgct	tattaacgat	tcattataac	1920
cacttatttt	ttgtttgggt	gataatgaac	tgtgctgatt	acaaaaatac	taaaaatgcc	1980
catatttttt	cctccttata	aaattagtat	aattatagca	cgagctctga	taaatatgaa	2040
catgatgagt	gatcgttaaa	tttatactgc	aatcggatgc	gattattgaa	taaaagatat	2100
gagagattta	tctaatttct	tttttcttgt	aaaaaaagaa	agttcttaaa	ggttttatag	2160
ttttggctgt	agagcacacg	gtttaacgac	ttaattacga	agtaaataag	tctagtgtgt	2220
tagactttat	gaaatctata	tacgtttata	tatatttatt	atccggaggt	gtagcatgtc	2280
tcattcaatt	ttgagggttg	ccagagttaa	aggatcaagt	aatacaaacg	ggatacaaag	2340
acataatcaa	agagagaata	aaaactataa	taataaagac	ataaatcatg	aggaaacata	2400
taaaaattat	gatttgatta	acgcacaaaa	tataaagtat	aaagataaaa	ttgatgaaac	2460
gattgatgag	aattattcag	ggaaacgtaa	aattcgggtc	gatgcaattc	gacatgtgga	2520
cggactgggt	acaagtgata	aagatttctt	tgatgattta	agcggagaag	aaatagaacg	2580
attttttaaa	gatagcttgg	agtttctaga	aaatgaatac	ggtaaggaaa	atatgctgta	2640

10022.204-WO.ST25

tgcgactgtc	catctggatg	aaagagtccc	acatatgcac	tttggttttg	tccttttaac	2700
agaggacggg	agattgtctg	caaaagaaca	gtaggcaac	aagaaagact	ttactcaatt	2760
acaagataga	tttaatgagt	atgtgaatga	gaaaggttat	gaacttgaaa	gaggcacgtc	2820
caaagagggt	acagaacgag	aacataaagc	gatggatcag	tacaagaaag	atactgtatt	2880
tcataaacag	gaactgcaag	aagttaagga	tgagttacag	aaggcaaata	agcagttaca	2940
gagtggaata	gagcatatga	ggtctacgaa	accctttgat	tatgaaaatg	agcgtacagg	3000
tttgtttctt	ggacgtgaag	agactggtag	aaagatatta	actgctgatg	aatttgaacg	3060
cctgcaagaa	acaatctctt	ctgcagaacg	gattgttgat	gattacgaaa	atattaagag	3120
cacagactat	tacacagaaa	atcaagaatt	aaaaaacgt	agagagagtt	tgaaagaagt	3180
agtgaataca	tggaagagg	ggtatcacga	aaaaagtaaa	gagggttaata	aattaaagcg	3240
agagaatgat	agtttgaatg	agcagttgaa	tgtatcagag	aaatttcaag	ctagtacagt	3300
gactttatat	cgtgctgcca	gggcgaattt	ccctgggttt	gagaaagggg	ttaataggct	3360
taaagagaaa	ttctttaatg	attccaaatt	tgagcgtgtg	ggacagttta	tggtgtttgt	3420
acaggataat	gtccagaagg	tcgatagaaa	gcgtgagaaa	cagcgtacag	acgatttaga	3480
gatgtagagg	tacttttatg	ccgagaaaac	tttttgctg	tgacagtcct	taaaatatac	3540
ttagagcgta	agcgaaagta	gtagcgacag	ctattaactt	tcggtttcaa	agctctagga	3600
tttttaatgg	acgcagcgca	tcacacgcaa	aaaggaaatt	ggaataaatg	cgaaatttga	3660
gatgttaatt	aaagaccttt	ttgaggtcct	tttttcttag	atttttgggg	ttatttaggg	3720
gagaaaacat	aggggggtac	tacgacctcc	cccctagggtg	tccattgtcc	attgtccaaa	3780
caaataaata	aatattgggt	ttttaatggt	aaaaggttgt	tttttatggt	aaagtgaaaa	3840
aaacagatgt	tgggaggtac	agtgatggtt	gtagatagaa	aagaagagaa	aaaagttgct	3900
gttactttta	gacttacaac	agaagaaaat	gagatattaa	atagaatcaa	agaaaaatat	3960
aatatttagca	aatcagatgc	aaccgggtatt	ctaataaaaa	aatatgcaaa	ggaggaatac	4020
ggtgcatttt	aaacaaaaaa	agatagacag	cactggcatg	ctgcctatct	atgactaaat	4080
tttgtttaagt	gtatttagcac	cgttattata	tcatgagcga	aaatgtaata	aaagaaactg	4140
aaaacaagaa	aaattcaaga	ggacgtaatt	ggacatttgt	tttatatcca	gaatcagcaa	4200
aagccgagtg	gttagagtat	ttaaaagagt	tacacattca	atttgtagtg	tctccattac	4260
atgatagggg	tactgataca	gaaggtagga	tgaaaaaaga	gcattatcat	attctagtga	4320
tgtatgaggg	taataaatct	tatgaacaga	taaaaataat	tacagaagaa	ttgaatgcga	4380
ctattccgca	gattgcagga	agtgtgaaag	gtcttgtgag	atatatgctt	cacatggacg	4440
atcctaataa	atttaaatat	caaaaagaag	atatgatagt	ttatggcggt	gtagatgttg	4500
atgaattatt	aaagaaaaca	acaacagata	gatataaatt	aattaaagaa	atgattgagt	4560
ttattgatga	acaaggaatc	gtagaattta	agagtttaat	ggattatgca	atgaagttta	4620
aatttgatga	ttggttcccg	cttttatgtg	ataactcggc	gtatgttatt	caagaatata	4680

10022.204-WO.ST25

taaaatcaaa	tcggtataaa	tctgaccgat	agattttgaa	tttaggtgtc	acaagacact	4740
cttttttcgc	accagcgaaa	actggtttaa	gccgactgcg	caaaagacat	aatcgactct	4800
agaggatcct	tttagtccag	ctgatttcac	tttttgcatt	ctacaaactg	cataactcat	4860
atgtaaatcg	ctccttttta	ggtggcacia	atgtgaggca	ttttcgctct	ttccggcaac	4920
cactttcaag	taaagtataa	cacactatac	tttatattca	taaagtgtgt	gctctgcgag	4980
gctgtcggca	gtgccgacca	aaaccataaa	acctttaaga	cctttctttt	ttttacgaga	5040
aaaaagaaac	aaaaaaacct	gccctctgcc	acctcagcaa	agggggggtt	tgctctcgtg	5100
ctcgttttaa	aatcagcaag	ggacaggtag	tattttttga	gaagatcact	caaaaaatct	5160
ccacctttta	acccttgcca	atttttattt	tgtccgtttt	gtctagctta	ccgaaagcca	5220
gactcagcaa	gaataaaatt	tttattgtct	ttcggttttc	tagtgtaacg	gacaaaacca	5280
ctcaaaataa	aaaagataca	agagaggctc	ctcgtatctt	ttattcagca	atcgcgcccg	5340
attgctgaac	agattaataa	tgagccgcgg	atatcgatgc	cttgtcagag	agattcctga	5400
agagcggcag	gataaggat	ttagaatgat	taatgtgctg	atcttaattt	tattgatctc	5460
atcattcatt	gagatttcct	ttacgggtga	aagaaaaagg	atagctgccg	atcgtattga	5520
tccggcagct	atccttttgt	ttattagcat	atccaagaag	caccaataat	aattaataag	5580
atgaacagca	ccacaagcag	cgcaaagccg	ccagcgaaac	ctcctgcata	accgtcgccc	5640
atattgacac	ctcctctgcc	ccagtcgtta	cattagtgtg	tgacgaatg	tcatgaaacg	5700
attaggctat	cgtccaaaag	aaaagaaccg	cctgaaaaaa	tgacggttct	tttctcattt	5760
tctaaggttt	tagtacagat	aagctgcacc	aacgatgatt	aataaaatga	acaacacgac	5820
caataaagca	aaaccgcttg	agtatcctcc	gctcatgtta	ttgacctcga	attctgatca	5880
aatggttcag	tgagagcgaa	gcgaacactt	gattttttta	ttttctatct	tttatagggtc	5940
attagagtat	acttatttgt	cctataaaact	atttagcagc	ataatagatt	tattgaatag	6000
gtcatttaag	ttgagcatat	tagaggagga	aaatcttgga	gaaatatttg	aagaaccgga	6060
acgcgtgagt	agttcaacaa	acgggccagt	ttgttgaaga	ttagatgcta	taattgttat	6120
taaaaggatt	gaaggatgct	taggaagacg	agttattaat	agctgaataa	gaacgggtgct	6180
ctccaaatat	tcttatttag	aaaagcaa	ctaaaattat	ctgaaaaggg	aatgagaata	6240
gtgaatggac	caataataat	gactagagaa	gaaagaatga	agattgttca	tgaaattaag	6300
gaacgaatat	tggataaata	tggggatgat	gttaaggcta	ttgggtgtta	tggctctctt	6360
ggtcgtcaga	ctgatgggcc	ctattcggat	attgagatga	tgtgtgtcat	gtcaacagag	6420
gaagcagagt	tcagccatga	atggacaacc	ggtgagtgga	aggtggaagt	gaattttgat	6480
agcgaagaga	ttctactaga	ttatgcatct	cagggtggaat	cagattggcc	gcttacacat	6540
ggtcaatttt	tctctatttt	gccgatttat	gattcagggtg	gatacttaga	gaaagtgtat	6600
caaactgcta	aatcggtaga	agcccaaacc	ttccacgatg	cgatttgtgc	ccttatcgta	6660
gaagagctgt	ttgaatatgc	aggcaa	cgtaatat	gtgtgcaagg	accgacaaca	6720

10022.204-wo.ST25

tttctaccat ccttgactgt acaggtagca atggcaggtg ccatgttgat tggctctcat 6780
 catcgcatct gttatacgac gagcgcttcg gtcttaactg aagcagttaa gcaatca 6837

<210> 50

<211> 817

<212> DNA

<213> Artificial sequence: repF expression cassette

<400> 50

gaattccggc ccaacgatgg ctgatttccg ggttgacggc cggcggaacc aaggggtgat 60
 cggtcggcgg aaatgaaggc ctgcggcgag tgcgggcctt ctgttttgag gattataatc 120
 agagtatatt gaaagtttcg cgatcttttc gtataattgt tttaggcata gtgcaatcga 180
 taagcttgaa ttcggaggcc gttattatat catgagcgaa aatgtaataa aagaaactga 240
 aaacaagaaa aattcaagag gacgtaattg gacatttggt ttatatccag aatcagcaaa 300
 agccgagtgg ttagagtatt taaaagagtt acacattcaa tttgtagtgt ctccattaca 360
 tgatagggat actgatacag aaggtaggat gaaaaaagag cattatcata ttctagtgat 420
 gtatgagggg aataaatctt atgaacagat aaaaataatt acagaagaat tgaatgcgac 480
 tattccgcag attgcaggaa gtgtgaaagg tcttgtagaga tatatgcttc acatggacga 540
 tcctaataaa tttaaataatc aaaaagaaga tatgatagtt tatggcgggtg tagatgttga 600
 tgaattatta aagaaaacaa caacagatag atataaatta attaaagaaa tgattgagtt 660
 tattgatgaa caaggaatcg tagaatttaa gagtttaatg gattatgcaa tgaagtttaa 720
 atttgatgat tggttccgcg ttttatgtga taactcggcg tatgttattc aagaatatat 780
 aaaatcaaat cgggtataaat ctgaccgata gggatcc 817

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 01/00436

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C12N 15/90, C12N 15/68, C12N 15/67 // C12N 15/75

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9941358 A1 (NOVO NORDISK A/S), 19 August 1999 (19.08.99) --	1-66
A	EP 0185512 A1 (NOVO INDUSTRI A/S), 25 June 1986 (25.06.86) --	1-66
A	EP 0972838 A1 (ROCHE DIAGNOSTICS GMBH), 19 January 2000 (19.01.00) -- -----	1-66

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

23 November 2001

Date of mailing of the international search report

27 -11- 2001

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Yvonne Siösteen/Eö

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Information on patent family members

06/11/01

International application No.

PCT/DK 01/00436

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	9941358	A1	19/08/99	AU	2610399 A	30/08/99
				CN	1272135 T	01/11/00
				EP	1062318 A	27/12/00
				US	6100063 A	08/08/00

EP	0185512	A1	25/06/86	SE	0185512 T3	
				AT	55413 T	15/08/90
				AU	592542 B	18/01/90
				AU	5108185 A	19/06/86
				CA	1292197 A	19/11/91
				DE	3579133 D	00/00/00
				DK	159282 B,C	24/09/90
				DK	571985 A	13/06/86
				DK	594084 A	13/06/86
				FI	85876 B,C	28/02/92
				FI	854893 A	13/06/86
				JP	2571338 B	16/01/97
				JP	2576970 B	29/01/97
				JP	6086669 A	29/03/94
				JP	61139392 A	26/06/86
				NO	172063 B,C	22/02/93
				NO	854966 A	13/06/86
				US	4920048 A	24/04/90

EP	0972838	A1	19/01/00	AU	720627 B	08/06/00
				AU	4011599 A	10/02/00
				BR	9902792 A	09/05/00
				JP	2000050888 A	22/02/00
				TR	9901650 A	00/00/00
				US	6291245 B	18/09/01
